CA2229741C - Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology - Google Patents
Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology Download PDFInfo
- Publication number
- CA2229741C CA2229741C CA2229741A CA2229741A CA2229741C CA 2229741 C CA2229741 C CA 2229741C CA 2229741 A CA2229741 A CA 2229741A CA 2229741 A CA2229741 A CA 2229741A CA 2229741 C CA2229741 C CA 2229741C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- peptide
- adrenomedullin
- antibody
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101800004616 Adrenomedullin Proteins 0.000 title claims abstract description 477
- 102000004379 Adrenomedullin Human genes 0.000 title claims abstract description 432
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title claims abstract description 406
- 230000035479 physiological effects, processes and functions Effects 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 title description 30
- 230000007170 pathology Effects 0.000 title description 3
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 58
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 230000003914 insulin secretion Effects 0.000 claims abstract description 24
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 114
- 230000012010 growth Effects 0.000 claims description 40
- 210000004072 lung Anatomy 0.000 claims description 31
- 210000003630 histaminocyte Anatomy 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 22
- 230000001105 regulatory effect Effects 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 210000000496 pancreas Anatomy 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 201000011461 pre-eclampsia Diseases 0.000 claims description 12
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 230000004153 glucose metabolism Effects 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 230000001919 adrenal effect Effects 0.000 claims description 7
- 230000028709 inflammatory response Effects 0.000 claims description 7
- 230000001537 neural effect Effects 0.000 claims description 7
- 230000002611 ovarian Effects 0.000 claims description 7
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 238000000034 method Methods 0.000 abstract description 50
- 239000000203 mixture Substances 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 12
- 231100000673 dose–response relationship Toxicity 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000003305 autocrine Effects 0.000 abstract description 6
- 239000003102 growth factor Substances 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 230000001613 neoplastic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 112
- 102000004196 processed proteins & peptides Human genes 0.000 description 52
- 238000010240 RT-PCR analysis Methods 0.000 description 49
- 108020004999 messenger RNA Proteins 0.000 description 46
- 210000004881 tumor cell Anatomy 0.000 description 44
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 35
- 241000700159 Rattus Species 0.000 description 30
- 239000013615 primer Substances 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- 238000011065 in-situ storage Methods 0.000 description 26
- 230000000845 anti-microbial effect Effects 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 230000027455 binding Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 230000000692 anti-sense effect Effects 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 18
- 210000000981 epithelium Anatomy 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 238000010186 staining Methods 0.000 description 18
- 241000222122 Candida albicans Species 0.000 description 16
- 238000009826 distribution Methods 0.000 description 16
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 15
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 15
- 102100021243 G-protein coupled receptor 182 Human genes 0.000 description 15
- 101001040797 Homo sapiens G-protein coupled receptor 182 Proteins 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 108060003100 Magainin Proteins 0.000 description 13
- 238000002105 Southern blotting Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 230000035784 germination Effects 0.000 description 12
- 230000002055 immunohistochemical effect Effects 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000003636 conditioned culture medium Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 11
- 208000000587 small cell lung carcinoma Diseases 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 208000002458 carcinoid tumor Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 9
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 8
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 8
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 238000003365 immunocytochemistry Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 241000699800 Cricetinae Species 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000008045 co-localization Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000009036 growth inhibition Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 6
- 101150096544 AM gene Proteins 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 6
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 6
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 239000012130 whole-cell lysate Substances 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 102100025841 Cholecystokinin Human genes 0.000 description 5
- 101800001982 Cholecystokinin Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102400000921 Gastrin Human genes 0.000 description 5
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 5
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 5
- 108010052343 Gastrins Proteins 0.000 description 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 5
- 238000000134 MTT assay Methods 0.000 description 5
- 231100000002 MTT assay Toxicity 0.000 description 5
- 101710142969 Somatoliberin Proteins 0.000 description 5
- 102100022831 Somatoliberin Human genes 0.000 description 5
- 102000005157 Somatostatin Human genes 0.000 description 5
- 108010056088 Somatostatin Proteins 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 5
- 229940107137 cholecystokinin Drugs 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 5
- 229960000553 somatostatin Drugs 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 230000000304 vasodilatating effect Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 101710151321 Melanostatin Proteins 0.000 description 4
- 102400000064 Neuropeptide Y Human genes 0.000 description 4
- 102400000050 Oxytocin Human genes 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- -1 aMSH Proteins 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 210000001132 alveolar macrophage Anatomy 0.000 description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 210000003890 endocrine cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000005062 synaptic transmission Effects 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 3
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108050004290 Cecropin Proteins 0.000 description 3
- 241000557626 Corvus corax Species 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- NNBWMLHQXBTIIT-HVTMNAMFSA-N His-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N NNBWMLHQXBTIIT-HVTMNAMFSA-N 0.000 description 3
- 101500024172 Homo sapiens Adrenomedullin Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 description 3
- 101800004761 Magainin-2 Proteins 0.000 description 3
- 102000005717 Myeloma Proteins Human genes 0.000 description 3
- 108010045503 Myeloma Proteins Proteins 0.000 description 3
- 108010088847 Peptide YY Proteins 0.000 description 3
- 102100029909 Peptide YY Human genes 0.000 description 3
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 3
- 108010071479 Tabanus atratus hypotrehalosemic hormone Proteins 0.000 description 3
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 3
- 239000007997 Tricine buffer Substances 0.000 description 3
- FXYOYUMPUJONGW-FHWLQOOXSA-N Tyr-Gln-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 FXYOYUMPUJONGW-FHWLQOOXSA-N 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000000465 brunner gland Anatomy 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000000254 ciliated cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 239000003630 growth substance Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 3
- 108010072906 phosphoramidon Proteins 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 108010012004 proadrenomedullin Proteins 0.000 description 3
- 102000034567 proadrenomedullin Human genes 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 229950009811 ubenimex Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102400000059 Arg-vasopressin Human genes 0.000 description 2
- 101800001144 Arg-vasopressin Proteins 0.000 description 2
- XFJKRRCWLTZIQA-XIRDDKMYSA-N Asn-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N XFJKRRCWLTZIQA-XIRDDKMYSA-N 0.000 description 2
- CBWCQCANJSGUOH-ZKWXMUAHSA-N Asn-Val-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O CBWCQCANJSGUOH-ZKWXMUAHSA-N 0.000 description 2
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 2
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000052651 Pancreatic hormone Human genes 0.000 description 2
- 108700020479 Pancreatic hormone Proteins 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 2
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- QGVBFDIREUUSHX-IFFSRLJSSA-N Thr-Val-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O QGVBFDIREUUSHX-IFFSRLJSSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 101710201242 Tracheal antimicrobial peptide Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 2
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000010309 neoplastic transformation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000004025 pancreas hormone Substances 0.000 description 2
- 229940032957 pancreatic hormone Drugs 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 201000005608 severe pre-eclampsia Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- QHTGVJBNKLTDJN-ONHACJEVSA-N tracheal antimicrobial peptide Chemical compound N([C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC2=O)C(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)=O)CSSC1)C(C)C)C(C)C)=O)[C@@H](C)CC)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O QHTGVJBNKLTDJN-ONHACJEVSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010060934 Allergic oedema Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- HXMXZULYDOHHGE-UHFFFAOYSA-N Cl.[Cs+].[N-]=C=S Chemical compound Cl.[Cs+].[N-]=C=S HXMXZULYDOHHGE-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 101001080057 Homo sapiens 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 101000980673 Homo sapiens Multicilin Proteins 0.000 description 1
- 101000667595 Homo sapiens Ribonuclease pancreatic Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- 102000023108 LH Receptors Human genes 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- BEGQVWUZFXLNHZ-IHPCNDPISA-N Lys-Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 BEGQVWUZFXLNHZ-IHPCNDPISA-N 0.000 description 1
- 101800004760 Magainin-1 Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100039832 Ribonuclease pancreatic Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 108091005466 amylin receptors Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000001277 anti-dipsogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 1
- 108010050923 calcitonin gene-related peptide (8-37) Proteins 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000003764 chromatophore Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000674 effect on sodium Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000004795 endocrine process Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003059 ependyma Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000002434 gonadorelin derivative Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000035414 hereditary 1 prostate cancer Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- OFIZOVDANLLTQD-ZVNXOKPXSA-N magainin i Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 OFIZOVDANLLTQD-ZVNXOKPXSA-N 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 210000005034 parasympathetic neuron Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000024351 regulation of hormone secretion Effects 0.000 description 1
- 230000010656 regulation of insulin secretion Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000003728 serous cell Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- NDACAFBDTQIYCQ-YVQXRMNASA-N val(8)-phe(37)-cgrp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C1=CN=CN1 NDACAFBDTQIYCQ-YVQXRMNASA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
Description
FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND
THE GENE-RELATED PRODUCT (PAMP) IN
HUMAN PATHOLOGY AND PHYSIOLOGY
BACKGROUND OF THE INVENTION
Adrenomedullin (AM) is a recently identified hypotensive peptide initially isolated from human pheochromocytoma (K. Kitamura, et al., Biochem. Biophys.
Res. Commun. 192, 553 (1993)). AM is generated from a 185 amino acid preprohormone through consecutive enzymatic cleavage and amidation. This process culminates in the liberation of a 52 amino acid bioactive peptide (T.
Ishimitsu et al., Biochem. Biophys. Res. Commun. 203, 631 (1994)). AM and its gene-related peptide, PAMP, are the two known bioactive products generated from the post--translational enzymatic processing of the 185 amino acid-preproAM molecule (K. Kitamura, et al., Biochem.
Biophys. Res. Commun. 192, 553 (1993); K. Kitamura, et al., Biochem. Biophys. Res. Commun. 194, 720 (1993);
Kitamura, et al. FEBS Lett. 351, 35-37 (1994)).
The complete genomic infrastructure for human AM
has recently been reported (Ishimitsu, et al., Biochem Biophys Res Commun 203:631-639 (1994)). The porcine (Kitamura, et al., FEES Lett 338:306-310 (1994)) and rat (Sakata, et al., Biochem Biophys Res Commun 195:921-927 (1993)) AM complementary DNAs have also been cloned/sequenced and demonstrate high homology to the human counterpart. Human cDNA of AM has been cloned and mRNA expression identified in the adrenal glands, lung, kidney, and heart (K. Kitamura, et al., Biochem. Biophys.
Res. Commun. 194, 720 (1993)). A high degree of base sequence homology has been found between AM mRNAs isolated from other mammalian species, including rat and porcine (J. Sakata, et al., Biochem. Biophys. Res. Commun. 195, 921 (1993); and K. Kitamura, et al., FEBS Lett. 338, 306 (1994)).
THE GENE-RELATED PRODUCT (PAMP) IN
HUMAN PATHOLOGY AND PHYSIOLOGY
BACKGROUND OF THE INVENTION
Adrenomedullin (AM) is a recently identified hypotensive peptide initially isolated from human pheochromocytoma (K. Kitamura, et al., Biochem. Biophys.
Res. Commun. 192, 553 (1993)). AM is generated from a 185 amino acid preprohormone through consecutive enzymatic cleavage and amidation. This process culminates in the liberation of a 52 amino acid bioactive peptide (T.
Ishimitsu et al., Biochem. Biophys. Res. Commun. 203, 631 (1994)). AM and its gene-related peptide, PAMP, are the two known bioactive products generated from the post--translational enzymatic processing of the 185 amino acid-preproAM molecule (K. Kitamura, et al., Biochem.
Biophys. Res. Commun. 192, 553 (1993); K. Kitamura, et al., Biochem. Biophys. Res. Commun. 194, 720 (1993);
Kitamura, et al. FEBS Lett. 351, 35-37 (1994)).
The complete genomic infrastructure for human AM
has recently been reported (Ishimitsu, et al., Biochem Biophys Res Commun 203:631-639 (1994)). The porcine (Kitamura, et al., FEES Lett 338:306-310 (1994)) and rat (Sakata, et al., Biochem Biophys Res Commun 195:921-927 (1993)) AM complementary DNAs have also been cloned/sequenced and demonstrate high homology to the human counterpart. Human cDNA of AM has been cloned and mRNA expression identified in the adrenal glands, lung, kidney, and heart (K. Kitamura, et al., Biochem. Biophys.
Res. Commun. 194, 720 (1993)). A high degree of base sequence homology has been found between AM mRNAs isolated from other mammalian species, including rat and porcine (J. Sakata, et al., Biochem. Biophys. Res. Commun. 195, 921 (1993); and K. Kitamura, et al., FEBS Lett. 338, 306 (1994)).
Data from several publications have demonstrated a wide range of tissues that express AN. Using RIA and Northern blot techniques, high levels of AM have been found in human plasma, adrenal medulla, heart atrium, lung, and kidney (Kitamura, et al., Biochem Biophys Res Commun 194:720-725 (1993); Kitamura, et al., FEES Lett 341:288-290 (1994)), but, to date, the cell source of AM
in these organs has not been identified.
Although both AM and PAMP are amidated peptides, they have been shown to mediate their vasodilatory effects through distinctly different receptor systems (T.
Shimosawa, et al., J. Clin. Invest. 96, 1672 (1995)). AM
stimulates adenyl cyclase activity, which elevates cAMP
levels in smooth muscle cells. AM is structurally related to calcitonin gene-related peptide (CGRP), and its vasodilatory effect is inhibited by the CGRP antagonist, CGRP8_37 (Y. Ishiyama, et al., Eur. J. Pharmacol. 241, 271 (1993); Ishizaka, et al., Biochem. Biophys. Res. Commun.
200, 642 (1994); J. A. Santago, et al., Life Sci. 55, 85 (1994); D. Y. Cheng, et al., Life Sci. 55, 251 (1994); H.
Lippton, et al., J. Apt)l. Physiol. 76, 2154 (1994); Y.
Shimekake, et al., J. Biol. Chem. 270, 4412 (1995)).
Conversely, the fact that PAMP has no amino acid sequence homology to CGRP and its biological effects are not blocked by CGRP8-37 suggests the involvement of a separate receptor system (T. Shimosawa, et al., J. Clin. Invest.
96, 1672 (1995)). AM has also been implicated as an important regulator of renal function having natriuretic and diuretic action (T. Ebara, et al., Eur. J. Pharmacol.
263, 69 (1994); M. Jougasaki, et al., Amer. J. Physiol.
37, F657 (1995)). AM is also reported to be a potent bronchodilator, a regulator of certain central brain actions (vasopressor and antidipsogenic peptide), and a suppressor of aldosterone and adrenocorticotropin release (H. Kanazawa, et al., Biochem. Biophvs. Res. Commun. 205, 251 (1994); H. Takahashi, et al., Am. J. Hypertens. 7, 478 , f (1994); T. A. Murphy and W. K. Samson, Endocrinology 136, 2459 (1995); T. Yamaguchi, K. Baba, Y. Doi, K. Yano, Life Sci. 56, 379 (1995); W. K. Samson, T. Murphy, D. A.
Schell, Endocrinology 136, 2349 (1995)). Finally, AM has been shown to be expressed in a variety of human tumors of both neural and pulmonary lineage including ganglioblastoma/neuroblastoma (F. Satoh, et al., J. Clin.
Endocrinol. Metabol. 80, 1750 (1995)), small cell lung cancer, adenocarcinoma, bronchoalveolar carcinoma, squamous cell carcinoma, and. lung carcinoids (Martinez, et al., Endocrinology 136, 4099 (1995)). In an attempt to further study the distribution of AM in human tumors and determine its role in these malignant disorders, we used molecular, biochemical and in vitro techniques to analyze 59 human cancer cell lines from solid tumors and hemopoietic lineage.
AM's role as a vasodilatory agent has been extensively studied (C. Nuki et al., Biochem. Biophys.
Res. Commun. 196, 245 (1993); Q. Hao et al., Life Sci.
54, 265 (1994) ; D. Y. Cheng et al. , Life Sci. , 55, 251 (1994); C. J. Feng, B. Kang, A. D. Kaye, P. J. Kadowitz, B. D. Nossaman, Life Sci., 433 (1994)). It acts through specific receptors in the plasma membrane to activate adenylate cyclase activity and modulate Ca2+ flux in the target cells (S. Eguchi et al., Endocrinology 135, 2454 (1994); Y. Shimekake et al., J. Biol. Chem. 270, 4412 (1995)). These signal transduction pathways are involved in numerous physiological processes, including the regulation of hormone secretion. It is well established that regulation of intracellular cAMP modulates hormone release in the pancreas (Y. Korman, S. J. Bhathena, N. R.
Voyles, H. K. Oie, L. Recant, Diabetes 34, 717 (1985); C.
B. Woliheim, Diabetes 29, 74 (1980)). AM has also been reported to have an effect on Na+ channel activity (EP
Application No. 0 622 458 A2). Since AM has been reported to influence the. _se Cj --Elon rate of several hormones, including catecholamine (F. Kato et al., J.
), ~ to Neurochem. 64, 459 (1995); EP Application No. 0 622 458 A2), adrezocorticotropin (W. K.
in these organs has not been identified.
Although both AM and PAMP are amidated peptides, they have been shown to mediate their vasodilatory effects through distinctly different receptor systems (T.
Shimosawa, et al., J. Clin. Invest. 96, 1672 (1995)). AM
stimulates adenyl cyclase activity, which elevates cAMP
levels in smooth muscle cells. AM is structurally related to calcitonin gene-related peptide (CGRP), and its vasodilatory effect is inhibited by the CGRP antagonist, CGRP8_37 (Y. Ishiyama, et al., Eur. J. Pharmacol. 241, 271 (1993); Ishizaka, et al., Biochem. Biophys. Res. Commun.
200, 642 (1994); J. A. Santago, et al., Life Sci. 55, 85 (1994); D. Y. Cheng, et al., Life Sci. 55, 251 (1994); H.
Lippton, et al., J. Apt)l. Physiol. 76, 2154 (1994); Y.
Shimekake, et al., J. Biol. Chem. 270, 4412 (1995)).
Conversely, the fact that PAMP has no amino acid sequence homology to CGRP and its biological effects are not blocked by CGRP8-37 suggests the involvement of a separate receptor system (T. Shimosawa, et al., J. Clin. Invest.
96, 1672 (1995)). AM has also been implicated as an important regulator of renal function having natriuretic and diuretic action (T. Ebara, et al., Eur. J. Pharmacol.
263, 69 (1994); M. Jougasaki, et al., Amer. J. Physiol.
37, F657 (1995)). AM is also reported to be a potent bronchodilator, a regulator of certain central brain actions (vasopressor and antidipsogenic peptide), and a suppressor of aldosterone and adrenocorticotropin release (H. Kanazawa, et al., Biochem. Biophvs. Res. Commun. 205, 251 (1994); H. Takahashi, et al., Am. J. Hypertens. 7, 478 , f (1994); T. A. Murphy and W. K. Samson, Endocrinology 136, 2459 (1995); T. Yamaguchi, K. Baba, Y. Doi, K. Yano, Life Sci. 56, 379 (1995); W. K. Samson, T. Murphy, D. A.
Schell, Endocrinology 136, 2349 (1995)). Finally, AM has been shown to be expressed in a variety of human tumors of both neural and pulmonary lineage including ganglioblastoma/neuroblastoma (F. Satoh, et al., J. Clin.
Endocrinol. Metabol. 80, 1750 (1995)), small cell lung cancer, adenocarcinoma, bronchoalveolar carcinoma, squamous cell carcinoma, and. lung carcinoids (Martinez, et al., Endocrinology 136, 4099 (1995)). In an attempt to further study the distribution of AM in human tumors and determine its role in these malignant disorders, we used molecular, biochemical and in vitro techniques to analyze 59 human cancer cell lines from solid tumors and hemopoietic lineage.
AM's role as a vasodilatory agent has been extensively studied (C. Nuki et al., Biochem. Biophys.
Res. Commun. 196, 245 (1993); Q. Hao et al., Life Sci.
54, 265 (1994) ; D. Y. Cheng et al. , Life Sci. , 55, 251 (1994); C. J. Feng, B. Kang, A. D. Kaye, P. J. Kadowitz, B. D. Nossaman, Life Sci., 433 (1994)). It acts through specific receptors in the plasma membrane to activate adenylate cyclase activity and modulate Ca2+ flux in the target cells (S. Eguchi et al., Endocrinology 135, 2454 (1994); Y. Shimekake et al., J. Biol. Chem. 270, 4412 (1995)). These signal transduction pathways are involved in numerous physiological processes, including the regulation of hormone secretion. It is well established that regulation of intracellular cAMP modulates hormone release in the pancreas (Y. Korman, S. J. Bhathena, N. R.
Voyles, H. K. Oie, L. Recant, Diabetes 34, 717 (1985); C.
B. Woliheim, Diabetes 29, 74 (1980)). AM has also been reported to have an effect on Na+ channel activity (EP
Application No. 0 622 458 A2). Since AM has been reported to influence the. _se Cj --Elon rate of several hormones, including catecholamine (F. Kato et al., J.
), ~ to Neurochem. 64, 459 (1995); EP Application No. 0 622 458 A2), adrezocorticotropin (W. K.
Samson, T. Murphy, D. A. Schell, Endocrinology 136, 2349 (1995)), and aldosterone (T. Yamaguchi, K. Baba, Y. Doi, K. Yano, Life Sci. 56, 379 (1995)), we investigated the potential role of AM in regulating endocrine physiology of the pancreas.
Accordingly, due to the numerous therapeutic and diagnostic applications of AM peptides, there is an enormous medical and health requirement for potent, stable and selective AM peptides for therapeutic uses in the prevention, diagnosis, and treatment of AM related disease and conditions.
SUMMARY OF THE INVENTION
The present invention provides novel adrenomedullin (AM) peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions.
In addition, the present invention provides methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the novel AM peptides and antibodies. In particular, the therapeutic, diagnostic and preventative objects of the invention are described below.
It is an object of the present invention to provide methods for the prevention and treatment of cancers, in particular, adrenal, nervous system, lung, colon, ovarian, and breast cancers, by contacting the cancerous cells with an effective amount of AM peptides or antibodies of the present invention to inhibit the growth of cells. The AM peptides and antibodies of the present invention may also be used for the treatment of chondrosarcoma.
A further object of this invention is to provide AM peptides and antibodies for use as generic targets for intervention strategies to disrupt neoplastic transformation.
4a Specific aspects of the invention include:
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), in the manufacture of a medicament for use in treating a patient suffering from a cancer or tumor;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), for the treatment of a patient suffering from a cancer or tumor;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3), for use in the treatment of a patient suffering from a cancer or tumor;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), in the manufacture of a medicament for use in prevention or treatment of a patient suffering from type II diabetes, wherein said medicament is effective to regulate insulin secretion and blood glucose metabolism;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) for treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID NO:
3) for use in treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) for diagnosis of preeclampsia or diabetes;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3) for use in diagnosis of preeclampsia or diabetes;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), in the manufacture of a medicament for regulating neuronal activity in areas of the central nervous system;
4b - use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), for regulating neuronal activity in areas of the central nervous system;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3), for use in regulating neuronal activity in areas of the central nervous system;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) in the manufacture of a medicament for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said medicament is effective to lessen or inhibit the degranulation of mast cells;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3) for use in regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells;
- a pharmaceutical composition comprising an antibody reactive with adrenomedullin peptide P072 (SEQ ID NO: 3) and a pharmaceutically acceptable excipient;
- use of isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) in the manufacture of a medicament for treatment of a bacterial infection in a subject, wherein said medicament is effective to inhibit or prevent bacterial growth;
- use of isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) for treatment of a bacterial infection in a subject, wherein said peptide is effective to inhibit or prevent bacterial growth;
4c - an isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) for use in treatment of a bacterial infection in a subject, wherein said peptide is effective to inhibit or prevent bacterial growth; and - an isolated adrenomedullin oligonucleotide, wherein the oligonucleotide is AM94-114 (SEQ ID NO: 4), AM444-464 (SEQ ID NO: 5) or AM289-309 (SEQ ID NO: 6).
Accordingly, due to the numerous therapeutic and diagnostic applications of AM peptides, there is an enormous medical and health requirement for potent, stable and selective AM peptides for therapeutic uses in the prevention, diagnosis, and treatment of AM related disease and conditions.
SUMMARY OF THE INVENTION
The present invention provides novel adrenomedullin (AM) peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions.
In addition, the present invention provides methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the novel AM peptides and antibodies. In particular, the therapeutic, diagnostic and preventative objects of the invention are described below.
It is an object of the present invention to provide methods for the prevention and treatment of cancers, in particular, adrenal, nervous system, lung, colon, ovarian, and breast cancers, by contacting the cancerous cells with an effective amount of AM peptides or antibodies of the present invention to inhibit the growth of cells. The AM peptides and antibodies of the present invention may also be used for the treatment of chondrosarcoma.
A further object of this invention is to provide AM peptides and antibodies for use as generic targets for intervention strategies to disrupt neoplastic transformation.
4a Specific aspects of the invention include:
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), in the manufacture of a medicament for use in treating a patient suffering from a cancer or tumor;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), for the treatment of a patient suffering from a cancer or tumor;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3), for use in the treatment of a patient suffering from a cancer or tumor;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), in the manufacture of a medicament for use in prevention or treatment of a patient suffering from type II diabetes, wherein said medicament is effective to regulate insulin secretion and blood glucose metabolism;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) for treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID NO:
3) for use in treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) for diagnosis of preeclampsia or diabetes;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3) for use in diagnosis of preeclampsia or diabetes;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), in the manufacture of a medicament for regulating neuronal activity in areas of the central nervous system;
4b - use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3), for regulating neuronal activity in areas of the central nervous system;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3), for use in regulating neuronal activity in areas of the central nervous system;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) in the manufacture of a medicament for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said medicament is effective to lessen or inhibit the degranulation of mast cells;
- use of an antibody reactive with adrenomedullin peptide P072 (SEQ
ID NO: 3) for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells;
- an antibody reactive with adrenomedullin peptide P072 (SEQ ID
NO: 3) for use in regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells;
- a pharmaceutical composition comprising an antibody reactive with adrenomedullin peptide P072 (SEQ ID NO: 3) and a pharmaceutically acceptable excipient;
- use of isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) in the manufacture of a medicament for treatment of a bacterial infection in a subject, wherein said medicament is effective to inhibit or prevent bacterial growth;
- use of isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) for treatment of a bacterial infection in a subject, wherein said peptide is effective to inhibit or prevent bacterial growth;
4c - an isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) for use in treatment of a bacterial infection in a subject, wherein said peptide is effective to inhibit or prevent bacterial growth; and - an isolated adrenomedullin oligonucleotide, wherein the oligonucleotide is AM94-114 (SEQ ID NO: 4), AM444-464 (SEQ ID NO: 5) or AM289-309 (SEQ ID NO: 6).
It is also an object of this invention to provide methods for diagnosing or monitoring diseases by measuring the levels of AM in a sample, wherein the presence or absence of AM indicates the existence of, or predisposition to, a disease. Examples of diseases which may be diagnosed or monitored by the methods of the present invention include, but are not limited to, diabetes, renal diseases, such as severe uremia; bone diseases, such as neoplastic disease; skin diseases; and blood related diseases, such as leukemia.
Another object of the present invention is to provide a method of preventing or treating type II
diabetes using the peptides and antibodies of the present invention. Specifically, the AM peptides and antibodies of the present invention may be used to regulate insulin secretion and blood glucose metabolism.
Another object of the present invention is to provide AM peptides and antibodies for use in conditions related to pregnancy. In particular, a method for diagnosis and treatment of preeclampsia utilizing the AM
peptides and antibodies of this invention is described.
Further, AM peptides and antibodies may be used to promote fetal growth.
An additional object of the present invention is to provide methods of regulating activity in areas of the central nervous system by administering to a subject an effective amount of AM peptides or antibodies for the regulation of neurotransmission or neuron growth. A non-limiting example of a disease affecting the regulation of neurotransmission or neuron growth that may be treated by the AM peptides and antibodies of the present invention is Alzheimer's disease.
= It is also an object of the present invention to provide a method of lessening or inhibiting the allergic response due to the degranulation of mast cells by administering antibodies to AM in an amount effective to lessen or inhibit the degranulation of mast cells.
It is also an object of the present invention to provide a method of treating bacterial and fungal infections by administering to a subject an amount of the novel peptides of the present invention effective to inhibit bacterial or fungal growth or prevent the infection.
Another object of the present invention is to provide a method of facilitating the healing of chaffed skin, skin lesions, wound repair, and surgical incisions by applying to the surface of the skin of a subject an amount of one or more of the novel AM peptides of the present invention effective to facilitate healing.
An additional object of the present invention is to provide means of promoting organ and bone development using the AM peptides and antibodies of the claimed invention.
The present invention further provides for pharmaceutical compositions comprising the novel AM
peptides and antibodies of the present invention, and for pharmacological, therapeutic and diagnostic uses for the novel AM peptides and antibodies and pharmacological compositions comprising the same.
These and other objects of the present invention will become apparent in light of the accompanying disclosure and annexed figures.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Figure 1 sets forth a schematic drawing showing the structures of the human AM gene, mRNA, and preprohormone containing the two biologically active molecules, AM and pro-AM peptide (PAMP). The positions of the oligonucleotides and peptides synthesized are shown.
Numbers in the gene and mRNA indicate base pairs from the initiation codon. Numbers in the protein correspond to 0 amino acids. Data are modified from the report of Ishimitsu, et al., Biochem Biophys Res Commun 203:631-639 (1994).
Figure 2: Figure 2 sets forth a titration curve for rabbit anti-P072 immunogen (bleed 2343) binding to solid phase test peptides. A measurable antibody interaction was observed in AM, P072, P071, NPY, and CGRP. All other target peptides (P070, gastrin-releasing peptide, glucagon-like peptide 1, vasoactive intestinal peptide, arginine vasopressin, GRF, cholecystokinin, gastrin, oxytocin, calcitonin, aMSH, and BSA) showed negligible binding.
Figure 3: Detection of AM-like immunoreactive species in the whole cell lysate of a human lung carcinoid cell line, NCI-H720. The right lane contains 2 ng synthetic P072 (molecular weight, 3576). The specificity of detection is demonstrated by antigen absorption of anti-P072 antiserum (right panel).
Figures 4A, 4B, 4C, and 4D: Figures 4A-4D set forth a cross-section (magnification x450) of a bronchiolus showing immunoreactivity to the anti-AM antiserum in the epithelium (Figure 4A) and labeling of the AM mRNA after in situ RT-PCR (Figure 4C). Absorption controls (Figure 4B) and omission of the RT (Figure 4D) confirmed the specificity of the staining.
Figures 5A, 5B, 5C, and 5D: Figures 5A-5D set forth photographs of a section through the adventitia layer of a bronchus showing a small nervous ganglion where the perykaria of the neurons and some nerves are immunostained (Figure 5A), whereas a serial section treated with preabsorbed antiserum was negative (Figure 5B).
(Magnification x450). Another ganglion appears labeled, at lower magnification (x120), after application of the in situ RT-PCR technique (Figure 5C). Arrows point to blood vessels whose endothelial layers are clearly positive. Omission of primers in the PCR mixture gave negative staining (Figure 5D).
Figures 6A and 6B: Figure 6A and 6B set forth photographs of the detail of chondrocytes immunostained with anti-AM (Figure 6A) and with the antiserum preabsorbed with P072 (Figure 6B). (Magnification x700).
Figure 7A and 7B: Figures 7A and 7B set forth photographs of alveolar macrophages labeled for AM mRNA
after in situ RT-PCR (Figure 7A) and negative control without reverse transcriptase (Figure 7B).
(Magnification x450).
Figure 8A and 8B: Characterization of AM by RT-PCR in mRNA from normal tissues and pulmonary tumor cell lines.
The PCR products had the proper size (410bp) when visualized with UV light (Figure 8B), and they hybridized with the specific probe after Southern blot (Figure 8A).
H146 and H345 are small cell carcinomas, H676 is an adenocarcinoma, H720 is a carcinoid, and H820 is a bronchioalveolar carcinoma. H146 was the only cell line that tested negative for AM.
Figures 9A and 9B: Figures 9A and 9B set forth photographs of cell line H820 (bronchioalveolar carcinoma) showing a cytoplasmic distribution of AM mRNA, as revealed by in situ RT-PCR (Figure 9A), and a serial section demonstrating that the staining disappears when the reverse transcription step is omitted (Figure 9B).
(Magnification x550) Figures 10A and lOB: Figures lOA and lOB set forth photographs of serial sections of an adenocarcinoma showing AM mRNA in the tumor cells by in situ RT-PCR
(Figure 10A) and immunocytochemistry (Figure 10B).
(Magnification x550) Figure 11: Figure 11 sets forth a chart indicating histamine release from rat mast cells.
Figures 12A and 12B: Figures 12A and 12B indicate the effect of anti-AM MoAb on the growth of human tumor cell lines.
Figure 13: Figure 13 sets forth a characterization of the monoclonal antibody MoAb-G6 showing binding to AM (o) and to two P072 molecules: an in-house peptide (0) and a Peninsula peptide product (0). All other peptides: P070, GRP, GLP1, VIP, AVP, GRF, CCK, amylin, gastrin, oxytocin, aMSH, pancreatic P oiypep-tide-, peptide YY, Taa-HoTH
(Tabanus atratus Hypotrehalosemic Hormone), and BSA, showed negligible binding. Solid-phase assays were conducted using previously described methods (Cuttitta, et al., Nature 316, 823 (1985)).
Figures 14A, 14B, 14C and 14D: Figures 14A and 14B show a representative sample of human tumor cell lines (H157, H720, MCF-7, OVCAR-3, SNUC-1) and normal human tissues (brain, lung, heart, adrenal) screened for AM mRNA and its translated protein. Figure 14A is a Southern. blot analysis and Figure 14B is the ethidium bromide 1%- agarose gel which demonstrates the predicted 410 bp product for AM
mRNA as evaluated by RT-PCR analysis. Figure 14C sets forth a Western blot analysis showing immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM.
Figures 15A, 15B and 15C: Figures 15A-15C set forth an HPLC profile, solid phase plate assay and Western blot analysis of H720 conditioned medium (CM). Figure 15A
illustrates the fractionation of 5 L of H720 CM compared with the elution time of synthetic AM at 89.4 min (arrow).
Figures 16A, 16B, 16C and 16D: A representative human tumor cell line, MCF-7, was used to show the growth effects, cAMP activity and receptor binding by AM under serumfree, hormone-free conditions. Figure 16A shows the inhibitory effects of MoAb-G6 (s) compared with no effect from its mouse myeloma isotypic control, IgAic (Sigma)(0).
Figure 16B shows that the effects of MoAb-G6 were overcome by the addition of synthetic AM (0) compared with the addition of AM alone (s). Figure 16C indicates that cyclic AMP is activated with the addition of synthetic AM.
Figure 16D shows that specific receptor binding is higher for AM (0) than for PAMP (0) or P072 (s). MTT (Carney, et al., Proc. Natl. Acad Sci. U.S.A. 79, 3185 (1981)) and receptor binding/cAMP assay techniques (T. W. Moody, et al., Proc. Natl. Acad. Sci U.S.A. 90, 4345 (1993)) are described elsewhere.
Figures 17A-17H: Figures 17A-17H set forth the distribution of adrenomedullin (AM) in the pancreas as shown by immunocytochemistry.
Figures 18A and 18B: Effects of AM and MoAb-G6 (a-AM) on the release of insulin from rat isolated islets. (Figure 18A) Increasing concentration of AM reduces insulin secretion in the presence (0) or absence (s) of MoAb-G6 antibody. Note dramatic increase in insulin secretion mediated by the antibody. (Figure 18B) Figures 19A and 19B: Figure 19A shows a Southern blot for AM in six cell lines expressing insulin and in human adrenal and pancreas mRNA. Figure 19B shows the same gel as seen by W before transfer.
Another object of the present invention is to provide a method of preventing or treating type II
diabetes using the peptides and antibodies of the present invention. Specifically, the AM peptides and antibodies of the present invention may be used to regulate insulin secretion and blood glucose metabolism.
Another object of the present invention is to provide AM peptides and antibodies for use in conditions related to pregnancy. In particular, a method for diagnosis and treatment of preeclampsia utilizing the AM
peptides and antibodies of this invention is described.
Further, AM peptides and antibodies may be used to promote fetal growth.
An additional object of the present invention is to provide methods of regulating activity in areas of the central nervous system by administering to a subject an effective amount of AM peptides or antibodies for the regulation of neurotransmission or neuron growth. A non-limiting example of a disease affecting the regulation of neurotransmission or neuron growth that may be treated by the AM peptides and antibodies of the present invention is Alzheimer's disease.
= It is also an object of the present invention to provide a method of lessening or inhibiting the allergic response due to the degranulation of mast cells by administering antibodies to AM in an amount effective to lessen or inhibit the degranulation of mast cells.
It is also an object of the present invention to provide a method of treating bacterial and fungal infections by administering to a subject an amount of the novel peptides of the present invention effective to inhibit bacterial or fungal growth or prevent the infection.
Another object of the present invention is to provide a method of facilitating the healing of chaffed skin, skin lesions, wound repair, and surgical incisions by applying to the surface of the skin of a subject an amount of one or more of the novel AM peptides of the present invention effective to facilitate healing.
An additional object of the present invention is to provide means of promoting organ and bone development using the AM peptides and antibodies of the claimed invention.
The present invention further provides for pharmaceutical compositions comprising the novel AM
peptides and antibodies of the present invention, and for pharmacological, therapeutic and diagnostic uses for the novel AM peptides and antibodies and pharmacological compositions comprising the same.
These and other objects of the present invention will become apparent in light of the accompanying disclosure and annexed figures.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Figure 1 sets forth a schematic drawing showing the structures of the human AM gene, mRNA, and preprohormone containing the two biologically active molecules, AM and pro-AM peptide (PAMP). The positions of the oligonucleotides and peptides synthesized are shown.
Numbers in the gene and mRNA indicate base pairs from the initiation codon. Numbers in the protein correspond to 0 amino acids. Data are modified from the report of Ishimitsu, et al., Biochem Biophys Res Commun 203:631-639 (1994).
Figure 2: Figure 2 sets forth a titration curve for rabbit anti-P072 immunogen (bleed 2343) binding to solid phase test peptides. A measurable antibody interaction was observed in AM, P072, P071, NPY, and CGRP. All other target peptides (P070, gastrin-releasing peptide, glucagon-like peptide 1, vasoactive intestinal peptide, arginine vasopressin, GRF, cholecystokinin, gastrin, oxytocin, calcitonin, aMSH, and BSA) showed negligible binding.
Figure 3: Detection of AM-like immunoreactive species in the whole cell lysate of a human lung carcinoid cell line, NCI-H720. The right lane contains 2 ng synthetic P072 (molecular weight, 3576). The specificity of detection is demonstrated by antigen absorption of anti-P072 antiserum (right panel).
Figures 4A, 4B, 4C, and 4D: Figures 4A-4D set forth a cross-section (magnification x450) of a bronchiolus showing immunoreactivity to the anti-AM antiserum in the epithelium (Figure 4A) and labeling of the AM mRNA after in situ RT-PCR (Figure 4C). Absorption controls (Figure 4B) and omission of the RT (Figure 4D) confirmed the specificity of the staining.
Figures 5A, 5B, 5C, and 5D: Figures 5A-5D set forth photographs of a section through the adventitia layer of a bronchus showing a small nervous ganglion where the perykaria of the neurons and some nerves are immunostained (Figure 5A), whereas a serial section treated with preabsorbed antiserum was negative (Figure 5B).
(Magnification x450). Another ganglion appears labeled, at lower magnification (x120), after application of the in situ RT-PCR technique (Figure 5C). Arrows point to blood vessels whose endothelial layers are clearly positive. Omission of primers in the PCR mixture gave negative staining (Figure 5D).
Figures 6A and 6B: Figure 6A and 6B set forth photographs of the detail of chondrocytes immunostained with anti-AM (Figure 6A) and with the antiserum preabsorbed with P072 (Figure 6B). (Magnification x700).
Figure 7A and 7B: Figures 7A and 7B set forth photographs of alveolar macrophages labeled for AM mRNA
after in situ RT-PCR (Figure 7A) and negative control without reverse transcriptase (Figure 7B).
(Magnification x450).
Figure 8A and 8B: Characterization of AM by RT-PCR in mRNA from normal tissues and pulmonary tumor cell lines.
The PCR products had the proper size (410bp) when visualized with UV light (Figure 8B), and they hybridized with the specific probe after Southern blot (Figure 8A).
H146 and H345 are small cell carcinomas, H676 is an adenocarcinoma, H720 is a carcinoid, and H820 is a bronchioalveolar carcinoma. H146 was the only cell line that tested negative for AM.
Figures 9A and 9B: Figures 9A and 9B set forth photographs of cell line H820 (bronchioalveolar carcinoma) showing a cytoplasmic distribution of AM mRNA, as revealed by in situ RT-PCR (Figure 9A), and a serial section demonstrating that the staining disappears when the reverse transcription step is omitted (Figure 9B).
(Magnification x550) Figures 10A and lOB: Figures lOA and lOB set forth photographs of serial sections of an adenocarcinoma showing AM mRNA in the tumor cells by in situ RT-PCR
(Figure 10A) and immunocytochemistry (Figure 10B).
(Magnification x550) Figure 11: Figure 11 sets forth a chart indicating histamine release from rat mast cells.
Figures 12A and 12B: Figures 12A and 12B indicate the effect of anti-AM MoAb on the growth of human tumor cell lines.
Figure 13: Figure 13 sets forth a characterization of the monoclonal antibody MoAb-G6 showing binding to AM (o) and to two P072 molecules: an in-house peptide (0) and a Peninsula peptide product (0). All other peptides: P070, GRP, GLP1, VIP, AVP, GRF, CCK, amylin, gastrin, oxytocin, aMSH, pancreatic P oiypep-tide-, peptide YY, Taa-HoTH
(Tabanus atratus Hypotrehalosemic Hormone), and BSA, showed negligible binding. Solid-phase assays were conducted using previously described methods (Cuttitta, et al., Nature 316, 823 (1985)).
Figures 14A, 14B, 14C and 14D: Figures 14A and 14B show a representative sample of human tumor cell lines (H157, H720, MCF-7, OVCAR-3, SNUC-1) and normal human tissues (brain, lung, heart, adrenal) screened for AM mRNA and its translated protein. Figure 14A is a Southern. blot analysis and Figure 14B is the ethidium bromide 1%- agarose gel which demonstrates the predicted 410 bp product for AM
mRNA as evaluated by RT-PCR analysis. Figure 14C sets forth a Western blot analysis showing immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM.
Figures 15A, 15B and 15C: Figures 15A-15C set forth an HPLC profile, solid phase plate assay and Western blot analysis of H720 conditioned medium (CM). Figure 15A
illustrates the fractionation of 5 L of H720 CM compared with the elution time of synthetic AM at 89.4 min (arrow).
Figures 16A, 16B, 16C and 16D: A representative human tumor cell line, MCF-7, was used to show the growth effects, cAMP activity and receptor binding by AM under serumfree, hormone-free conditions. Figure 16A shows the inhibitory effects of MoAb-G6 (s) compared with no effect from its mouse myeloma isotypic control, IgAic (Sigma)(0).
Figure 16B shows that the effects of MoAb-G6 were overcome by the addition of synthetic AM (0) compared with the addition of AM alone (s). Figure 16C indicates that cyclic AMP is activated with the addition of synthetic AM.
Figure 16D shows that specific receptor binding is higher for AM (0) than for PAMP (0) or P072 (s). MTT (Carney, et al., Proc. Natl. Acad Sci. U.S.A. 79, 3185 (1981)) and receptor binding/cAMP assay techniques (T. W. Moody, et al., Proc. Natl. Acad. Sci U.S.A. 90, 4345 (1993)) are described elsewhere.
Figures 17A-17H: Figures 17A-17H set forth the distribution of adrenomedullin (AM) in the pancreas as shown by immunocytochemistry.
Figures 18A and 18B: Effects of AM and MoAb-G6 (a-AM) on the release of insulin from rat isolated islets. (Figure 18A) Increasing concentration of AM reduces insulin secretion in the presence (0) or absence (s) of MoAb-G6 antibody. Note dramatic increase in insulin secretion mediated by the antibody. (Figure 18B) Figures 19A and 19B: Figure 19A shows a Southern blot for AM in six cell lines expressing insulin and in human adrenal and pancreas mRNA. Figure 19B shows the same gel as seen by W before transfer.
Figures 20A and 20B: Glucose tolerance tests were performed on Sprague-Dawley rats (250 to 300 g) in the presence (0) or absence (=) of AM.
Figures 21A-21I: Figure 21 sets forth in panels A-I the localization of AM mRNA and immunoreactivity in various organs of different species. Panel A shows mRNA for AM
detected by in situ RT-PCR in the epithelial cells of the rat trachea. Panel B sets forth guinea pig trachea displaying a strong immunoreactivity to the AM antibody, specially in the apical region. Panel C depicts a Xenopus respiratory tract, with intense immunostaining in the supranuclear region. Panel D shows Xenopus integument with AM immunoreactivity concentrated in the unicellular glands of the epidermis (two of which appear in this figure). The dark spot to the left is a chromatophore.
Panel E shows skin of a 16-day old mouse embryo. An intense immunoreactivity to AM is observed in the epidermis and in the subjacent developing muscles. Panel F sets forth a hamster uterus showing immunostaining for AM in both the lining epithelium and the glands. Panel G
shows a small salivary gland found in the hamster tongue.
Discrete secretory cells store the AM-like material.
Panel H shows rat duodenum with intensely immunostained Brunner's glands. Panel I shows a section of cat colon containing an AM-positive endocrine cell.
Figure 22: Figure 22 indicates the effect of AM and PAMP
on the inhibition of growth of E. coli. AM demonstrated higher growth inhibitory activity than albumin (Alb) (negative control) (*, p=0.03), P070 ( , p=0.04), P071 ( , p=0.006), and P072 ( , p=0.03). Magainin (M) exerted greater inhibitory activity against E. coli than did AM (*
t, p=0.03) and PAMP ( t, p=0.009). Data were compiled from 14 experiments.
Figures 21A-21I: Figure 21 sets forth in panels A-I the localization of AM mRNA and immunoreactivity in various organs of different species. Panel A shows mRNA for AM
detected by in situ RT-PCR in the epithelial cells of the rat trachea. Panel B sets forth guinea pig trachea displaying a strong immunoreactivity to the AM antibody, specially in the apical region. Panel C depicts a Xenopus respiratory tract, with intense immunostaining in the supranuclear region. Panel D shows Xenopus integument with AM immunoreactivity concentrated in the unicellular glands of the epidermis (two of which appear in this figure). The dark spot to the left is a chromatophore.
Panel E shows skin of a 16-day old mouse embryo. An intense immunoreactivity to AM is observed in the epidermis and in the subjacent developing muscles. Panel F sets forth a hamster uterus showing immunostaining for AM in both the lining epithelium and the glands. Panel G
shows a small salivary gland found in the hamster tongue.
Discrete secretory cells store the AM-like material.
Panel H shows rat duodenum with intensely immunostained Brunner's glands. Panel I shows a section of cat colon containing an AM-positive endocrine cell.
Figure 22: Figure 22 indicates the effect of AM and PAMP
on the inhibition of growth of E. coli. AM demonstrated higher growth inhibitory activity than albumin (Alb) (negative control) (*, p=0.03), P070 ( , p=0.04), P071 ( , p=0.006), and P072 ( , p=0.03). Magainin (M) exerted greater inhibitory activity against E. coli than did AM (*
t, p=0.03) and PAMP ( t, p=0.009). Data were compiled from 14 experiments.
Figures 23A and 23B: Figures 23A and 23B set forth the antimicrobial activity of AM and PAMP.
Figure 24: Figure 24 indicates the effect of AM on the germination of C. albicans.
Figures 25A and 25B: Figures 25A and 25B set forth the distribution of amphipathic regions for AM and=PAMP
as calculated for a-helix/b-sheet angle parameters (Eisenberg), and the helical wheel projection display for AM and PAMP (DNASTAR).
Figures 26A-26D: Figure 26 sets forth a representative sample of human tumor cell lines and normal human tissues screened for AM and AM-R. Southern blot analysis demonstrates the predicted 410 bp product for AM (A) and a 471 bp product for AM-R mRNA (B) after RT-PCR
amplification. (C) Western blot analysis of cell extracts shows immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM. In addition, there is a 22 kDa immunoreactive entity that may be attributed to post-translational processing. (D) The absorption control was negative.
Figures 27A-27D: Figure 27 sets forth the immunohistochemical and in situ RT-PCR analysis of human cancer cell lines for AN. (A) Immunohistochemical analysis for AM in SCLC H774 and (B) ovarian carcinoma cell line NIH: Ovcar-3. Note the peripheral distribution of AM immunoreactivity in H774 colonies. (C) In situ RT-PCR for AM mRNA in carcinoid cell line H720 and (D) negative control in a serial section where primers were substituted by water in the PCR mixture.
Figures 28A and 28B: Figure 28 sets forth the growth effects of AM. A representative human tumor cell line, MCF-7, was used to show the growth effects, receptor binding and cAMP variation by AM under serum-free, hormone-free conditions. (A) Inhibitory effects of MoAb-G6 (0) compared with no effect from its mouse myeloma isotypic control, IgAK (0). (B) Effects of MoAb-G6 were overcome by the addition of synthetic AM (0) compared with the addition of AM alone (4). (C) Specific receptor binding is measurable for AM (0) while it is negligible for PAMP (i) or P072 (0). (D) Cyclic AMP is increased with the addition of synthetic AM in a dose-dependent manner.
DETAILED DESCRIPTION OF THE INVENTION
The present invention generally provides novel adrenomedullin (AM) peptides and AM antibodies, pharmaceutical compositions comprising said peptides and antibodies, and their use as pharmaceutically active agents.
Specifically, the present invention relates to the following novel isolated AM peptides and oligonucleotide sequences:
P070 (YY-PreproAM3440 ) Y-Y-W-N-K-W-A-L-S-R-NH, (SEQ. ID. NO. 1) P071 (YGG-PreproAM132,f31) Y-G-G-H-Q-I-Y-Q-F-T-D-K-D-NH, (SEQ. ID. NO. 2) P072 (PreproAMli6.,,6) T-V-Q-K-L-A-H-Q-I-Y-Q-F-T-D-K-D-K-D-N-V-A-P-R-S-K-I-S-P-Q-G-Y-NH, (SEQ. ID. NO. 3) Sense primer (AM 94-114) 5'-AAG-AAG-TGG-AAT-AAG-TGG-GCT-3' (SEQ. ID. NO. 4) Antisense primer (AM 444-464) 5'-TGG-CTT-AGA-AGA-CAC-CAG-AGT-3' (SEQ. ID. NO. 5) Antisense probe (AM 289-309) 5'-CTG-GAA-GTT-GTT-CAT-GCT-CTG-3' (SEQ. ID. NO. 6) Proadrenomedullin N-terminal A-R-L-D-V-A-S-E-F-R-K-K-W-N-K-W-20 peptide (PAMP-20) A-L-S-R-NH, (SEQ. ID. NO. 7) These peptides and others may be used to generate antibodies, whether polyclonal or monoclonal, which can then be used to prepare antibody containing compositions used in the methods of the present invention.
The antibodies are prepared via techniques well known to those having ordinary skill in the art. In particular, monoclonal antibodies to peptide P072 are particularly useful in the practice of the present invention.
The AM peptides and antibodies of the present invention are useful in a variety of therapeutic and diagnostic settings. These are described with more specificity below.
(1) Expression of Adrenomedullin in Normal Human Lung and Pulmonary Tumors Studies were carried out to localize the expression sites for AM in lung, as a first step to identification of novel functions for the AM peptide. The localization of AM in the endothelium of the blood vessels would be expected to be due to the involvement of the AM
peptide in blood pressure regulation (Nuki, et al., Biochem Biophys Res Commun 196:245-251 (1993); Ishiyama, et al., Eur J Pharmacol 241:271-273 (1993); Perret, et al., Life Sci 53:PL377-PL379 (1993); Lippton, et al., Life ci 54:PL409-PL412 (1994); Santiago, et al., Eur J.
Pharmacol 272:115-118 (1995); Lippton, et al., J AQAl Physiol 76:2154-2156 (1994); Sugo, et al., Biochem Biophys Res Commun 201:1160-1166 (1994)), and the expression of AM
in smooth muscle cells has been previously reported (Sugo, et al., Biochem Biophys Res Commun 203:719-726 (1994)).
The expression of AM in various pulmonary cell types implicates potential new roles for this molecule.
The abundant presence of AM at the apical interface of columnar epithelium with external environment suggests that AM could be secreted to the pulmonary lumen.
Usually the functions of the ciliated cells of the bronchial epithelium are supposed to be restricted to the mechanical transport of the mucous layer through ciliary beat, but other regulatory peptides, such as endothelins, have been described in this cell type (Giaid, et al., Am J Respir Cell Mol Biol 4:50-56 (1990)). The expression of AM in the lining epithelium and macrophages points to a possible protective action against pathogens, similar to that observed' for other peptides, such as the magainins present in the airway epithelium (Diamond, et al., Proc Natl Acad Sci USA 90:4596-4600 (1993)) or the tracheal antimicrobial peptide (Diamond, et al., Proc Natl Acad Sci USA 88:3952-3956 (1991)).
The distribution of AM in normal lung described herein colocalizes with the pattern previously reported for the peptide-amidating enzymes (Saldise, et al., J.
Histochem. Cytochem. 1996). In this reference, it was postulated the potential existence of yet unknown amidated peptides concomitantly expressed at the same sites of enzyme production. The studies herein suggest that AM may be one of those predicted peptides. It has been demonstrated that amidation is important for AM
activity; the amidated form of AM has 5o times greater affinity for the receptor than the nonamidated form (Eguchi, et al., Endocrinology 135:2454-2458 (1994)).
To characterize the functions of AM in normal tissues, the distribution of AM was studied in normal and malignant lung using immunocytochemical techniques to localize the peptide and in situ reverse transcriptase-polymerase chain reaction (RT-PCR) to study the expression of its messenger RNA (mRNA) in formalin-fixed paraffin-embedded specimens.
(2) Human AM/AM-R mRNA expression in normal and malignant cells RT-PCR was used to evaluate AM ligand and receptor mRNA in a variety of cancer cell lines of diverse origin and normal human tissues (Table 3, Figures 15A and 15B). Sense and antisense primers were derived from published human cDNA sequence (Kitamura, K., et al., Biochem. Biorhvs. Res. Commun. 194, 720 (1993)) based on computer analysis from the primer select DNAstar program.
The resulting 410bp and 471bp RT-PCR products for AM and AM-R mRNA were confirmed by Southern blotting with antisense nested probes. Cloned product for normal human adrenal gland and H720 was further verified as an authentic fragment of the AM message by nucleotide sequencing, showing homology for more than 200bp in either direction using sequencing primers at the Sp6 and T7 promoter regions. The majority of neoplastic cell lines tested (55/58, 95%) were shown to express AM message (see Figures 15A and 15B, and Table 3). Figures 15A and 15B
show a representative sample of human tumor cell lines (H157, H720, MCF-7, OVCAR-3, SNUC-1) and normal human tissues (brain, lung, heart, adrenal) screened for AM mRNA
and its translated protein. MoAb-G6 was absorbed with the addition of 10 g/mL of synthetic homolog P072.
AM mRNA was not found in the following cancer cell lines: H69c (SCLC), H23 (adenocarcinoma) and H460 (large cell carcinoma). The fact that certain tissues do not express AM by Northern blot evaluation does not preclude its presence as demonstrated by RT-PCR (Table 4).
For example, a heterogenous tissue, such as brain, showed AM expression by RT-PCR, but not by Northern analysis.
Though less extensively studied, similar data were observed for AM-R mRNA (27/36, 75%), (Table 3) showing colocalization of ligand and receptor message in normal tissue and in 75% of the neoplastic cell lines (Figures 14A-14D and Figures 26A-26B). The data demonstrates AM-R
mRNA, by RT-PCR, in the following normal tissues: brain, heart, lung and adrenal gland (Figure 26B).
AM has been shown to induce cAMP production in the target cells (Ishizaka, et al., Biochem Biophvs Res Commun 200:642-646 (1994)). It has been previously observed that most of the peptide hormones able to induce cAMP synthesis act as modulators of cell growth (Ishizuka, et al., Cancer Res 54:2129-2135 (1994); Moody, et al., Proc Natl Acad Sci USA 90:4345-4349 (1993)); thus, AM
could also function as a growth regulator of tumor proliferation. In addition, blood supply is a critical factor for the successful implantation of tumor cells at distant metastatic sites, and many neoplasms induce angiogenesis (Weinstat-Saslow, et al., FASEB J 8:401-407 (1994)). An alternative or synergistic survival method might be the production and secretion of vasodilatory substances such as AM to enhance the availability of nutrient factors to the tumor bed.
The regional distribution of AM, a regulatory peptide present in the airway epithelium and in tumors historically classified as nonendocrine, and the colocalization with one of the posttranslational processing enzymes required for synthesis of the active peptide, led us to reconsider the concept of "endocrine."
As new regulatory peptides are discovered, new cell types enter the arena of endocrinology. Similar trends have previously occurred with the gastrointestinal system (Bloom, et al., Adv Clin Chem 21:177-244 (1980)) and endothelial cells (Vane, et al., J Physiol Pharmacol 43:195-207 (1992)). AM expression challenges our notions of restricted expression of neuroendocrine features and highlights the pluripotency of the airway epithelium.
(3) Production and secretion of AM peptide by human tumor cell lines Select cancer cell lines, as shown in Figure 26, were adapted to grow under RO conditions and the resulting whole cell lysates from such lines were examined for AM
immunoreactivity by western blot analysis using a previously characterized rabbit antiserum (Martinez, A., 0 et al., Endocrinology 136:4099-4105 (1995)). Figure 26C
illustrates the electrophoretic profile of AM-like immunoreactive peptides identified.
Molecular weight species of 18, 14 and 6kDA were identified and presumably represent AM precursor, processed intermediates, and the authentic peptide, respectively. There is also a 22 kDa immunoreactive species in two cancer cell lines, H720 and MCF-7. The specificity of the immune-detection assay was confirmed by an antibody absorption control, which eliminated the specific bands (Figure 26D). To further corroborate the expression of authentic ASM by tumor cells, HPLC fractions were analyzed of ROCM from the lung carcinoid cell line NCI-H720. Column retintate contained AM-like immunoreactivity having an elution time consistent with the synthetic peptide (-89 min) (Figures 15A- 15B). In addition, immunoblot analysis of consecutive HPLC
fractions within the 88 to 92 min region revealed a major 6 kDa immunoreactive band, while the 124 to 129 min fractions expressed both the 18 and 14 kDa entity (Figure 15C). Additional immunoreactive peaks were identified at 26.4 min., 53.6 min., and 135.6 min., but they were not further characterized (Figure 15).
(4) AM regulates human tumor cell proliferation Results obtained by immunohistochemical (IHC) and in situ RT-PCR examination of paraffin-embedded RO-adapted cell lines were consistent with previously reported data on normal lung and pathological lung specimens (Martinez, A., et al., Endocrinolocrv 136:4099-4105 (1995)). Human tumor cell lines evaluated show AM
expression by IHC and in situ RT-PCR, as shown in Figure 27. It is interesting to note that AM expression in SCLC
H774 demonstrates the highest intensity of staining in the outer layers (proliferative zones) of individual colonies, a finding that could implicate AM in growth regulation a (Figure 27A). Consistent with this idea was the fact that AM had been shown to elevate cAMP, a signal transduction pathway known to modulate cellular growth (Ishiyama, Y., et al., Eur. J. Pharmacol. 241:271-273 (1993)). To further investigate this suspected phenomenon, MTT assay techniques were used to examine the effects of AM on the growth of several diverse tumor cell lines (lung, colon, breast, brain, and ovary). Exogenous addition of AM (with a final concentration range between 0.1 /.AM to 100 AM) to RO-grown cell cultures was ineffective in stimulating growth, although there was some non-specific toxicity at the higher range. Since the test cells were known to produce authentic AM peptide, we assumed that this inability to stimulate growth with extrinsic ligand could possibly mean that the cells has already achieved maximal proliferative effects using their own AM.
To verify this hypothesis, MoAb-G6 was used to block the biological activity of endogenous AM. During the characterization of MoAb-G6, it was demonstrated that it did not cross-react with other known tyrosine amide peptides or with the structurally related CGRP and amylin (Figure 13). The MTT assay was used to evaluate MoAb-G6 for its effect on the growth of 5 human tumor cell lines (NCI-H157, NCI-H720, MCF-7, NIH:OVCAR-3 and SNUC-1), and a dose dependent suppression was observed in 4 out of them (see Table 5). At the highest concentration of MoAb-G6 used (100 g/ml), a consistent 25-6% growth suppression was observed among cancer cell lines examined with the exception of SNUC-1. In the colon cancer cell line, SNUC-1, AM-R expression is undetectable by RT-PCR (Figure 26B), which may be the reason MoAb-G6 had very little effect on its growth. Representative data for MCF-7 are depicted in Figure 5A, which shows that an isotypic control mouse myeloma protein (TEPC 15, IgAK, Sigma) was ineffective in blocking growth over the same dose range. MoAb-G6 induced inhibition of tumor cell growth was abolished by exogenous addition of AN, with maximal recovery at 10 AM, thus verifying the specificity of growth suppression by the neutralizing antibody (Figure 5B).
(5) AM receptors are present in human tumor cell lines and AM increases intracellular cAMP
In addition to the RT-PCR analysis of the AM-R
mRNA (Figure 26B), the cAMP response to synthetic AM and 125I-AM binding to demonstrate the presence of functional AM receptors in responding tumor cell lines. Several cancer lines demonstrated selective binding of "I-AM, which was not competitively blocked by the synthetic homolog P072 or the gene-related peptide PAMP, as shown by representative data for breast cancer cell line MCF-7 (Figure 28C). The data shows that specific binding is inhibited by AM in a dose-dependent manner with an IC50 of 10 nM. As illustrated for MCF-7, AM binding to this receptor induced a rapid increase in cellular cAMP over a dose range of 10 pM to 1 M (Figure 28D). In contrast, P072 and PAMP had no effect on cAMP.
(6) The Role of Adrenomedullin as an Autocrine Growth Factor for Human Breast Epithelial Cells During Development and Carcinogenesis AM mRNA expression was identified in 4/4 normal and 6/6 normal malignant breast cells using RT-PCR.
Immunohistochemical and in situ PCR analysis of paraffin-embedded tissue localized AM expression preferentially to the apical areas of epithelial cells in 11/11 normal specimens. Similar analysis on malignant tissue demonstrated AM in 10/12 breast CA. To further identify the potential role of AM in breast CA, the tumor cell line MCF-7 was analyzed, which was adapted to grow in serum-free/hormone-free medium. When evaluated by SDS-PAGE/immuno blot, these cells were shown to express immunoreactive AM-like species of 18 kiloDaltons (kDa), 14 kDa, 9kDa, and 6kDa. These various molecular weight entities are thought to represent the precursor, authentic peptide, and process intermediates of AM. In addition, the inventors have shown that MCF-7 expresses high affinity receptors for this ligand (Kd - 2nM) and response to exogenous AM by increasing intracellular cAMP resulting in elevated clonal growth in soft agar assays. The anti-AM monoclonal antibody MoAb-G6 was shown to induce a dose-dependent inhibition of MCF-7 growth in liquid culture.
An isotopic control mouse myeloma protein (IgAK) was ineffective over the same dose range. Mo-Ab-G6 growth inhibition was abrogated by exogenous AM. The collective data implicates AM as a potential autocrine growth factor involved in normal breast development and carcinogenesis.
(7) Modulation of Adrenomedullin in Severe Preeclampsia AM is a potent long-acting hypotensive peptide that is present in human plasma at considerable concentrations and is proposed to be a new circulating hormone participating in blood pressure control.
Specifically, AM is thought to have a role in preeclampsia. Preeclampsia is a condition associated with high blood pressure and spontaneous abortion.
Hypertension complicates 7% of pregnancies and preeclampsia is responsible for 70% of all hypertension in pregnancies. Currently, there are no diagnostic tools available to identify women who may be likely candidates for developing preeclampsia. Accordingly, specific diagnostic tools and treatments are required.
To further understand the etiopathogenesis of preeclampsia and the associated hypertension, the cellular localization of AM in sections of formalin-fixed paraffin embedded placentas of normal and preeclamptic patients was evaluated. Established immunohistochemical techniques were used with a well characterized rabbit polyclonal antibody specific to AM and a streptavadin-peroxidase 0 detection system (Vector laboratories). Significantly decreased immunoreactive AM was found in the placentas of patients with severe preeclampsia in comparison to the immunostaining exhibited by the placentas of normal patients. These results suggest that AM may play a role in the regulation of placental perfusion and the cardiovascular system during pregnancy and that dysregulation may be associated with preeclampsia.
The present invention provides for novel AM
peptides which are useful in the diagnosis and treatment of preeclampsia, thereby overcoming the inadequacies of the current state of the art. Furthermore, the novel AM
peptides and antibodies of the present invention allow for early detection of a predisposition of a subject to a particular disease state.
(8) Stimulation of Adrenomedullin Protein Levels During Estrogen-Induced Growth of the Uterus and Vagina Increasing evidence suggests that estrogen mediates its effects on the growth and differentiation of the reproductive tract in part due to the regulation of autocrine/paracrine factors. Occurring within minutes after estrogen treatment is the induction of hyperemia, increased vascular permeability, and edema, which is followed later by synchronized growth of the uterine epithelium. Despite the dramatic nature of these physiological changes, relatively little is known concerning the mechanism by which estrogen brings them about. In light of the known vascular effects of AM, the cell-specific and temporal regulation of AM protein levels following a single treatment with a physiological dose of estrogen using established immunohistochemical techniques.
Estrogen treatment induced in a time-dependent manner distinctive epithelial cell-specific localization of AM protein in both the uterus and vagina (evident at the earliest timepoint investigated, 12 hrs). The induction of AM in the uterine epithelium was transient and fell to control levels within 24 hours after estrogen exposure; whereas, marked vaginal expression was maintained in the epithelium for up to 48 hours post-treatment. Smooth muscle cells in both organs showed considerable immunoreactivity that did not seem to fluctuate with estrogen treatment. These results indicate that estrogen stimulates AM protein levels in the epithelium of the uterus and vagina in a time-dependent and organ-specific manner. The induction of AM occurs prior to the initiation of DNA synthesis; thus AM may play a role in the estrogen action by increasing vascular permeability and perfusion to the uterus and vagina that is necessary to provide conditions favorable for synchronized growth.
(9) The Role of Adrenomedullin in Ovarian Function.
Dynamic changes in blood vessel growth and vascular flow occurs in the ovary during the periovulatory and luteal phases. The initiation of neovascularization in selected follicles has been shown to parallel the appearance of various differentiation markers such as aromatase, LH receptor, and inhibin subunits. In addition, the new capillaries that develop during the formation of the corpus luteum are known to be highly permeable, which facilitates the delivery of large protein molecules such as low density lipoproteins that transport cholesterol required for progesterone biosynthesis. In light of the known role of AM in regulation of vascular flow, the specific aim of the studies herein was to examine the cell and stage-specific expression of AM
protein in the rat ovary by immunohistochemistry. The ovary demonstrated prominent AM protein expression. AM
was immunolocalized to capillary endothelial cells, smooth muscle cells of major vessels, germinal epithelium, thecal cells, in scattered granulosa cells within the cumulus oophorus of mature antral follicles, and to many cells C within the corposa lutea. The most striking immunoreactivity for AM in the ovary was exhibited by the corpus lutea where the more mature corpus lutea demonstrated the greatest number of positive staining cells. In addition, intense localization of AM was found associated with the apical surface of the oviductal epithelium. The prominent expression of AM in the corpus lutea, in the mature follicles, and the oviduct, implicates AM as a potential contributor to ovarian steroidogenesis, ovulation, and possibly to providing an environment within the oviduct conducive for implantation, fertilization and early development. The presence of AM
protein in different reproductive tissues under the influence of steroid and gonadotrophin hormones suggests that AM may play a pivotal role in reproduction possibly by ensuring the acquisition of an adequate blood supply need to maintain rapid growth and/or differentiated function.
(10) The Role of Adrenomedullin in Neurotransmission The presence of AM in the neurons of the pulmonary intrinsic nervous system points to a possible involvement in neurotransmission. A similar function has been assigned to CGRP, a molecule with which AM shares some structural homology (Kitamura, et al., Biochem Bio hys Res Commun 192:553-560 (1993)) and which is particularly abundant in the lung (Springall, et al., J
Auton Nerv Syst 20:155-166 (1987)). Recently, some effects on blood pressure regulation were described after injection of AM in the rat central nervous system (Takahashi, et al., Am J Hypertens 7:478-482 (1994)).
Figure 24: Figure 24 indicates the effect of AM on the germination of C. albicans.
Figures 25A and 25B: Figures 25A and 25B set forth the distribution of amphipathic regions for AM and=PAMP
as calculated for a-helix/b-sheet angle parameters (Eisenberg), and the helical wheel projection display for AM and PAMP (DNASTAR).
Figures 26A-26D: Figure 26 sets forth a representative sample of human tumor cell lines and normal human tissues screened for AM and AM-R. Southern blot analysis demonstrates the predicted 410 bp product for AM (A) and a 471 bp product for AM-R mRNA (B) after RT-PCR
amplification. (C) Western blot analysis of cell extracts shows immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM. In addition, there is a 22 kDa immunoreactive entity that may be attributed to post-translational processing. (D) The absorption control was negative.
Figures 27A-27D: Figure 27 sets forth the immunohistochemical and in situ RT-PCR analysis of human cancer cell lines for AN. (A) Immunohistochemical analysis for AM in SCLC H774 and (B) ovarian carcinoma cell line NIH: Ovcar-3. Note the peripheral distribution of AM immunoreactivity in H774 colonies. (C) In situ RT-PCR for AM mRNA in carcinoid cell line H720 and (D) negative control in a serial section where primers were substituted by water in the PCR mixture.
Figures 28A and 28B: Figure 28 sets forth the growth effects of AM. A representative human tumor cell line, MCF-7, was used to show the growth effects, receptor binding and cAMP variation by AM under serum-free, hormone-free conditions. (A) Inhibitory effects of MoAb-G6 (0) compared with no effect from its mouse myeloma isotypic control, IgAK (0). (B) Effects of MoAb-G6 were overcome by the addition of synthetic AM (0) compared with the addition of AM alone (4). (C) Specific receptor binding is measurable for AM (0) while it is negligible for PAMP (i) or P072 (0). (D) Cyclic AMP is increased with the addition of synthetic AM in a dose-dependent manner.
DETAILED DESCRIPTION OF THE INVENTION
The present invention generally provides novel adrenomedullin (AM) peptides and AM antibodies, pharmaceutical compositions comprising said peptides and antibodies, and their use as pharmaceutically active agents.
Specifically, the present invention relates to the following novel isolated AM peptides and oligonucleotide sequences:
P070 (YY-PreproAM3440 ) Y-Y-W-N-K-W-A-L-S-R-NH, (SEQ. ID. NO. 1) P071 (YGG-PreproAM132,f31) Y-G-G-H-Q-I-Y-Q-F-T-D-K-D-NH, (SEQ. ID. NO. 2) P072 (PreproAMli6.,,6) T-V-Q-K-L-A-H-Q-I-Y-Q-F-T-D-K-D-K-D-N-V-A-P-R-S-K-I-S-P-Q-G-Y-NH, (SEQ. ID. NO. 3) Sense primer (AM 94-114) 5'-AAG-AAG-TGG-AAT-AAG-TGG-GCT-3' (SEQ. ID. NO. 4) Antisense primer (AM 444-464) 5'-TGG-CTT-AGA-AGA-CAC-CAG-AGT-3' (SEQ. ID. NO. 5) Antisense probe (AM 289-309) 5'-CTG-GAA-GTT-GTT-CAT-GCT-CTG-3' (SEQ. ID. NO. 6) Proadrenomedullin N-terminal A-R-L-D-V-A-S-E-F-R-K-K-W-N-K-W-20 peptide (PAMP-20) A-L-S-R-NH, (SEQ. ID. NO. 7) These peptides and others may be used to generate antibodies, whether polyclonal or monoclonal, which can then be used to prepare antibody containing compositions used in the methods of the present invention.
The antibodies are prepared via techniques well known to those having ordinary skill in the art. In particular, monoclonal antibodies to peptide P072 are particularly useful in the practice of the present invention.
The AM peptides and antibodies of the present invention are useful in a variety of therapeutic and diagnostic settings. These are described with more specificity below.
(1) Expression of Adrenomedullin in Normal Human Lung and Pulmonary Tumors Studies were carried out to localize the expression sites for AM in lung, as a first step to identification of novel functions for the AM peptide. The localization of AM in the endothelium of the blood vessels would be expected to be due to the involvement of the AM
peptide in blood pressure regulation (Nuki, et al., Biochem Biophys Res Commun 196:245-251 (1993); Ishiyama, et al., Eur J Pharmacol 241:271-273 (1993); Perret, et al., Life Sci 53:PL377-PL379 (1993); Lippton, et al., Life ci 54:PL409-PL412 (1994); Santiago, et al., Eur J.
Pharmacol 272:115-118 (1995); Lippton, et al., J AQAl Physiol 76:2154-2156 (1994); Sugo, et al., Biochem Biophys Res Commun 201:1160-1166 (1994)), and the expression of AM
in smooth muscle cells has been previously reported (Sugo, et al., Biochem Biophys Res Commun 203:719-726 (1994)).
The expression of AM in various pulmonary cell types implicates potential new roles for this molecule.
The abundant presence of AM at the apical interface of columnar epithelium with external environment suggests that AM could be secreted to the pulmonary lumen.
Usually the functions of the ciliated cells of the bronchial epithelium are supposed to be restricted to the mechanical transport of the mucous layer through ciliary beat, but other regulatory peptides, such as endothelins, have been described in this cell type (Giaid, et al., Am J Respir Cell Mol Biol 4:50-56 (1990)). The expression of AM in the lining epithelium and macrophages points to a possible protective action against pathogens, similar to that observed' for other peptides, such as the magainins present in the airway epithelium (Diamond, et al., Proc Natl Acad Sci USA 90:4596-4600 (1993)) or the tracheal antimicrobial peptide (Diamond, et al., Proc Natl Acad Sci USA 88:3952-3956 (1991)).
The distribution of AM in normal lung described herein colocalizes with the pattern previously reported for the peptide-amidating enzymes (Saldise, et al., J.
Histochem. Cytochem. 1996). In this reference, it was postulated the potential existence of yet unknown amidated peptides concomitantly expressed at the same sites of enzyme production. The studies herein suggest that AM may be one of those predicted peptides. It has been demonstrated that amidation is important for AM
activity; the amidated form of AM has 5o times greater affinity for the receptor than the nonamidated form (Eguchi, et al., Endocrinology 135:2454-2458 (1994)).
To characterize the functions of AM in normal tissues, the distribution of AM was studied in normal and malignant lung using immunocytochemical techniques to localize the peptide and in situ reverse transcriptase-polymerase chain reaction (RT-PCR) to study the expression of its messenger RNA (mRNA) in formalin-fixed paraffin-embedded specimens.
(2) Human AM/AM-R mRNA expression in normal and malignant cells RT-PCR was used to evaluate AM ligand and receptor mRNA in a variety of cancer cell lines of diverse origin and normal human tissues (Table 3, Figures 15A and 15B). Sense and antisense primers were derived from published human cDNA sequence (Kitamura, K., et al., Biochem. Biorhvs. Res. Commun. 194, 720 (1993)) based on computer analysis from the primer select DNAstar program.
The resulting 410bp and 471bp RT-PCR products for AM and AM-R mRNA were confirmed by Southern blotting with antisense nested probes. Cloned product for normal human adrenal gland and H720 was further verified as an authentic fragment of the AM message by nucleotide sequencing, showing homology for more than 200bp in either direction using sequencing primers at the Sp6 and T7 promoter regions. The majority of neoplastic cell lines tested (55/58, 95%) were shown to express AM message (see Figures 15A and 15B, and Table 3). Figures 15A and 15B
show a representative sample of human tumor cell lines (H157, H720, MCF-7, OVCAR-3, SNUC-1) and normal human tissues (brain, lung, heart, adrenal) screened for AM mRNA
and its translated protein. MoAb-G6 was absorbed with the addition of 10 g/mL of synthetic homolog P072.
AM mRNA was not found in the following cancer cell lines: H69c (SCLC), H23 (adenocarcinoma) and H460 (large cell carcinoma). The fact that certain tissues do not express AM by Northern blot evaluation does not preclude its presence as demonstrated by RT-PCR (Table 4).
For example, a heterogenous tissue, such as brain, showed AM expression by RT-PCR, but not by Northern analysis.
Though less extensively studied, similar data were observed for AM-R mRNA (27/36, 75%), (Table 3) showing colocalization of ligand and receptor message in normal tissue and in 75% of the neoplastic cell lines (Figures 14A-14D and Figures 26A-26B). The data demonstrates AM-R
mRNA, by RT-PCR, in the following normal tissues: brain, heart, lung and adrenal gland (Figure 26B).
AM has been shown to induce cAMP production in the target cells (Ishizaka, et al., Biochem Biophvs Res Commun 200:642-646 (1994)). It has been previously observed that most of the peptide hormones able to induce cAMP synthesis act as modulators of cell growth (Ishizuka, et al., Cancer Res 54:2129-2135 (1994); Moody, et al., Proc Natl Acad Sci USA 90:4345-4349 (1993)); thus, AM
could also function as a growth regulator of tumor proliferation. In addition, blood supply is a critical factor for the successful implantation of tumor cells at distant metastatic sites, and many neoplasms induce angiogenesis (Weinstat-Saslow, et al., FASEB J 8:401-407 (1994)). An alternative or synergistic survival method might be the production and secretion of vasodilatory substances such as AM to enhance the availability of nutrient factors to the tumor bed.
The regional distribution of AM, a regulatory peptide present in the airway epithelium and in tumors historically classified as nonendocrine, and the colocalization with one of the posttranslational processing enzymes required for synthesis of the active peptide, led us to reconsider the concept of "endocrine."
As new regulatory peptides are discovered, new cell types enter the arena of endocrinology. Similar trends have previously occurred with the gastrointestinal system (Bloom, et al., Adv Clin Chem 21:177-244 (1980)) and endothelial cells (Vane, et al., J Physiol Pharmacol 43:195-207 (1992)). AM expression challenges our notions of restricted expression of neuroendocrine features and highlights the pluripotency of the airway epithelium.
(3) Production and secretion of AM peptide by human tumor cell lines Select cancer cell lines, as shown in Figure 26, were adapted to grow under RO conditions and the resulting whole cell lysates from such lines were examined for AM
immunoreactivity by western blot analysis using a previously characterized rabbit antiserum (Martinez, A., 0 et al., Endocrinology 136:4099-4105 (1995)). Figure 26C
illustrates the electrophoretic profile of AM-like immunoreactive peptides identified.
Molecular weight species of 18, 14 and 6kDA were identified and presumably represent AM precursor, processed intermediates, and the authentic peptide, respectively. There is also a 22 kDa immunoreactive species in two cancer cell lines, H720 and MCF-7. The specificity of the immune-detection assay was confirmed by an antibody absorption control, which eliminated the specific bands (Figure 26D). To further corroborate the expression of authentic ASM by tumor cells, HPLC fractions were analyzed of ROCM from the lung carcinoid cell line NCI-H720. Column retintate contained AM-like immunoreactivity having an elution time consistent with the synthetic peptide (-89 min) (Figures 15A- 15B). In addition, immunoblot analysis of consecutive HPLC
fractions within the 88 to 92 min region revealed a major 6 kDa immunoreactive band, while the 124 to 129 min fractions expressed both the 18 and 14 kDa entity (Figure 15C). Additional immunoreactive peaks were identified at 26.4 min., 53.6 min., and 135.6 min., but they were not further characterized (Figure 15).
(4) AM regulates human tumor cell proliferation Results obtained by immunohistochemical (IHC) and in situ RT-PCR examination of paraffin-embedded RO-adapted cell lines were consistent with previously reported data on normal lung and pathological lung specimens (Martinez, A., et al., Endocrinolocrv 136:4099-4105 (1995)). Human tumor cell lines evaluated show AM
expression by IHC and in situ RT-PCR, as shown in Figure 27. It is interesting to note that AM expression in SCLC
H774 demonstrates the highest intensity of staining in the outer layers (proliferative zones) of individual colonies, a finding that could implicate AM in growth regulation a (Figure 27A). Consistent with this idea was the fact that AM had been shown to elevate cAMP, a signal transduction pathway known to modulate cellular growth (Ishiyama, Y., et al., Eur. J. Pharmacol. 241:271-273 (1993)). To further investigate this suspected phenomenon, MTT assay techniques were used to examine the effects of AM on the growth of several diverse tumor cell lines (lung, colon, breast, brain, and ovary). Exogenous addition of AM (with a final concentration range between 0.1 /.AM to 100 AM) to RO-grown cell cultures was ineffective in stimulating growth, although there was some non-specific toxicity at the higher range. Since the test cells were known to produce authentic AM peptide, we assumed that this inability to stimulate growth with extrinsic ligand could possibly mean that the cells has already achieved maximal proliferative effects using their own AM.
To verify this hypothesis, MoAb-G6 was used to block the biological activity of endogenous AM. During the characterization of MoAb-G6, it was demonstrated that it did not cross-react with other known tyrosine amide peptides or with the structurally related CGRP and amylin (Figure 13). The MTT assay was used to evaluate MoAb-G6 for its effect on the growth of 5 human tumor cell lines (NCI-H157, NCI-H720, MCF-7, NIH:OVCAR-3 and SNUC-1), and a dose dependent suppression was observed in 4 out of them (see Table 5). At the highest concentration of MoAb-G6 used (100 g/ml), a consistent 25-6% growth suppression was observed among cancer cell lines examined with the exception of SNUC-1. In the colon cancer cell line, SNUC-1, AM-R expression is undetectable by RT-PCR (Figure 26B), which may be the reason MoAb-G6 had very little effect on its growth. Representative data for MCF-7 are depicted in Figure 5A, which shows that an isotypic control mouse myeloma protein (TEPC 15, IgAK, Sigma) was ineffective in blocking growth over the same dose range. MoAb-G6 induced inhibition of tumor cell growth was abolished by exogenous addition of AN, with maximal recovery at 10 AM, thus verifying the specificity of growth suppression by the neutralizing antibody (Figure 5B).
(5) AM receptors are present in human tumor cell lines and AM increases intracellular cAMP
In addition to the RT-PCR analysis of the AM-R
mRNA (Figure 26B), the cAMP response to synthetic AM and 125I-AM binding to demonstrate the presence of functional AM receptors in responding tumor cell lines. Several cancer lines demonstrated selective binding of "I-AM, which was not competitively blocked by the synthetic homolog P072 or the gene-related peptide PAMP, as shown by representative data for breast cancer cell line MCF-7 (Figure 28C). The data shows that specific binding is inhibited by AM in a dose-dependent manner with an IC50 of 10 nM. As illustrated for MCF-7, AM binding to this receptor induced a rapid increase in cellular cAMP over a dose range of 10 pM to 1 M (Figure 28D). In contrast, P072 and PAMP had no effect on cAMP.
(6) The Role of Adrenomedullin as an Autocrine Growth Factor for Human Breast Epithelial Cells During Development and Carcinogenesis AM mRNA expression was identified in 4/4 normal and 6/6 normal malignant breast cells using RT-PCR.
Immunohistochemical and in situ PCR analysis of paraffin-embedded tissue localized AM expression preferentially to the apical areas of epithelial cells in 11/11 normal specimens. Similar analysis on malignant tissue demonstrated AM in 10/12 breast CA. To further identify the potential role of AM in breast CA, the tumor cell line MCF-7 was analyzed, which was adapted to grow in serum-free/hormone-free medium. When evaluated by SDS-PAGE/immuno blot, these cells were shown to express immunoreactive AM-like species of 18 kiloDaltons (kDa), 14 kDa, 9kDa, and 6kDa. These various molecular weight entities are thought to represent the precursor, authentic peptide, and process intermediates of AM. In addition, the inventors have shown that MCF-7 expresses high affinity receptors for this ligand (Kd - 2nM) and response to exogenous AM by increasing intracellular cAMP resulting in elevated clonal growth in soft agar assays. The anti-AM monoclonal antibody MoAb-G6 was shown to induce a dose-dependent inhibition of MCF-7 growth in liquid culture.
An isotopic control mouse myeloma protein (IgAK) was ineffective over the same dose range. Mo-Ab-G6 growth inhibition was abrogated by exogenous AM. The collective data implicates AM as a potential autocrine growth factor involved in normal breast development and carcinogenesis.
(7) Modulation of Adrenomedullin in Severe Preeclampsia AM is a potent long-acting hypotensive peptide that is present in human plasma at considerable concentrations and is proposed to be a new circulating hormone participating in blood pressure control.
Specifically, AM is thought to have a role in preeclampsia. Preeclampsia is a condition associated with high blood pressure and spontaneous abortion.
Hypertension complicates 7% of pregnancies and preeclampsia is responsible for 70% of all hypertension in pregnancies. Currently, there are no diagnostic tools available to identify women who may be likely candidates for developing preeclampsia. Accordingly, specific diagnostic tools and treatments are required.
To further understand the etiopathogenesis of preeclampsia and the associated hypertension, the cellular localization of AM in sections of formalin-fixed paraffin embedded placentas of normal and preeclamptic patients was evaluated. Established immunohistochemical techniques were used with a well characterized rabbit polyclonal antibody specific to AM and a streptavadin-peroxidase 0 detection system (Vector laboratories). Significantly decreased immunoreactive AM was found in the placentas of patients with severe preeclampsia in comparison to the immunostaining exhibited by the placentas of normal patients. These results suggest that AM may play a role in the regulation of placental perfusion and the cardiovascular system during pregnancy and that dysregulation may be associated with preeclampsia.
The present invention provides for novel AM
peptides which are useful in the diagnosis and treatment of preeclampsia, thereby overcoming the inadequacies of the current state of the art. Furthermore, the novel AM
peptides and antibodies of the present invention allow for early detection of a predisposition of a subject to a particular disease state.
(8) Stimulation of Adrenomedullin Protein Levels During Estrogen-Induced Growth of the Uterus and Vagina Increasing evidence suggests that estrogen mediates its effects on the growth and differentiation of the reproductive tract in part due to the regulation of autocrine/paracrine factors. Occurring within minutes after estrogen treatment is the induction of hyperemia, increased vascular permeability, and edema, which is followed later by synchronized growth of the uterine epithelium. Despite the dramatic nature of these physiological changes, relatively little is known concerning the mechanism by which estrogen brings them about. In light of the known vascular effects of AM, the cell-specific and temporal regulation of AM protein levels following a single treatment with a physiological dose of estrogen using established immunohistochemical techniques.
Estrogen treatment induced in a time-dependent manner distinctive epithelial cell-specific localization of AM protein in both the uterus and vagina (evident at the earliest timepoint investigated, 12 hrs). The induction of AM in the uterine epithelium was transient and fell to control levels within 24 hours after estrogen exposure; whereas, marked vaginal expression was maintained in the epithelium for up to 48 hours post-treatment. Smooth muscle cells in both organs showed considerable immunoreactivity that did not seem to fluctuate with estrogen treatment. These results indicate that estrogen stimulates AM protein levels in the epithelium of the uterus and vagina in a time-dependent and organ-specific manner. The induction of AM occurs prior to the initiation of DNA synthesis; thus AM may play a role in the estrogen action by increasing vascular permeability and perfusion to the uterus and vagina that is necessary to provide conditions favorable for synchronized growth.
(9) The Role of Adrenomedullin in Ovarian Function.
Dynamic changes in blood vessel growth and vascular flow occurs in the ovary during the periovulatory and luteal phases. The initiation of neovascularization in selected follicles has been shown to parallel the appearance of various differentiation markers such as aromatase, LH receptor, and inhibin subunits. In addition, the new capillaries that develop during the formation of the corpus luteum are known to be highly permeable, which facilitates the delivery of large protein molecules such as low density lipoproteins that transport cholesterol required for progesterone biosynthesis. In light of the known role of AM in regulation of vascular flow, the specific aim of the studies herein was to examine the cell and stage-specific expression of AM
protein in the rat ovary by immunohistochemistry. The ovary demonstrated prominent AM protein expression. AM
was immunolocalized to capillary endothelial cells, smooth muscle cells of major vessels, germinal epithelium, thecal cells, in scattered granulosa cells within the cumulus oophorus of mature antral follicles, and to many cells C within the corposa lutea. The most striking immunoreactivity for AM in the ovary was exhibited by the corpus lutea where the more mature corpus lutea demonstrated the greatest number of positive staining cells. In addition, intense localization of AM was found associated with the apical surface of the oviductal epithelium. The prominent expression of AM in the corpus lutea, in the mature follicles, and the oviduct, implicates AM as a potential contributor to ovarian steroidogenesis, ovulation, and possibly to providing an environment within the oviduct conducive for implantation, fertilization and early development. The presence of AM
protein in different reproductive tissues under the influence of steroid and gonadotrophin hormones suggests that AM may play a pivotal role in reproduction possibly by ensuring the acquisition of an adequate blood supply need to maintain rapid growth and/or differentiated function.
(10) The Role of Adrenomedullin in Neurotransmission The presence of AM in the neurons of the pulmonary intrinsic nervous system points to a possible involvement in neurotransmission. A similar function has been assigned to CGRP, a molecule with which AM shares some structural homology (Kitamura, et al., Biochem Bio hys Res Commun 192:553-560 (1993)) and which is particularly abundant in the lung (Springall, et al., J
Auton Nerv Syst 20:155-166 (1987)). Recently, some effects on blood pressure regulation were described after injection of AM in the rat central nervous system (Takahashi, et al., Am J Hypertens 7:478-482 (1994)).
(11) The Role of Adrenomedullin and its Gene-Related Peptide, Proadrenomedullin Peptide-20 (PAMP-20), in the Induction of IgE Independent Degranulation of Mast Cells Mast cells are intimately involved in allergic responses. They contain granules which in turn release histamines when degranulation occurs. Mast cells stained and observed immunohistochemically show the presence of AM
in the granules and murine mast cell lines produce mRNA
for AM. The ability of the mast cell to produce their own degranulation agent allows for autocrine degranulation or recruitment. Thus, the release of AM by a mast cell which has been primed (expresses IgE for an antigen) and then activated due to presentation of the antigen (i.e.
degranulation occurs) results in the release of AM into the system with AM being able to cause the degranulation of mast cells which have not been primed (increases the allergic response).
AM and PAMP-20 are basic peptide amides with respective isoelectric points of pI,v,,t=10.2 and pIpAmp=10.1.
It has previously been demonstrated that certain basic peptides (substance P, VIP, somatostatin, magainin-2, gastrin, melittin and Nal-arg-LHRH analog) are capable of inducing IgE independent release of histamine from rat mast cells. A similar analysis of AM and PAMP-20 has shown these peptides to be potent degranulators of rat mast cells with a respective EC50 of 7.9 3.9 M and 0.47 0.23 M. AM was effective as magainin-2 in inducing histamine release, while PAMP-20 was twenty times more potent with bioactivity analogous to Nal-arg-LHRH.
Immunohistochemical examination of rat skin and respiratory tract has identified AM expression in mast tissue cells. Furthermore, 2/4 mouse mast cell lines (MC/9, lOP2, 10P12, and 11PO-1) have been shown to express AM message when analyzed by RT-PCR. The collective data implicates AM/PAMP-20 as new vasodilators which could contribute to the fluid infiltrative process of allergic edema. In addition, these peptides have been shown to induce rat mast cell degranulation through an IgE
independent mechanism and may define a previously unknown pathway of the normal immune response whereby adjacent mast cells are recruited in the absence of allergen.
Further, the monoclonal antibodies to AM of the present invention (see Example 4) are useful as therapeutics to block the allergic reaction induced by mast cell degranulation.
(12) Investigation of the protective action of AM/PAMP
It was previously demonstrated that AM is apically expressed in normal human bronchial epithelium and in resident pulmonary macrophages (Martinez, et al., Endocrinology 136:4099 (1995)) implicating a possible protective action similar to that of magainins and tracheal antimicrobial peptide (Diamond, et al., P roc.
Natl. Acad. Sci. USA 90:4596 (1993); Diamond, et al., Proc. Natl. Acad. Sci. USA 88:3952 (1991); Schonwetter, et al., Science 267:1645 (1995); Zasloff, M., Proc. Natl.
Acad. Sci. USA, 84:5449 (1987).
This possibility was further investigated by examining the expression of AM in a variety of epithelial surfaces, such as integument, respiratory, alimentary and genitourinary tracts, from different species including rats, mice, rabbits, guinea-pigs, hamsters, cats, dogs, pigs, and the toad Xenopus laevis using previously described methods of immunohistochemistry and in situ RT-PCR (Martinez, et al., Endocrinolocrv 136:4099 (1995)) (see also Figure 22). Immunohistochemical studies demonstrate that AM is expressed in high levels within mammalian epithelial cells of the respiratory, alimentary, and urinary tracts, as well as within pulmonary alveolar macrophages. In the respiratory tracts of the species studied, all the ciliated and Clara cells were strongly positive for both the mRNA (Figure 22A) and the peptide (Figure 22B, 22C). In the case of the peptide, it was always accumulated in the apical region, suggesting an active secretion of AM to the pulmonary lumen.
When the skin was subjected to immunocytochemical study, an intense staining was also observed. In the amphibian epidermis, most keratinocytes had a mild staining, but the strongest immunoreactivity to AM was located in the unicellular glands of the skin (Figure 22D). The other glands, so characteristic of the amphibian integument, were devoid of staining. In mammals, the AM-like material was homogeneously distributed throughout the epidermis of both adults and the last stages of developing embryos (Figure 22E).
The genitourinary tract was also found to be positive for AM. Most of the tubules in the kidney, such as the collector tubules, and the epithelium lining the ureter were immunoreactive, together with the fallopian tubes, the uterus (Figure 22F) and the vagina, in all the species studied.
The digestive tube had previously been shown as one of the main sources for antimicrobial peptides (Schonwetter, et al., Science 267:1645 (1995)), and indeed AM was also expressed in this system. The immunoreactivity was mainly found in salivary glands (Figure 22G), the epithelium of the hepatic bile ducts and the gallbladder, the Brunner's glands in the duodenum (Figure 22H), the lumenal epithelium of the colon and some bottle shaped endocrine cells on the same organ (Figure 221).
Some other immunoreactive cell types included the ciliated cells lining the frog esophagus, the ductal system of the guinea-pig pancreas and the ependyma of the third ventricle in the rat brain.
The wide distribution of AM in epithelial cells, the apical cellular localization of AM along muco-cutaneous surfaces, and its localization to the Brunner's glands in the intestinal epithelium suggest a role in mucosal host defenses. Such a distribution is consistent with that of other antimicrobial peptides involved in antimicrobial protection (Zasloff, M., Proc. Natl. Acad.
Sci. USA 84:5449 (1987)).
(13) Assessment of the antimicrobial activity of AM and its gene-related peptides (PAMP) against bacterial and fungal pa thogens.
In order to assess the antimicrobial activity of AM and its gene related peptides, both microdilution and macrodilution assays were performed against Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), Pseudomonas aeruainosa (P. aeruginosa) and Candida albicans (C. albicans). A germination assay was also performed in order to further assess anti-candidal activity (Ghannoum, M.A. and Radwan, S.S., Candida Adherence to Epithelial Cells. CRC Press; Boca Raton, FLA.
1990 pp. 72-104).
Initial experiments using conventional techniques (National Committee for Clinical Laboratory Standards. Villanova, PA. M7-A3, M27-P (1993)) for determination of minimum inhibitory concentrations (MICs) assessed by turbidity at 24 hours did not reveal significant differences in MCIs between AM or AM gene-related peptides and controls. In order to assess the presence of subtle antimicrobial activity of AM and gene-related peptides not detectable by routine turbidimetric tests, more sensitive quantitative methods were performed as modifications of bacterial and fungal timed kill assays that would evaluate growth inhibition over time (Walsh, et al., Antimicrob. Chemother. 17:75 (1986); Roilides, et al., J. Infect. Dis. 163:579 (1991); Roilides, et al., J.
Leukocyte Biol. 57:651 (1995)).
AM and PAMP were found to have activity after 6 hours of incubation against E. calf, P. aeruainosa, and C.
in the granules and murine mast cell lines produce mRNA
for AM. The ability of the mast cell to produce their own degranulation agent allows for autocrine degranulation or recruitment. Thus, the release of AM by a mast cell which has been primed (expresses IgE for an antigen) and then activated due to presentation of the antigen (i.e.
degranulation occurs) results in the release of AM into the system with AM being able to cause the degranulation of mast cells which have not been primed (increases the allergic response).
AM and PAMP-20 are basic peptide amides with respective isoelectric points of pI,v,,t=10.2 and pIpAmp=10.1.
It has previously been demonstrated that certain basic peptides (substance P, VIP, somatostatin, magainin-2, gastrin, melittin and Nal-arg-LHRH analog) are capable of inducing IgE independent release of histamine from rat mast cells. A similar analysis of AM and PAMP-20 has shown these peptides to be potent degranulators of rat mast cells with a respective EC50 of 7.9 3.9 M and 0.47 0.23 M. AM was effective as magainin-2 in inducing histamine release, while PAMP-20 was twenty times more potent with bioactivity analogous to Nal-arg-LHRH.
Immunohistochemical examination of rat skin and respiratory tract has identified AM expression in mast tissue cells. Furthermore, 2/4 mouse mast cell lines (MC/9, lOP2, 10P12, and 11PO-1) have been shown to express AM message when analyzed by RT-PCR. The collective data implicates AM/PAMP-20 as new vasodilators which could contribute to the fluid infiltrative process of allergic edema. In addition, these peptides have been shown to induce rat mast cell degranulation through an IgE
independent mechanism and may define a previously unknown pathway of the normal immune response whereby adjacent mast cells are recruited in the absence of allergen.
Further, the monoclonal antibodies to AM of the present invention (see Example 4) are useful as therapeutics to block the allergic reaction induced by mast cell degranulation.
(12) Investigation of the protective action of AM/PAMP
It was previously demonstrated that AM is apically expressed in normal human bronchial epithelium and in resident pulmonary macrophages (Martinez, et al., Endocrinology 136:4099 (1995)) implicating a possible protective action similar to that of magainins and tracheal antimicrobial peptide (Diamond, et al., P roc.
Natl. Acad. Sci. USA 90:4596 (1993); Diamond, et al., Proc. Natl. Acad. Sci. USA 88:3952 (1991); Schonwetter, et al., Science 267:1645 (1995); Zasloff, M., Proc. Natl.
Acad. Sci. USA, 84:5449 (1987).
This possibility was further investigated by examining the expression of AM in a variety of epithelial surfaces, such as integument, respiratory, alimentary and genitourinary tracts, from different species including rats, mice, rabbits, guinea-pigs, hamsters, cats, dogs, pigs, and the toad Xenopus laevis using previously described methods of immunohistochemistry and in situ RT-PCR (Martinez, et al., Endocrinolocrv 136:4099 (1995)) (see also Figure 22). Immunohistochemical studies demonstrate that AM is expressed in high levels within mammalian epithelial cells of the respiratory, alimentary, and urinary tracts, as well as within pulmonary alveolar macrophages. In the respiratory tracts of the species studied, all the ciliated and Clara cells were strongly positive for both the mRNA (Figure 22A) and the peptide (Figure 22B, 22C). In the case of the peptide, it was always accumulated in the apical region, suggesting an active secretion of AM to the pulmonary lumen.
When the skin was subjected to immunocytochemical study, an intense staining was also observed. In the amphibian epidermis, most keratinocytes had a mild staining, but the strongest immunoreactivity to AM was located in the unicellular glands of the skin (Figure 22D). The other glands, so characteristic of the amphibian integument, were devoid of staining. In mammals, the AM-like material was homogeneously distributed throughout the epidermis of both adults and the last stages of developing embryos (Figure 22E).
The genitourinary tract was also found to be positive for AM. Most of the tubules in the kidney, such as the collector tubules, and the epithelium lining the ureter were immunoreactive, together with the fallopian tubes, the uterus (Figure 22F) and the vagina, in all the species studied.
The digestive tube had previously been shown as one of the main sources for antimicrobial peptides (Schonwetter, et al., Science 267:1645 (1995)), and indeed AM was also expressed in this system. The immunoreactivity was mainly found in salivary glands (Figure 22G), the epithelium of the hepatic bile ducts and the gallbladder, the Brunner's glands in the duodenum (Figure 22H), the lumenal epithelium of the colon and some bottle shaped endocrine cells on the same organ (Figure 221).
Some other immunoreactive cell types included the ciliated cells lining the frog esophagus, the ductal system of the guinea-pig pancreas and the ependyma of the third ventricle in the rat brain.
The wide distribution of AM in epithelial cells, the apical cellular localization of AM along muco-cutaneous surfaces, and its localization to the Brunner's glands in the intestinal epithelium suggest a role in mucosal host defenses. Such a distribution is consistent with that of other antimicrobial peptides involved in antimicrobial protection (Zasloff, M., Proc. Natl. Acad.
Sci. USA 84:5449 (1987)).
(13) Assessment of the antimicrobial activity of AM and its gene-related peptides (PAMP) against bacterial and fungal pa thogens.
In order to assess the antimicrobial activity of AM and its gene related peptides, both microdilution and macrodilution assays were performed against Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), Pseudomonas aeruainosa (P. aeruginosa) and Candida albicans (C. albicans). A germination assay was also performed in order to further assess anti-candidal activity (Ghannoum, M.A. and Radwan, S.S., Candida Adherence to Epithelial Cells. CRC Press; Boca Raton, FLA.
1990 pp. 72-104).
Initial experiments using conventional techniques (National Committee for Clinical Laboratory Standards. Villanova, PA. M7-A3, M27-P (1993)) for determination of minimum inhibitory concentrations (MICs) assessed by turbidity at 24 hours did not reveal significant differences in MCIs between AM or AM gene-related peptides and controls. In order to assess the presence of subtle antimicrobial activity of AM and gene-related peptides not detectable by routine turbidimetric tests, more sensitive quantitative methods were performed as modifications of bacterial and fungal timed kill assays that would evaluate growth inhibition over time (Walsh, et al., Antimicrob. Chemother. 17:75 (1986); Roilides, et al., J. Infect. Dis. 163:579 (1991); Roilides, et al., J.
Leukocyte Biol. 57:651 (1995)).
AM and PAMP were found to have activity after 6 hours of incubation against E. calf, P. aeruainosa, and C.
0 albicans but were ineffective against S. aureus. Several peptide fragments (Martinez, et al. Endocrinology 136:4099 (1995) representing the carboxy-terminal portion of AM
(P071 and P072) and of PAMP (P070) had little or no activity against these pathogens. However, preliminary findings suggest that the amino-terminal homologue of AM
(AM1-12) exerted antimicrobial effects similar to those of intact AM in the microdilutional assay implicating that this fragment of AM could be responsible for the antimicrobial activity. AM and PAMP at 6 hours incubation showed higher growth inhibitory activity than albumin (negative control), P070, P071 and P072 (p=0.03) and PAMP
(0.0009). Am was five fold more active in the microdilution assay against P. aeruginosa than equimolar of human albumin controls (p=0.0666).
Antimicrobial activity was then evaluated in the macrodilution assay. There was initially no activity observed for AM at 6 hours, moderate activity for magainin, and even greater activity generated by PAMP
(Figure 23A). As of 24 hours incubation, however, the macrodilution pattern resembled that of the microdilutional assay with AM being somewhat more active than PAMP and magainin being significantly greater in antimicrobial activity than either AM or PAMP (Figure 24B). Magainin was the only peptide that resulted in an optically clear suspension of bacteria. There was greater antimicrobial activity of AM and PAMP against P.
aeruginosa at 24 hours exposure than at 6 hours incubation (P=0.061).
There was no apparent growth suppressive activity for AM, AM1-12, PAMP or the carboxypeptides against S. aureus in either microdilutional or macrodilutional assays. This may reflect a natural resistance which this pathogen has for the peptide which in turn could relate to surface charge repulsion phenomenology, proteolytic degradation of the peptide, or the lack of appropriate peptide/host interaction mediated by polysaccharide barrier of the bacterium.
(14) The antimicrobial effect of AM and gene-related peptides (PAMP) against C. albicans The antimicrobial effect of AM and gene-related peptides was evaluated by macrodilutional and microdilutional assays against C. albicans, the common mucosal fungal pathogen of humans. The trends of antitrophic activity were less than those observed against E. coli and P. aerucrinosa, particularly when compared with the albumin standard. However, there was a highly significant structure/function relationship found between the antimicrobial effect of AM (73% 8.1) or PAMP
(79.7k 2.4) versus the carboxy-terminal portion of the peptide (46.8% 11.1, p<=0.004). While the overall activity of AM and PAMP was reduced in the macrodilutional assay, the relative patterns of antimicrobial activity were similar. Consistent with patterns observed for bacteria, magainin was more potent than AM and PAMP
against C. albicans.
Germination is an important step in the pathogenesis of attachment and invasion of C. albicans to mucosal surfaces (Ghannoum, M.A. and Radwan, S.S., Candida Adherence to Epithelial Cells, CRC Press; Boca Raton, FLA., pp 72-104). The effects of AM and PAMP on germination of C. albicans were then studied as another indicator of antifungal activity. There was a significant inhibition of germination of C. albicans by increasing concentrations of AM at 4 hours incubation (Figure 25) (p=0.048, ANOVA). There was a non-significant trend in the suppression of germination after 2 hours incubation.
The growth inhibitory properties of AM and PAMP
were more active against the aerobic gram-negative bacteria, E. coli and P. aeruginosa, than against C.
albicans and S. aureus. Such differential antimicrobial activity is also observed for the defensins and cecropins (Maloy, W.L. and Kari, U.P., Biopolvmers (Peptide Science) 37:105 (1995); Lehrer, et al., Cell, 64:229 (1991)). For example, depending upon the amino acid sequences of cecropin peptides, which are found within porcine intestine, there are profound differences in antimicrobial activity against aerobic gram-negative bacilli (E. coli and P. aeruginosa) and gram-positive cocci (Micrococcus luteus). While there was minimum growth inhibitory activity of AM-related peptides against C. albicans, AM
exerted a time-dependent inhibitory effect upon germination in cell culture media.
The concentrations at which these antimicrobial properties are achieved are generally 10 to 100 times greater than those of magainins and cecropins. However, if the tissue levels of these AM-related peptides are highly concentrated in the microenvironment, then the reported in vitro antimicrobial activity may also be active along epithelial cell surfaces. The antimicrobial effect was best observed at low inoculum concentrations, suggesting that organisms may degrade these AM-related peptides or that their cell targets may require a higher molar concentration for microbial effect. The antimicrobial mechanisms of the AM-related peptides remains to be further elucidated. Many of the antimicrobial peptides share in common highly basic properties and amphipathic activity with target cell membranes. Both AM and PAMP are highly charged moieties with isoelectric points of 9.7 and 11.1, respectively.
Their amino acid structures contain extensive alpha/beta amphipathic regions which may simulate the membrane intercalation capabilities of magainin 1 and 2 (Oppenheim, et al., J. Biol. Chem., 263:7472 (1988)). Figure 26 gives the amphipathic distribution and theoretical helical wheel symmetry of both peptides as calculated by DNASTAR
software.
(P071 and P072) and of PAMP (P070) had little or no activity against these pathogens. However, preliminary findings suggest that the amino-terminal homologue of AM
(AM1-12) exerted antimicrobial effects similar to those of intact AM in the microdilutional assay implicating that this fragment of AM could be responsible for the antimicrobial activity. AM and PAMP at 6 hours incubation showed higher growth inhibitory activity than albumin (negative control), P070, P071 and P072 (p=0.03) and PAMP
(0.0009). Am was five fold more active in the microdilution assay against P. aeruginosa than equimolar of human albumin controls (p=0.0666).
Antimicrobial activity was then evaluated in the macrodilution assay. There was initially no activity observed for AM at 6 hours, moderate activity for magainin, and even greater activity generated by PAMP
(Figure 23A). As of 24 hours incubation, however, the macrodilution pattern resembled that of the microdilutional assay with AM being somewhat more active than PAMP and magainin being significantly greater in antimicrobial activity than either AM or PAMP (Figure 24B). Magainin was the only peptide that resulted in an optically clear suspension of bacteria. There was greater antimicrobial activity of AM and PAMP against P.
aeruginosa at 24 hours exposure than at 6 hours incubation (P=0.061).
There was no apparent growth suppressive activity for AM, AM1-12, PAMP or the carboxypeptides against S. aureus in either microdilutional or macrodilutional assays. This may reflect a natural resistance which this pathogen has for the peptide which in turn could relate to surface charge repulsion phenomenology, proteolytic degradation of the peptide, or the lack of appropriate peptide/host interaction mediated by polysaccharide barrier of the bacterium.
(14) The antimicrobial effect of AM and gene-related peptides (PAMP) against C. albicans The antimicrobial effect of AM and gene-related peptides was evaluated by macrodilutional and microdilutional assays against C. albicans, the common mucosal fungal pathogen of humans. The trends of antitrophic activity were less than those observed against E. coli and P. aerucrinosa, particularly when compared with the albumin standard. However, there was a highly significant structure/function relationship found between the antimicrobial effect of AM (73% 8.1) or PAMP
(79.7k 2.4) versus the carboxy-terminal portion of the peptide (46.8% 11.1, p<=0.004). While the overall activity of AM and PAMP was reduced in the macrodilutional assay, the relative patterns of antimicrobial activity were similar. Consistent with patterns observed for bacteria, magainin was more potent than AM and PAMP
against C. albicans.
Germination is an important step in the pathogenesis of attachment and invasion of C. albicans to mucosal surfaces (Ghannoum, M.A. and Radwan, S.S., Candida Adherence to Epithelial Cells, CRC Press; Boca Raton, FLA., pp 72-104). The effects of AM and PAMP on germination of C. albicans were then studied as another indicator of antifungal activity. There was a significant inhibition of germination of C. albicans by increasing concentrations of AM at 4 hours incubation (Figure 25) (p=0.048, ANOVA). There was a non-significant trend in the suppression of germination after 2 hours incubation.
The growth inhibitory properties of AM and PAMP
were more active against the aerobic gram-negative bacteria, E. coli and P. aeruginosa, than against C.
albicans and S. aureus. Such differential antimicrobial activity is also observed for the defensins and cecropins (Maloy, W.L. and Kari, U.P., Biopolvmers (Peptide Science) 37:105 (1995); Lehrer, et al., Cell, 64:229 (1991)). For example, depending upon the amino acid sequences of cecropin peptides, which are found within porcine intestine, there are profound differences in antimicrobial activity against aerobic gram-negative bacilli (E. coli and P. aeruginosa) and gram-positive cocci (Micrococcus luteus). While there was minimum growth inhibitory activity of AM-related peptides against C. albicans, AM
exerted a time-dependent inhibitory effect upon germination in cell culture media.
The concentrations at which these antimicrobial properties are achieved are generally 10 to 100 times greater than those of magainins and cecropins. However, if the tissue levels of these AM-related peptides are highly concentrated in the microenvironment, then the reported in vitro antimicrobial activity may also be active along epithelial cell surfaces. The antimicrobial effect was best observed at low inoculum concentrations, suggesting that organisms may degrade these AM-related peptides or that their cell targets may require a higher molar concentration for microbial effect. The antimicrobial mechanisms of the AM-related peptides remains to be further elucidated. Many of the antimicrobial peptides share in common highly basic properties and amphipathic activity with target cell membranes. Both AM and PAMP are highly charged moieties with isoelectric points of 9.7 and 11.1, respectively.
Their amino acid structures contain extensive alpha/beta amphipathic regions which may simulate the membrane intercalation capabilities of magainin 1 and 2 (Oppenheim, et al., J. Biol. Chem., 263:7472 (1988)). Figure 26 gives the amphipathic distribution and theoretical helical wheel symmetry of both peptides as calculated by DNASTAR
software.
The antimicrobial properties of these AM-related peptides are dependent upon the assay used to measure their activity. For example, the activity of AM and PAMP
appeared to be greater in the microdilutional assay than in the macrodilutional assay, suggesting that there may be interaction between the peptides and the glass or plastic surfaces. The kinetics of growth inhibition of those peptides, as well as other antimicrobial peptides, may differ substantially. As a case in point, the microbial activity of magainins became increasingly apparent at 24 hours by macrodilution, while adrenomedullin appeared to lose activity, possibly due to proteolytic cleavage. In a similar way, the class of salivary peptides known as histatins exert potent but transient activity lasting only for one to two hours before proteolysis inactivates activity (Oppenheim, et al., J. Biol. Chem., 263:7472 (1988)).
Consistent with a potential role of AM in host defense are the recent observations of Shoji, et al., Biochemical and Biophysical Research, 215:531 (1995), demonstrating the highest level of increased expression of AM in lung, liver, and spleen in rats challenged intravenously with lipopolysaccharide. These findings suggest an upregulation of this antimicrobial peptide in the reticuloendothelial system that may mediate host response to bacterial and fungal pathogens. The diverse endocrinologic and hemodynamic properties of AM and its genetically related peptides leads to the suggestion that perhaps other antimicrobial peptides may have a wider range of non-antimicrobial physiological activities than heretofore appreciated.
Accordingly, the present invention provides for novel adrenomedullin peptides for use as antibacterial and anti-fungal agents. Specifically, AM peptides are useful for the treatment of vaginal yeast infections, athlete's foot, and thrush, a yeast infection which typically causes fatal pneumonia in cancer patients.
The AM peptides of the present invention may also be used to relieve discomfort and prevent bacterial and fungi infections of skin disorders. For example, the AM peptides may be applied topically to surgical incisions to prevent infections. Further, the AM peptides may be applied topically to chaffed skin, rashes, and skin lesions to prevent infection and promote healing.
(15) Adrenomedullin as a Regulator of Insulin Secretion AM has been implicated in the regulation of insulin production. AM elevates cAMP in the target cells and regulates secretion of certain hormones. To determine if AM mediates any functional role in the rat endocrine pancreas a multiple analytical approach was utilized.
Immunocytochemistry using a well characterized antibody showed that AM is present in the periphery of the islets of Langerhans. Double immunostaining and immunoelectron microscopy demonstrated that AM is stored in the D
(delta), somatostatin-producing cells. In situ RT-PCR
technology was used to confirm AM mRNA expression in the islets. Using isolated islets, it was shown that AM
inhibits insulin secretion in a dose-dependent manner. In addition, the MoAb G6 (anti-AM) increased insulin secretion 6 fold by suppressing endogenous AM activity (see Figure 19A). Elevating levels of cAMP, as shown by RIA, followed addition of AM. In conclusion, AM is expressed in the D-cells of the pancreas and reduces insulin secretion.
Because AM is secreted in insulin and urine, a diagnostic tool for the detection of levels of insulin in serum and urine as predictive of the disease state would be extremely useful. Accordingly, the novel AM peptides of the present invention are useful in the determination and diagnosis of various disease states. Specifically, the peptides and antibodies of the present invention are useful in the diagnosis, treatment, and prevention of type II diabetes.
(16) The Distribution of AM in the Pancreas Pancreata from different species were examined by immunocytochemistry using a well-characterized polyclonal antibody (Martinez, et al., Endocrinology 136, 4099 (1995)). In humans, rats, and hamsters, the islets of Langerhans were immunoreactive for AM in all cells.
However, specific cells in the periphery presented a stronger positivity than others (Figures 18A and 18B). In addition, a few strongly stained cells were found scattered through the pancreatic parenchyma or among the ductal epithelial cells. In the guinea pig, cat, and dog pancreata, the staining pattern was different: Most of the AM-like cells were scattered in the parenchyma and only occasional immunoreactive cells were found in the periphery of the islets. In these cases, no immunoreactivity was evident in the 13-cells (Figure 18C).
In addition, low intensity staining was consistently found in the ductal epithelia of the guinea pig pancreas (Figure 18D). The presence of AM in the ductal pancreatic cells is consistent with the identification of AM in numerous epithelia, where the peptide is associated with notable antimicrobial activity (T. Walsh et al., Science (under editorial consideration)).
To further characterize the nature of the cells containing the AM-like material, serial sections were stained with antibodies against AM and the major pancreatic hormones. Where weak immunoreactivity for AM
was noted throughout the islet, colocalization with all the other hormones was evident, but the cells strongly positive for AM colocalized only with pancreatic polypeptide (Figures 18E and 18F). This result differs from a previous report (H. Washimine et al., 0 Histochemistry 103, 251 (1995)), which suggested a colocalization with somatostatin based on the peripheral distribution of AM immunoreactivity. Double immunogold staining at the electron microscopic level confirmed the colocalization of AM with pancreatic polypeptide in peripheral cells of rat pancreas (Figure 18G). Consistent with the light immunohistochemical data, few immunogold particles detecting AM were found in other endocrine cell types by electron microscopy (Figure 18H).
AM has some structural similarities to calcitonin gene-related peptide (CGRP) and amylin (K.
Kitamura, K. Kangawa, H. Matsuo, T. Eto, Drugs 49, 485 (1995)), both of which are involved in pancreatic physiology. Nevertheless, the distribution of these three peptides in the pancreas varies: Amylin is mainly located in the 0-cells, colocalizing with insulin (Mulder, et al., Cell Tissue Res. 274, 467 (1993)), and CGRP is present in pancreatic nerves as well as in peripheral cells of the islets (B. Ahren and F. Sundler, Cell Tissue Res. 269, 315 (1992)). The differential distribution of the immunoreactivities, together with the absorption controls, excludes a possible cross-reactivity of the AM antibody with amylin or CGRP.
(17) Physiological Effects Of AM In Endocrine Pancreas Regulation To identify the potential biological role of AM
in the secretion of pancreatic hormones, three experimental models were used: isolated islets of Langerhans from rat, 0-cell lines in culture, and oral glucose tolerance tests in rats.
The addition of AM to freshly isolated islets resulted in a dose-dependent reduction of insulin secretion (Figure 19A). This inhibition reaches 78= s for an AM concentration of 1 M. Using MoAb-G6, a monoclonal antibody that neutralizes AM (M. J. Miller et al., Science (under editorial consideration)), a fivefold increase of insulin secretion was observed in the absence of extrinsic AM (Figure 19A). Evidently, this striking effect was caused by neutralization of endogenous AM produced by the islets. The addition of extrinsic AM again resulted in a dose-dependent competitive inhibition (Figure 19A).
Consistent with this observation, cAMP levels increased in the islets when AM was added (Figure 19B).
To investigate AM's effect on 0-cells, the influence of AM in six well-characterized, insulin-producing cell lines was studied: RINm, N289, TR4, CRL 2057, CRL 1777, CRL 2055 (American Type Culture Collection, Rockville, MD). Although these cell lines expressed AM mRNA, as shown by reverse transcription-polymerase chain reaction (RT-PCR) (Figure 20), no change in insulin secretion rate was observed after administration of either AM or the monoclonal antibody (results not shown). These results suggest that 0-cells, at least in culture, do not express AM receptors and apparently more complex interactions occur in the islets. To confirm this hypothesis, binding of 125I-AM
(0.2 nM per 5x105 cells) was investigated in RINm cells and in NCI-H1264, a lung adenocarcinoma used as a positive control. No binding (25 cpm) was observed in the RINm cells, but strong radioactivity (2265 cpm) was found in NCI-H1264. Possibly AM modulates a different cell type that, in turn, inhibits insulin secretion through endocrine or paracrine pathways. A similar mechanism has been described for amylin (R. A. Pittner et al., J. Cell.
Biochem. 55S, 19 (1994)). Nevertheless, the existence of AM receptors in 0-cells in vivo cannot be ruled out, although it has been shown that receptor systems that act in the 0-cell through an increase in cAMP and Ca" induce rather than inhibit secretion of insulin (Holz, et al., J.
Biol. Chem. 270, 17749 (1995)). On the other hand, the possibility that AM acts through other receptors cannot be excluded. There is evidence that AM binds to CGRP
receptors with lower affinity (Eguchi, et al., Endocrinology 135, 2454 (1994); Hall, et al., Brit. J.
Pharmacol. 114, 592 (1995); Zimmermann, et al., Peptides 16, 421 (1995)) and could bind the amylin receptors similarly, since the three peptides are structurally related (K. Kitamura, et al., Drugs 49, 485 (1995)).
In a third experiment, the influence of AM in oral glucose tolerance testing of nonanesthetized rats was measured (protocol No. 95-062, NCI). AM dramatically (p=0.003) blocks insulin secretion for at least 20 min after intravenous injection, so the levels of circulating glucose were significantly higher (p=0.006) than in the control animals (Figure 21B).
The collective data of the present invention implicates AM as a new diabetogenic peptide capable of modulating insulin secretion and blood glucose metabolism.
Although the exact mechanism remains to be elucidated, isolated islet studies and analysis of cultured (3-cell lines indicate that an unidentified secondary mediator is involved. It should be noted that insulin-producing cell lines express AM message and are faintly immunoreactive for the peptide, but their ability to secrete insulin is not directly affected by either exogenous AM or MoAb-G6.
Thus AM regulation of insulin secretion in isolated islet experiments and rat physiology involves more complex interactions than initially surmised. Since the expression of AM (at least in cardiovascular systems, is affected by levels of tumor necrosis factor-a, interleukin- 1, lipopolysaccharide, interferon-y, endothelin-1, angiotensin II, substance P, bradykinin, thrombin, and vasoactive intestinal peptide (S. Sugo, et al., FEBS Lett. 369, 311 (1995)), any combination of these bioactive substances may be involved with AM in regulating insulin secretion. In fact, some reports link different forms of diabetes with these substances (G. S.
appeared to be greater in the microdilutional assay than in the macrodilutional assay, suggesting that there may be interaction between the peptides and the glass or plastic surfaces. The kinetics of growth inhibition of those peptides, as well as other antimicrobial peptides, may differ substantially. As a case in point, the microbial activity of magainins became increasingly apparent at 24 hours by macrodilution, while adrenomedullin appeared to lose activity, possibly due to proteolytic cleavage. In a similar way, the class of salivary peptides known as histatins exert potent but transient activity lasting only for one to two hours before proteolysis inactivates activity (Oppenheim, et al., J. Biol. Chem., 263:7472 (1988)).
Consistent with a potential role of AM in host defense are the recent observations of Shoji, et al., Biochemical and Biophysical Research, 215:531 (1995), demonstrating the highest level of increased expression of AM in lung, liver, and spleen in rats challenged intravenously with lipopolysaccharide. These findings suggest an upregulation of this antimicrobial peptide in the reticuloendothelial system that may mediate host response to bacterial and fungal pathogens. The diverse endocrinologic and hemodynamic properties of AM and its genetically related peptides leads to the suggestion that perhaps other antimicrobial peptides may have a wider range of non-antimicrobial physiological activities than heretofore appreciated.
Accordingly, the present invention provides for novel adrenomedullin peptides for use as antibacterial and anti-fungal agents. Specifically, AM peptides are useful for the treatment of vaginal yeast infections, athlete's foot, and thrush, a yeast infection which typically causes fatal pneumonia in cancer patients.
The AM peptides of the present invention may also be used to relieve discomfort and prevent bacterial and fungi infections of skin disorders. For example, the AM peptides may be applied topically to surgical incisions to prevent infections. Further, the AM peptides may be applied topically to chaffed skin, rashes, and skin lesions to prevent infection and promote healing.
(15) Adrenomedullin as a Regulator of Insulin Secretion AM has been implicated in the regulation of insulin production. AM elevates cAMP in the target cells and regulates secretion of certain hormones. To determine if AM mediates any functional role in the rat endocrine pancreas a multiple analytical approach was utilized.
Immunocytochemistry using a well characterized antibody showed that AM is present in the periphery of the islets of Langerhans. Double immunostaining and immunoelectron microscopy demonstrated that AM is stored in the D
(delta), somatostatin-producing cells. In situ RT-PCR
technology was used to confirm AM mRNA expression in the islets. Using isolated islets, it was shown that AM
inhibits insulin secretion in a dose-dependent manner. In addition, the MoAb G6 (anti-AM) increased insulin secretion 6 fold by suppressing endogenous AM activity (see Figure 19A). Elevating levels of cAMP, as shown by RIA, followed addition of AM. In conclusion, AM is expressed in the D-cells of the pancreas and reduces insulin secretion.
Because AM is secreted in insulin and urine, a diagnostic tool for the detection of levels of insulin in serum and urine as predictive of the disease state would be extremely useful. Accordingly, the novel AM peptides of the present invention are useful in the determination and diagnosis of various disease states. Specifically, the peptides and antibodies of the present invention are useful in the diagnosis, treatment, and prevention of type II diabetes.
(16) The Distribution of AM in the Pancreas Pancreata from different species were examined by immunocytochemistry using a well-characterized polyclonal antibody (Martinez, et al., Endocrinology 136, 4099 (1995)). In humans, rats, and hamsters, the islets of Langerhans were immunoreactive for AM in all cells.
However, specific cells in the periphery presented a stronger positivity than others (Figures 18A and 18B). In addition, a few strongly stained cells were found scattered through the pancreatic parenchyma or among the ductal epithelial cells. In the guinea pig, cat, and dog pancreata, the staining pattern was different: Most of the AM-like cells were scattered in the parenchyma and only occasional immunoreactive cells were found in the periphery of the islets. In these cases, no immunoreactivity was evident in the 13-cells (Figure 18C).
In addition, low intensity staining was consistently found in the ductal epithelia of the guinea pig pancreas (Figure 18D). The presence of AM in the ductal pancreatic cells is consistent with the identification of AM in numerous epithelia, where the peptide is associated with notable antimicrobial activity (T. Walsh et al., Science (under editorial consideration)).
To further characterize the nature of the cells containing the AM-like material, serial sections were stained with antibodies against AM and the major pancreatic hormones. Where weak immunoreactivity for AM
was noted throughout the islet, colocalization with all the other hormones was evident, but the cells strongly positive for AM colocalized only with pancreatic polypeptide (Figures 18E and 18F). This result differs from a previous report (H. Washimine et al., 0 Histochemistry 103, 251 (1995)), which suggested a colocalization with somatostatin based on the peripheral distribution of AM immunoreactivity. Double immunogold staining at the electron microscopic level confirmed the colocalization of AM with pancreatic polypeptide in peripheral cells of rat pancreas (Figure 18G). Consistent with the light immunohistochemical data, few immunogold particles detecting AM were found in other endocrine cell types by electron microscopy (Figure 18H).
AM has some structural similarities to calcitonin gene-related peptide (CGRP) and amylin (K.
Kitamura, K. Kangawa, H. Matsuo, T. Eto, Drugs 49, 485 (1995)), both of which are involved in pancreatic physiology. Nevertheless, the distribution of these three peptides in the pancreas varies: Amylin is mainly located in the 0-cells, colocalizing with insulin (Mulder, et al., Cell Tissue Res. 274, 467 (1993)), and CGRP is present in pancreatic nerves as well as in peripheral cells of the islets (B. Ahren and F. Sundler, Cell Tissue Res. 269, 315 (1992)). The differential distribution of the immunoreactivities, together with the absorption controls, excludes a possible cross-reactivity of the AM antibody with amylin or CGRP.
(17) Physiological Effects Of AM In Endocrine Pancreas Regulation To identify the potential biological role of AM
in the secretion of pancreatic hormones, three experimental models were used: isolated islets of Langerhans from rat, 0-cell lines in culture, and oral glucose tolerance tests in rats.
The addition of AM to freshly isolated islets resulted in a dose-dependent reduction of insulin secretion (Figure 19A). This inhibition reaches 78= s for an AM concentration of 1 M. Using MoAb-G6, a monoclonal antibody that neutralizes AM (M. J. Miller et al., Science (under editorial consideration)), a fivefold increase of insulin secretion was observed in the absence of extrinsic AM (Figure 19A). Evidently, this striking effect was caused by neutralization of endogenous AM produced by the islets. The addition of extrinsic AM again resulted in a dose-dependent competitive inhibition (Figure 19A).
Consistent with this observation, cAMP levels increased in the islets when AM was added (Figure 19B).
To investigate AM's effect on 0-cells, the influence of AM in six well-characterized, insulin-producing cell lines was studied: RINm, N289, TR4, CRL 2057, CRL 1777, CRL 2055 (American Type Culture Collection, Rockville, MD). Although these cell lines expressed AM mRNA, as shown by reverse transcription-polymerase chain reaction (RT-PCR) (Figure 20), no change in insulin secretion rate was observed after administration of either AM or the monoclonal antibody (results not shown). These results suggest that 0-cells, at least in culture, do not express AM receptors and apparently more complex interactions occur in the islets. To confirm this hypothesis, binding of 125I-AM
(0.2 nM per 5x105 cells) was investigated in RINm cells and in NCI-H1264, a lung adenocarcinoma used as a positive control. No binding (25 cpm) was observed in the RINm cells, but strong radioactivity (2265 cpm) was found in NCI-H1264. Possibly AM modulates a different cell type that, in turn, inhibits insulin secretion through endocrine or paracrine pathways. A similar mechanism has been described for amylin (R. A. Pittner et al., J. Cell.
Biochem. 55S, 19 (1994)). Nevertheless, the existence of AM receptors in 0-cells in vivo cannot be ruled out, although it has been shown that receptor systems that act in the 0-cell through an increase in cAMP and Ca" induce rather than inhibit secretion of insulin (Holz, et al., J.
Biol. Chem. 270, 17749 (1995)). On the other hand, the possibility that AM acts through other receptors cannot be excluded. There is evidence that AM binds to CGRP
receptors with lower affinity (Eguchi, et al., Endocrinology 135, 2454 (1994); Hall, et al., Brit. J.
Pharmacol. 114, 592 (1995); Zimmermann, et al., Peptides 16, 421 (1995)) and could bind the amylin receptors similarly, since the three peptides are structurally related (K. Kitamura, et al., Drugs 49, 485 (1995)).
In a third experiment, the influence of AM in oral glucose tolerance testing of nonanesthetized rats was measured (protocol No. 95-062, NCI). AM dramatically (p=0.003) blocks insulin secretion for at least 20 min after intravenous injection, so the levels of circulating glucose were significantly higher (p=0.006) than in the control animals (Figure 21B).
The collective data of the present invention implicates AM as a new diabetogenic peptide capable of modulating insulin secretion and blood glucose metabolism.
Although the exact mechanism remains to be elucidated, isolated islet studies and analysis of cultured (3-cell lines indicate that an unidentified secondary mediator is involved. It should be noted that insulin-producing cell lines express AM message and are faintly immunoreactive for the peptide, but their ability to secrete insulin is not directly affected by either exogenous AM or MoAb-G6.
Thus AM regulation of insulin secretion in isolated islet experiments and rat physiology involves more complex interactions than initially surmised. Since the expression of AM (at least in cardiovascular systems, is affected by levels of tumor necrosis factor-a, interleukin- 1, lipopolysaccharide, interferon-y, endothelin-1, angiotensin II, substance P, bradykinin, thrombin, and vasoactive intestinal peptide (S. Sugo, et al., FEBS Lett. 369, 311 (1995)), any combination of these bioactive substances may be involved with AM in regulating insulin secretion. In fact, some reports link different forms of diabetes with these substances (G. S.
Hotamisligil and B. M. Spiegelman, Diabetes 43, 1271 (1994); T. H. Jones, Clin. Endocrinol. 40, 703 (1994)).
It has also been observed that AM's physiological effects are somehow connected with those produced by nitric oxide (C. J. Feng, et al., Life Sci.
55, 433 (1994)). This relationship may be due to the cross talk in the target cell between the signal transduction pathways for AM, which increases cAMP, and nitric oxide, which increases cGMP (Fiscus, et al.,, Neuropeptides 26, 133 (1994)). Since nitric oxide synthase is present in the islets of Langerhans and nitric oxide regulates insulin secretion (Schmidt, et al., Science 255, 721 (1992); Worl, et al., Histochemistry 102, 353 (1994)), it would be interesting to investigate the interactions between these two regulatory systems.
The well-known vasodilatory effect of AM may also influence the insulin secretion rate by increasing pancreatic perfusion. Although this cannot be the main mechanism, as demonstrated in the islet experiments where blood flux is irrelevant, it merits further evaluation.
A better understanding of AM interactions in normal pancreatic physiology and in different pathological states, such as diabetes and obesity, may help define new areas of therapeutic intervention to obviate these metabolic disorders.
(18) The role of CAMP as a growth regulator The role of cAMP as a growth regulator has been previously established in a variety of human tumor cell lines (T. W. Moody, et al., Proc. Natl. Acad. Sci U.S.A.
90, 4345 (1993); Cho-Chung, et al., Life Sci. 48, 1123 (1991); Ishizuka, et al., Cancer Res. 54, 2129 (1994);
Hoosein, et al., Regul. Pept. 24, 15 (1989); Yu, et al., Endocrinology 131, 1188 (1992)). This secondary signal transducer has been reported to have a biphasic effect on tumor proliferation whereby in certain instances it can mediate growth promotion while in others it functions as a growth inhibitor (Cho-Chung, et al., Life Sci. 48, 1123 (1991); Ishizuka, et al., Cancer Res. 54, 2129 (1994); Yu, et al., Endocrinology 131, 1188 (1992)). This dual function has been shown to depend on the relative amounts of two distinct cAMP-dependent protein kinase isoforms, RI
and RII (Ishizuka, et al., Cancer Res. 54, 2129 (1994)).
RI/RII isoforms are inversely expressed during embryogenesis, cell differentiation, and malignant transformation (S. M. Lohmann and U. Walter, in Advances in Cyclin Nucleotide and Protein Phosphorylation Research, P. Greengard, et al., Eds. (Raven Press, New York, 1984), vol. 18, pp. 63-117). Elevation of the RI isoform correlates with cell growth and transformation, while increases in the RII type correlate with growth inhibition and differentiation ((S. M. Lohmann and U. Walter, in Advances in Cyclin Nucleotide and Protein Phosphorylation Research, P. Greengard, et al., Eds. (Raven Press, New York, 1984), vol. 18, pp. 63-117)). Thus, depending on the relative amounts of these isoforms, cAMP induces either growth-promotion or growth-suppression effects.
Several reagents that regulate the expression of AM have been identified. These include enhancing factors such as interleukin-la/0 (IL-la/j3), tumor necrosis factor-a/-j3 (TNF-a/-f3), lipopolysaccharide (LPS), certain adrenocortical steroids, angiotensin II, endothelin- 1, bradykinin, substance P, and adrenaline and suppressor factors such as forskolin, 8-bromo-cAMP, thrombin, vasoactive intestinal polypeptide, and interferon--y (S.
Sugo, et al., Biochem. Biophys. Res. Commun. 203, 719 (1994); Sugo, S., et al., Biochem. Biophys. Res. Commun.
207, 25 (1995); N. Minamino, et al., Biochem. Biophys.
Res. Commun. 211, 686 (1995); S. Sugo, et al., FEBS Lett.
369, 311 (1995)). Many of these factors help activate the immune system during an inflammatory response. A recent review on the causes and prevention of cancer made two interesting points: i) Increased cell division gives rise to increased risk of cancer, which can be driven by increased levels of particular hormones, and ii) Chronic infection or inflammation contribute to one-third of the world's cancers (Ames, et al., Proc. Natl. Acad. Sci.
U.S.A. 92, 5258 (1995)). Given that IL-1a//3, TNF-a/-13, and LPS are agents of immune inflammation that are known to increase the expression of AM and that AM can mediate trophic effects on tumor cell lines, these findings indirectly implicate AM as a potential risk factor for malignant conversion. Since most of the tumor cell lines examined expressed this peptide, it may represent a generic target for intervention strategies to disrupt neoplastic transformation.
The present invention demonstrates that AM is expressed in most of the human tumor cell lines tested and that it can function as an autocrine growth factor capable of driving a self-perpetuating state in malignant disorders. Responding tumor cell lines were shown to express AM receptors and showed peptide-mediated increases in intracellular cAMP. These findings, together with reports that AM is found in tumor tissue from pathological specimens (Martinez, et al., Endocrinoloav 136, 4099 (1995); Martinez, et al., J. Histochem. Cytochem. 43, 739 (1995)), point towards the need for additional investigative studies to determine the precise role of AM
in carcinogenesis.
Additionally, given the similar amino acid sequence of AM between species and its implicated action on cell growth, the present invention provides for methods of evaluating the relationships of this peptide with other sites of rapid cellular proliferation (e.g., embryogenesis, wound repair, and gastrointestinal turnover) and the way these relationships track down evolutionary lines.
It has also been observed that AM's physiological effects are somehow connected with those produced by nitric oxide (C. J. Feng, et al., Life Sci.
55, 433 (1994)). This relationship may be due to the cross talk in the target cell between the signal transduction pathways for AM, which increases cAMP, and nitric oxide, which increases cGMP (Fiscus, et al.,, Neuropeptides 26, 133 (1994)). Since nitric oxide synthase is present in the islets of Langerhans and nitric oxide regulates insulin secretion (Schmidt, et al., Science 255, 721 (1992); Worl, et al., Histochemistry 102, 353 (1994)), it would be interesting to investigate the interactions between these two regulatory systems.
The well-known vasodilatory effect of AM may also influence the insulin secretion rate by increasing pancreatic perfusion. Although this cannot be the main mechanism, as demonstrated in the islet experiments where blood flux is irrelevant, it merits further evaluation.
A better understanding of AM interactions in normal pancreatic physiology and in different pathological states, such as diabetes and obesity, may help define new areas of therapeutic intervention to obviate these metabolic disorders.
(18) The role of CAMP as a growth regulator The role of cAMP as a growth regulator has been previously established in a variety of human tumor cell lines (T. W. Moody, et al., Proc. Natl. Acad. Sci U.S.A.
90, 4345 (1993); Cho-Chung, et al., Life Sci. 48, 1123 (1991); Ishizuka, et al., Cancer Res. 54, 2129 (1994);
Hoosein, et al., Regul. Pept. 24, 15 (1989); Yu, et al., Endocrinology 131, 1188 (1992)). This secondary signal transducer has been reported to have a biphasic effect on tumor proliferation whereby in certain instances it can mediate growth promotion while in others it functions as a growth inhibitor (Cho-Chung, et al., Life Sci. 48, 1123 (1991); Ishizuka, et al., Cancer Res. 54, 2129 (1994); Yu, et al., Endocrinology 131, 1188 (1992)). This dual function has been shown to depend on the relative amounts of two distinct cAMP-dependent protein kinase isoforms, RI
and RII (Ishizuka, et al., Cancer Res. 54, 2129 (1994)).
RI/RII isoforms are inversely expressed during embryogenesis, cell differentiation, and malignant transformation (S. M. Lohmann and U. Walter, in Advances in Cyclin Nucleotide and Protein Phosphorylation Research, P. Greengard, et al., Eds. (Raven Press, New York, 1984), vol. 18, pp. 63-117). Elevation of the RI isoform correlates with cell growth and transformation, while increases in the RII type correlate with growth inhibition and differentiation ((S. M. Lohmann and U. Walter, in Advances in Cyclin Nucleotide and Protein Phosphorylation Research, P. Greengard, et al., Eds. (Raven Press, New York, 1984), vol. 18, pp. 63-117)). Thus, depending on the relative amounts of these isoforms, cAMP induces either growth-promotion or growth-suppression effects.
Several reagents that regulate the expression of AM have been identified. These include enhancing factors such as interleukin-la/0 (IL-la/j3), tumor necrosis factor-a/-j3 (TNF-a/-f3), lipopolysaccharide (LPS), certain adrenocortical steroids, angiotensin II, endothelin- 1, bradykinin, substance P, and adrenaline and suppressor factors such as forskolin, 8-bromo-cAMP, thrombin, vasoactive intestinal polypeptide, and interferon--y (S.
Sugo, et al., Biochem. Biophys. Res. Commun. 203, 719 (1994); Sugo, S., et al., Biochem. Biophys. Res. Commun.
207, 25 (1995); N. Minamino, et al., Biochem. Biophys.
Res. Commun. 211, 686 (1995); S. Sugo, et al., FEBS Lett.
369, 311 (1995)). Many of these factors help activate the immune system during an inflammatory response. A recent review on the causes and prevention of cancer made two interesting points: i) Increased cell division gives rise to increased risk of cancer, which can be driven by increased levels of particular hormones, and ii) Chronic infection or inflammation contribute to one-third of the world's cancers (Ames, et al., Proc. Natl. Acad. Sci.
U.S.A. 92, 5258 (1995)). Given that IL-1a//3, TNF-a/-13, and LPS are agents of immune inflammation that are known to increase the expression of AM and that AM can mediate trophic effects on tumor cell lines, these findings indirectly implicate AM as a potential risk factor for malignant conversion. Since most of the tumor cell lines examined expressed this peptide, it may represent a generic target for intervention strategies to disrupt neoplastic transformation.
The present invention demonstrates that AM is expressed in most of the human tumor cell lines tested and that it can function as an autocrine growth factor capable of driving a self-perpetuating state in malignant disorders. Responding tumor cell lines were shown to express AM receptors and showed peptide-mediated increases in intracellular cAMP. These findings, together with reports that AM is found in tumor tissue from pathological specimens (Martinez, et al., Endocrinoloav 136, 4099 (1995); Martinez, et al., J. Histochem. Cytochem. 43, 739 (1995)), point towards the need for additional investigative studies to determine the precise role of AM
in carcinogenesis.
Additionally, given the similar amino acid sequence of AM between species and its implicated action on cell growth, the present invention provides for methods of evaluating the relationships of this peptide with other sites of rapid cellular proliferation (e.g., embryogenesis, wound repair, and gastrointestinal turnover) and the way these relationships track down evolutionary lines.
EXAMPLES
The examples herein are meant to exemplify the various aspects of carrying out the invention and are not intended to limit the invention in any way.
Cell Culture Ten normal lung specimens from patients who died without pulmonary involvement were provided by the Department of Pharmacology, University of Pittsburgh (protocol ML1259). Twenty additional formalin-fixed paraffin-embedded blocks containing representative cases of lung tumors (Table 1) were obtained from the files of the NCI-Navy Medical Oncology Branch, National Medical Center (Bethesda, MD; protocol 83-15). Five lung tumor cell lines were used in this study: NCI-H146, H345 (small cell--lung-carcinomas), H676 (adenocarcinoma) H720 -(carcinoid), and H820 (bronchioalveolar carcinoma). Cells were grown in serum-free hormone-free medium, as previously described (Siegfried, et al., J Biol Chem 269:8596-8603 (1994)). Pellets of approximately 5 X 106 cells were fixed in 4% paraformaldehyde, washed in PBS, resuspended in 1 ml 2% low melting point agarose (NuSieve, FMC BioProducts, Rockland, ME), allowed to solidify, and embedded in paraffin after routine histopathology techniques. mRNA was extracted from fresh cell pellets using the isothiocyanate-cesium chloride method of Glisin, et al. (Glisin, et al., Biochemistry 13:2633-2637 (1974)).
Polyadenylated RNA from normal human lung and adrenals were purchased from Clontech Laboratories (Palo Alto, CA).
The examples herein are meant to exemplify the various aspects of carrying out the invention and are not intended to limit the invention in any way.
Cell Culture Ten normal lung specimens from patients who died without pulmonary involvement were provided by the Department of Pharmacology, University of Pittsburgh (protocol ML1259). Twenty additional formalin-fixed paraffin-embedded blocks containing representative cases of lung tumors (Table 1) were obtained from the files of the NCI-Navy Medical Oncology Branch, National Medical Center (Bethesda, MD; protocol 83-15). Five lung tumor cell lines were used in this study: NCI-H146, H345 (small cell--lung-carcinomas), H676 (adenocarcinoma) H720 -(carcinoid), and H820 (bronchioalveolar carcinoma). Cells were grown in serum-free hormone-free medium, as previously described (Siegfried, et al., J Biol Chem 269:8596-8603 (1994)). Pellets of approximately 5 X 106 cells were fixed in 4% paraformaldehyde, washed in PBS, resuspended in 1 ml 2% low melting point agarose (NuSieve, FMC BioProducts, Rockland, ME), allowed to solidify, and embedded in paraffin after routine histopathology techniques. mRNA was extracted from fresh cell pellets using the isothiocyanate-cesium chloride method of Glisin, et al. (Glisin, et al., Biochemistry 13:2633-2637 (1974)).
Polyadenylated RNA from normal human lung and adrenals were purchased from Clontech Laboratories (Palo Alto, CA).
Comparison between the results obtained using immunocytochemistry and in situ RT-PCR in surgical specimens representing the different major neoplasias of the lung Tumor type Immunocytochemistry In situ PT-PCR
Carcinoids 1 /2 1 /2 Large cell carcinomas 2/4 3/4 Adenocarcinomas 3/4 3/4 Squamous carcinomas 4/5 3/5 Total 10/20 12/20 SCLC, Small cell lung carcinomas. The numerator represents the number of positive cases, and the denominator indicates the total number of studied cases.
Standard Reverse Transcrihtase (RT)-Polvmerase Chain Reaction (PCR) Three oligonucleotides (Table 2) were made in a MilliGen/Biosearch 8700 DNA synthesizer (Millipore, Marlborough, MA) and used as primers and probes for PCR
and Southern blot experiments, with an expected PCR
product of 410 base pairs (bp). The primers were designed to bridge the third intron of the AM gene (see Figure 1) to distinguish possible genomic amplification by the presence of a longer product (644 bp).
Reverse transcription was performed using the Superscript Preamplification System (GIBCO-BRL, Gaithersburg, MD). A Perkin-Elmer 9600 Thermocycler (Perkin-Elmer, Norwalk, CT) was used to amplify the samples. All buffers, enzymes, and nucleotides used were SUBSTITUTE SHEET (RULE 26) obtained from Applied Biosystems (Perkin-Elmer/Cetus).
PCR products were analyzed electrophoretically using 1%
agarose gels, and the ethidium bromide staining was observed under UV light, followed by Southern analysis.
Sequences of the peptides and oligonucleotides synthesized:
P070 (YY-PreproAM1,.,,,) Y-Y-W-N-K-W-A-L-S-R-NH2 (SEQ ID NO: 1) P071 (YGG-PreproAM,M.12,) Y-G-G-H-Q-I-Y-Q-F-T-D-K-D-NH, (SEQ ID NO: 2) P072 (PreproAMõb,,) T-V-Q-K-L-A-H-Q-I-Y-Q-F-T-D-K-D-K-D-N-V-A-P-R-S-K-I-S-P-Q-G-Y-NH, (SEQ ID NO: 3) Sense primer (AM 94-114) 5'-AAG-AAG-TGG-AAT-AAG-TGG-GCT-3' (SEQ ID NO: 4) Antisense primer (AM 444-464) 5'-TGG-CTT-AGA-AGA-CAC-CAG-AGT-3' (SEQ ID NO: 5) Antisense probe (AM 289-309) 5'-CTG-GAA-GU-GTT-CAT-GCT-CTG-3' (SEQ ID NO: 6) ProadrenomedulIin N-terminal A-R-L-D-V-A-S-E-F-R-K-K-W-N-K-W-20 peptide (PAMP-20) A-L-S-R-NH2 (SEQ ID NO: 7) Southern blot analysis Gels were denatured in 1.5M NaCl-0.6M NaOH and 1.5M NaCl-2M Tris and blotted onto a 0.2-14m nitrocellulose filter in 20 X SSC by capillary flow transfer overnight.
The filter was cross-linked at 80 C under vacuum and incubated in hybridization buffer. The antisensenested probe was 32P end labeled using standard procedures.
Hybridization with the probe was performed overnight at 42 C. Room temperature stringency washing was performed in 5 X SSC-0.1% sodium dodecyl sulfate and 1 X SSC-0.1 sodium dodecyl sulfate. Filters were air dried and TM
autoradiographed on Kodak XAR5 film (Eastman Kodak, Rochester, NY).
Carcinoids 1 /2 1 /2 Large cell carcinomas 2/4 3/4 Adenocarcinomas 3/4 3/4 Squamous carcinomas 4/5 3/5 Total 10/20 12/20 SCLC, Small cell lung carcinomas. The numerator represents the number of positive cases, and the denominator indicates the total number of studied cases.
Standard Reverse Transcrihtase (RT)-Polvmerase Chain Reaction (PCR) Three oligonucleotides (Table 2) were made in a MilliGen/Biosearch 8700 DNA synthesizer (Millipore, Marlborough, MA) and used as primers and probes for PCR
and Southern blot experiments, with an expected PCR
product of 410 base pairs (bp). The primers were designed to bridge the third intron of the AM gene (see Figure 1) to distinguish possible genomic amplification by the presence of a longer product (644 bp).
Reverse transcription was performed using the Superscript Preamplification System (GIBCO-BRL, Gaithersburg, MD). A Perkin-Elmer 9600 Thermocycler (Perkin-Elmer, Norwalk, CT) was used to amplify the samples. All buffers, enzymes, and nucleotides used were SUBSTITUTE SHEET (RULE 26) obtained from Applied Biosystems (Perkin-Elmer/Cetus).
PCR products were analyzed electrophoretically using 1%
agarose gels, and the ethidium bromide staining was observed under UV light, followed by Southern analysis.
Sequences of the peptides and oligonucleotides synthesized:
P070 (YY-PreproAM1,.,,,) Y-Y-W-N-K-W-A-L-S-R-NH2 (SEQ ID NO: 1) P071 (YGG-PreproAM,M.12,) Y-G-G-H-Q-I-Y-Q-F-T-D-K-D-NH, (SEQ ID NO: 2) P072 (PreproAMõb,,) T-V-Q-K-L-A-H-Q-I-Y-Q-F-T-D-K-D-K-D-N-V-A-P-R-S-K-I-S-P-Q-G-Y-NH, (SEQ ID NO: 3) Sense primer (AM 94-114) 5'-AAG-AAG-TGG-AAT-AAG-TGG-GCT-3' (SEQ ID NO: 4) Antisense primer (AM 444-464) 5'-TGG-CTT-AGA-AGA-CAC-CAG-AGT-3' (SEQ ID NO: 5) Antisense probe (AM 289-309) 5'-CTG-GAA-GU-GTT-CAT-GCT-CTG-3' (SEQ ID NO: 6) ProadrenomedulIin N-terminal A-R-L-D-V-A-S-E-F-R-K-K-W-N-K-W-20 peptide (PAMP-20) A-L-S-R-NH2 (SEQ ID NO: 7) Southern blot analysis Gels were denatured in 1.5M NaCl-0.6M NaOH and 1.5M NaCl-2M Tris and blotted onto a 0.2-14m nitrocellulose filter in 20 X SSC by capillary flow transfer overnight.
The filter was cross-linked at 80 C under vacuum and incubated in hybridization buffer. The antisensenested probe was 32P end labeled using standard procedures.
Hybridization with the probe was performed overnight at 42 C. Room temperature stringency washing was performed in 5 X SSC-0.1% sodium dodecyl sulfate and 1 X SSC-0.1 sodium dodecyl sulfate. Filters were air dried and TM
autoradiographed on Kodak XAR5 film (Eastman Kodak, Rochester, NY).
Antibody production and characterization Three fragments of the AM prohormone (see Table TM
2 and Figure 1) were synthesized in a MilliGen/Biosearch 9050 peptide synthesizer using FMOC chemistry, purified by preparative high performance liquid chromatography (HPLC) RP-C18 on a Beckman System Gold (Beckman Instruments, Fullerton, CA), and the molecular weight of the peptide, designated P072, was confirmed by mass spectrometry (Perkin-Elmer Sciex API III Plus, Foster Cit, CA).
Peptide P072 was coupled to keyhole limpet hemocyanin (Calbiochem-Behring, La Jolla, CA) via glutaraldehyde cross-linkage, and the conjugate was used to hyperimmunize New Zealand White rabbits, as previously described (Cuttitta, et al., J Clin Endocrinol Metab 67:576-583 (1988)). Resulting antisera were characterized for binding specificity and respective titers using a solid phase (radioimmune assay) RIA with ['25I] protein A as the detector (Cuttitta, et al., J Clin Endocrinol Metab 67:576-583 (1988)). In brief, test peptides were passively absorbed to individual wells (50 ng/well;
overnight at 4 C) of a 96-well polyvinylchloride microtiter plate (Dynatech Laboratories, Chantily, VA), after which the plate was coated with to bovine serum albumin (BSA) in phosphate buffered saline (PBS) to minimize nonspecific bonding. Test peptides included P070, P071, and P072 (in-house synthesis), AN, gastrin, cholecystokinin, gastrin-releasing peptide, glucagon-like peptide 1, 8-arginine vasopressin, vasoactive intestinal peptide, oxytocin, GRF, calcitonin, CGRP, neuropeptide Y
(NPY), aMSH (Peninsula Laboratories, Belmont, CA), and BSA
(Sigma Chemical Co., St. Louis, MO) as a negative control.
The titration screen covered a range from 1:100 to 1:204,800 (2-fold dilutions). The antiserum with the highest titer for AM and minimal cross-reactivity to related peptides was selected for all immunohistochemical studies.
Western blotting Whole cell lysates of tumor cell line NCI-H720 were generated following a protocol slightly modified from the previously reported (Cuttitta, et al,., J Clin Endocrinol Metab 67:576-583 (1988)). In summary, cells were harvested 48 hours after their last feeding, washed three times in PBS, and pelleted by centrifugation (2000 rpm for 10 min at 4 C) . The pellet (-.5 X 107 cells) was resuspended in 1 ml PBS containing a 1-mM final concentration of each of the following protease TM
inhibitors: Pefabloc (Centerchem, Stanford, CT), and bestatin and phosphoramidon (Sigma). The cell suspension was then homogenized, sonicated, and clarified by ultracentrifugation, and the final protein concentration was determined (Bio-Rad Laboratories, Richmond, CA).
Cell lysates were electrophoretically fractionated on a 10-20% TricineMgel (Novex, San Diego, CA) at 100 V for 2 hours under nonreducing conditions.
Two nanograms of peptide P072 and AM were added to separate wells as positive control standards. Transfer blotting was accomplished in the same apparatus equipped with a titanium plate electrode insert, and proteins were affixed to a polyvinyldifluoride membrane (ImmobiloriMPVDF, Millipore) at 30 V for 2 hours. The membrane was blocked overnight in 1% BSA-PBS, incubated for 1 hr in a 1:1000 dilution of rabbit anti-P072 (bleed 2343), washed three time in PBS, exposed to 1 x 106 cpm ['sI] protein A for 1 hour at 28 C, washed six times in PBS, dried, and autoradiographed overnight at -80 C on Kodak XARS film.
The specificity control consisted of a duplicate membrane incubated in antigen-preabsorbed (10 nmol/ml P072) antiserum.
2 and Figure 1) were synthesized in a MilliGen/Biosearch 9050 peptide synthesizer using FMOC chemistry, purified by preparative high performance liquid chromatography (HPLC) RP-C18 on a Beckman System Gold (Beckman Instruments, Fullerton, CA), and the molecular weight of the peptide, designated P072, was confirmed by mass spectrometry (Perkin-Elmer Sciex API III Plus, Foster Cit, CA).
Peptide P072 was coupled to keyhole limpet hemocyanin (Calbiochem-Behring, La Jolla, CA) via glutaraldehyde cross-linkage, and the conjugate was used to hyperimmunize New Zealand White rabbits, as previously described (Cuttitta, et al., J Clin Endocrinol Metab 67:576-583 (1988)). Resulting antisera were characterized for binding specificity and respective titers using a solid phase (radioimmune assay) RIA with ['25I] protein A as the detector (Cuttitta, et al., J Clin Endocrinol Metab 67:576-583 (1988)). In brief, test peptides were passively absorbed to individual wells (50 ng/well;
overnight at 4 C) of a 96-well polyvinylchloride microtiter plate (Dynatech Laboratories, Chantily, VA), after which the plate was coated with to bovine serum albumin (BSA) in phosphate buffered saline (PBS) to minimize nonspecific bonding. Test peptides included P070, P071, and P072 (in-house synthesis), AN, gastrin, cholecystokinin, gastrin-releasing peptide, glucagon-like peptide 1, 8-arginine vasopressin, vasoactive intestinal peptide, oxytocin, GRF, calcitonin, CGRP, neuropeptide Y
(NPY), aMSH (Peninsula Laboratories, Belmont, CA), and BSA
(Sigma Chemical Co., St. Louis, MO) as a negative control.
The titration screen covered a range from 1:100 to 1:204,800 (2-fold dilutions). The antiserum with the highest titer for AM and minimal cross-reactivity to related peptides was selected for all immunohistochemical studies.
Western blotting Whole cell lysates of tumor cell line NCI-H720 were generated following a protocol slightly modified from the previously reported (Cuttitta, et al,., J Clin Endocrinol Metab 67:576-583 (1988)). In summary, cells were harvested 48 hours after their last feeding, washed three times in PBS, and pelleted by centrifugation (2000 rpm for 10 min at 4 C) . The pellet (-.5 X 107 cells) was resuspended in 1 ml PBS containing a 1-mM final concentration of each of the following protease TM
inhibitors: Pefabloc (Centerchem, Stanford, CT), and bestatin and phosphoramidon (Sigma). The cell suspension was then homogenized, sonicated, and clarified by ultracentrifugation, and the final protein concentration was determined (Bio-Rad Laboratories, Richmond, CA).
Cell lysates were electrophoretically fractionated on a 10-20% TricineMgel (Novex, San Diego, CA) at 100 V for 2 hours under nonreducing conditions.
Two nanograms of peptide P072 and AM were added to separate wells as positive control standards. Transfer blotting was accomplished in the same apparatus equipped with a titanium plate electrode insert, and proteins were affixed to a polyvinyldifluoride membrane (ImmobiloriMPVDF, Millipore) at 30 V for 2 hours. The membrane was blocked overnight in 1% BSA-PBS, incubated for 1 hr in a 1:1000 dilution of rabbit anti-P072 (bleed 2343), washed three time in PBS, exposed to 1 x 106 cpm ['sI] protein A for 1 hour at 28 C, washed six times in PBS, dried, and autoradiographed overnight at -80 C on Kodak XARS film.
The specificity control consisted of a duplicate membrane incubated in antigen-preabsorbed (10 nmol/ml P072) antiserum.
Immunocytochemistrv The avidin-biotin histochemical staining procedure (Hsu, et al., J Histochem Cvtochem 29:577-580 (1981)) was used to localize AM in normal lung, cell lines and tumors. All reagents were obtained from the TM
Vectastain ABC kit (Vector Laboratories, Burlingame, CA).
Titration of the antibody in paraffin sections showed that a concentration of 1:1000 was appropriate for immunocytochemical analysis. Rat adrenals were used as positive controls. Negative controls included (1) substitution of the primary antibody by a prebleed serum and (2) preabsorption of the antibody with 10 nmol/ml of the synthetic peptide P072. As the antibody showed a slight cross-reactivity with NPY (see Figure 2), preabsorptions with this peptide were also performed.
In situ RT-PCR
To localize the expression sites for AM, a direct method for in situ amplification of mRNA (Martinez, et al., J Histochem Cytochem, 43:739 (1995)) in a Hybaid OmniSlide System thermocycler (National Labnet Co., Woodbridge, N.J.) was used. After dewaxing, the sections were subjected to permeabilization with 10 gg/ml proteinase K (Sigma) for 15 min at 37 C. RT was performed TM
during the SuperScript Preamplification system (GIBCO-BRL) before the PCR reaction. The Taq polymerase was blocked TM
with a specific monoclonal antibody (TaqStart, Clontech) before being added to the PCR mixture to obtain a synchronous "hot start" for all slides. The PCR mixture contained 2.5 mM MgC1.,, 200 M deoxy-NTPs, 100 M
digoxigenin-deoxy-UTP (Boehringer Mannheim, Indianapolis, IN), 1 ng/ l primers, 50 mM KC1, and 10 mM Tris-HC1, pH
8.3. Twenty cycles with an annealing temperature of 55 C
were performed, and the PCR products were located using the Digoxigenin Detection Kit (Boehringer Mannheim) following the manufacturer's instructions. Controls included (1) omission of reverse transcriptase, and (2) substitution of the primers by water in the PCR mixture.
Antibody Characterization Antiserum from bleed 2343 was determined to have the highest titer to AM, with a resulting EC50 of 1:1 x 104, showing less than 1.0% (calculated 0.778) cross-reactivity with NPY at this dilution and less than 0.1%
binding with other test peptides (Figure 2). Binding differences between peptide P072 (original immunogen) and AM presumably reflect stearic interference generated during passive absorption to polyvinylchloride matrix.
The larger AM peptide, which contains the P072 antigen as an internal fragment, had a selective advantage of epitope availability when absorbed to the plastic support.
Alternatively, binding differences between these two peptide targets could reflect variation in adherence during passive absorption to the plate.
Western blot Electrophoretic fractionation of NCI-H720 cell lysate proteins revealed two immunoreactive AM-like species with molecular weight of approximately 18,000 and 6,000 (Figure 3). Presumably, these bands represent the AM precursor (185 amino acids) and the authentic peptide (52 amino acids). Immunostaining of these bands and the positive control was eliminated after antigen preabsorption of the antiserum, demonstrating specificity = of detection.
Vectastain ABC kit (Vector Laboratories, Burlingame, CA).
Titration of the antibody in paraffin sections showed that a concentration of 1:1000 was appropriate for immunocytochemical analysis. Rat adrenals were used as positive controls. Negative controls included (1) substitution of the primary antibody by a prebleed serum and (2) preabsorption of the antibody with 10 nmol/ml of the synthetic peptide P072. As the antibody showed a slight cross-reactivity with NPY (see Figure 2), preabsorptions with this peptide were also performed.
In situ RT-PCR
To localize the expression sites for AM, a direct method for in situ amplification of mRNA (Martinez, et al., J Histochem Cytochem, 43:739 (1995)) in a Hybaid OmniSlide System thermocycler (National Labnet Co., Woodbridge, N.J.) was used. After dewaxing, the sections were subjected to permeabilization with 10 gg/ml proteinase K (Sigma) for 15 min at 37 C. RT was performed TM
during the SuperScript Preamplification system (GIBCO-BRL) before the PCR reaction. The Taq polymerase was blocked TM
with a specific monoclonal antibody (TaqStart, Clontech) before being added to the PCR mixture to obtain a synchronous "hot start" for all slides. The PCR mixture contained 2.5 mM MgC1.,, 200 M deoxy-NTPs, 100 M
digoxigenin-deoxy-UTP (Boehringer Mannheim, Indianapolis, IN), 1 ng/ l primers, 50 mM KC1, and 10 mM Tris-HC1, pH
8.3. Twenty cycles with an annealing temperature of 55 C
were performed, and the PCR products were located using the Digoxigenin Detection Kit (Boehringer Mannheim) following the manufacturer's instructions. Controls included (1) omission of reverse transcriptase, and (2) substitution of the primers by water in the PCR mixture.
Antibody Characterization Antiserum from bleed 2343 was determined to have the highest titer to AM, with a resulting EC50 of 1:1 x 104, showing less than 1.0% (calculated 0.778) cross-reactivity with NPY at this dilution and less than 0.1%
binding with other test peptides (Figure 2). Binding differences between peptide P072 (original immunogen) and AM presumably reflect stearic interference generated during passive absorption to polyvinylchloride matrix.
The larger AM peptide, which contains the P072 antigen as an internal fragment, had a selective advantage of epitope availability when absorbed to the plastic support.
Alternatively, binding differences between these two peptide targets could reflect variation in adherence during passive absorption to the plate.
Western blot Electrophoretic fractionation of NCI-H720 cell lysate proteins revealed two immunoreactive AM-like species with molecular weight of approximately 18,000 and 6,000 (Figure 3). Presumably, these bands represent the AM precursor (185 amino acids) and the authentic peptide (52 amino acids). Immunostaining of these bands and the positive control was eliminated after antigen preabsorption of the antiserum, demonstrating specificity = of detection.
Normal l una In the normal human lung, immunoreactivity of AM
was found in the columnar cells of bronchi and bronchioli (Figures 4A-4D), in some of the serous cells of the bronchial glands, in the perikaryon of parasympathetic neurons (Figures 5A-5D), in the endothelium of blood vessels (Figure 5C), in select chondrocytes (Figures 6A
and 6B), in alveolar macrophages (Figure 7A), and in smooth muscle cells. When the chondrocytes were stained, only the more mature cells in the center of the cartilage plates showed immunoreactivity, whereas the chondroblastic cells in the periphery were negative. The in situ RT-PCR
approach showed that all cells demonstrating AM
immunoreactivity also express the mRNA for AM (Figures 4C, SC, and 7A). Negative controls for both immunocytochemistry and in situ RT-PCR demonstrated staining specificity (Figures 4B, 4D, 5B, 5D, 6B, and 7B).
Preabsorption with NPY did not affect staining (data not shown).
Expression of AM in tumor cells To determine whether tumor cells of pulmonary origin express AM, five cell lines were analyzed by RT-PCR
(Figure 8); four of them (one small and three non-small lung carcinomas) produced AM mRNA, whereas H-146, a small cell lung carcinoma, was negative. Immunocytochemical and in situ RT-PCR methods also detected AM in these cell lines following the same pattern (Figures 9A and 9B). To examine the production of AM by tumors in vivo and to ensure that the expression of AM was not an artifact of the culture procedure, 20 paraffin blocks of pulmonary malignancies with different diagnoses were analyzed (Table 3). All small cell lung carcinomas were negative by immunocytochemistry, whereas 10 of 15 of the non-small lung carcinomas were positive. The in situ RT-PCR
technique revealed that 2 of 5 of the small cell carcinomas expressed AM mRNA (Figures 10A and 10B), suggesting that the amount of AM peptide in these tumors was below the immunocytochemical detection limit.
Ex'Pression of AM mRNA in Normal Human Tissue and Tumor Cell Lines a. Cell Lines and Normal Tissue: Table 3 sets forth a summary of all tumor cell lines evaluated for AM
mRNA by RTPCR analysis showing widespread expression (95%). The tumor cell lines evaluated were as follows:
Small Cell Lung Carcinoma (SCLC): H60, H69c, H82, H146, H187, H209, H345, H446, N417, H510, N592, H735, H774, H889, H1092, and Non-small Lung Cell Carcinomas (NSCLC):
H23, H157, H460, H676, H720, H727, H820, H1264, H1385, H1404, H2087, H2228, A549, UMC11. Breast: SK-BR-3, ZR75-l, MCF-7, BT-20, MDA-MD231, BT-474, H2380. Colon: H630, SNUC-l. Nervous system: T98G (glioblastoma), C6 (glioma), and TC106, CHP100, TC17, PNET, Peii, SYSY, AS, LAN-1, KCNR-C, KCNR-DRA (neuroblastomas of the peripheral nervous system). Ovarian: NIH:OVCAR-3, SKOV3, OVT2, A2780, CP70.
Prostate: DU-145. Adrenal: H295. Chondrosarcoma: SW578.
Chronic monocytic leukemia: U937. All lung, adrenal, colon, and H2380 tumor cell lines were obtained from the NCI-Navy Medical Oncology Branch. Brain tumors were from the NCI, Pediatric Branch. The remaining cell lines came from ATCC, Rockville, MD. RNA extraction, cDNA
amplification and RTPCR were performed as previously described (T. A. Murphy and W. K. Samson, Endocrinology 136, 2459 (1995)). Cells were maintained under serum-free/hormone-free conditions in RPMI 1640 without phenol red (Life Technologies, Gaithersburg, MD) containing 3 x 10-8 M sodium selenite (Ro) at 37 C in 5% CO2. (Siegfried, et al., J. Biol. Chem. 269:8596-8603 (1994)).
was found in the columnar cells of bronchi and bronchioli (Figures 4A-4D), in some of the serous cells of the bronchial glands, in the perikaryon of parasympathetic neurons (Figures 5A-5D), in the endothelium of blood vessels (Figure 5C), in select chondrocytes (Figures 6A
and 6B), in alveolar macrophages (Figure 7A), and in smooth muscle cells. When the chondrocytes were stained, only the more mature cells in the center of the cartilage plates showed immunoreactivity, whereas the chondroblastic cells in the periphery were negative. The in situ RT-PCR
approach showed that all cells demonstrating AM
immunoreactivity also express the mRNA for AM (Figures 4C, SC, and 7A). Negative controls for both immunocytochemistry and in situ RT-PCR demonstrated staining specificity (Figures 4B, 4D, 5B, 5D, 6B, and 7B).
Preabsorption with NPY did not affect staining (data not shown).
Expression of AM in tumor cells To determine whether tumor cells of pulmonary origin express AM, five cell lines were analyzed by RT-PCR
(Figure 8); four of them (one small and three non-small lung carcinomas) produced AM mRNA, whereas H-146, a small cell lung carcinoma, was negative. Immunocytochemical and in situ RT-PCR methods also detected AM in these cell lines following the same pattern (Figures 9A and 9B). To examine the production of AM by tumors in vivo and to ensure that the expression of AM was not an artifact of the culture procedure, 20 paraffin blocks of pulmonary malignancies with different diagnoses were analyzed (Table 3). All small cell lung carcinomas were negative by immunocytochemistry, whereas 10 of 15 of the non-small lung carcinomas were positive. The in situ RT-PCR
technique revealed that 2 of 5 of the small cell carcinomas expressed AM mRNA (Figures 10A and 10B), suggesting that the amount of AM peptide in these tumors was below the immunocytochemical detection limit.
Ex'Pression of AM mRNA in Normal Human Tissue and Tumor Cell Lines a. Cell Lines and Normal Tissue: Table 3 sets forth a summary of all tumor cell lines evaluated for AM
mRNA by RTPCR analysis showing widespread expression (95%). The tumor cell lines evaluated were as follows:
Small Cell Lung Carcinoma (SCLC): H60, H69c, H82, H146, H187, H209, H345, H446, N417, H510, N592, H735, H774, H889, H1092, and Non-small Lung Cell Carcinomas (NSCLC):
H23, H157, H460, H676, H720, H727, H820, H1264, H1385, H1404, H2087, H2228, A549, UMC11. Breast: SK-BR-3, ZR75-l, MCF-7, BT-20, MDA-MD231, BT-474, H2380. Colon: H630, SNUC-l. Nervous system: T98G (glioblastoma), C6 (glioma), and TC106, CHP100, TC17, PNET, Peii, SYSY, AS, LAN-1, KCNR-C, KCNR-DRA (neuroblastomas of the peripheral nervous system). Ovarian: NIH:OVCAR-3, SKOV3, OVT2, A2780, CP70.
Prostate: DU-145. Adrenal: H295. Chondrosarcoma: SW578.
Chronic monocytic leukemia: U937. All lung, adrenal, colon, and H2380 tumor cell lines were obtained from the NCI-Navy Medical Oncology Branch. Brain tumors were from the NCI, Pediatric Branch. The remaining cell lines came from ATCC, Rockville, MD. RNA extraction, cDNA
amplification and RTPCR were performed as previously described (T. A. Murphy and W. K. Samson, Endocrinology 136, 2459 (1995)). Cells were maintained under serum-free/hormone-free conditions in RPMI 1640 without phenol red (Life Technologies, Gaithersburg, MD) containing 3 x 10-8 M sodium selenite (Ro) at 37 C in 5% CO2. (Siegfried, et al., J. Biol. Chem. 269:8596-8603 (1994)).
b. Antibodies: A previously characterized polyclonal antibody against P072(H,N-TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-CONH2), a fragment of AM
(Martinez, A., et al., Endocrinology 136:4099-4105 (1995)), was used for Western blot analysis.
A monoclonal antibody, designated as MoAb-G6, was developed against the P072 peptide of AM following a modified procedure to previously published methodology (Cuttitta, F., et al., Nature 316:823-826 (1985)). Balb/c mice were hyperimmunized with P072 peptide conjugated to keyhole limpet hemocyanin via glutaraldehyde cross-linkage (1 mg/1 mg coupling ratio). Splenic lymphocytes were fused to mouse myeloma cell line RNS1 following standard protocols. Resulting hybrids were screened for anti-P072 MoAb production using a solid phase ELISA technique.
Responding hybridomas were subcloned twice, expanded in mass culture, and utilized as the seed stock for ascites generation. MoAb-G6 (IgAx isotype) represented the highest titer antibody and was purified from ascites fluid by affinity chromatography on a solid phase P072 coupled TM
resin (BioRad Affi-Prep 10, Richmond, CA, coupling efficiency 10 mmoles peptide/ml resin). The antibody was characterized for binding specificity using a solid phase RIA with 125I-Protein A as the detector (Cuttitta, F., J.
Clin. Endocrinol. Metab. 67:576-583 (1988) (see Figure 13). In brief, test peptides were passively absorbed onto individual wells (50 ng/well; overnight at 4 C) of a 96-well polyvinylchloride microtiter plate (Dynatech Labs., Chantilly, VA) after which the plate was coated with 1.
BSA in PBS to minimize nonspecific binding. Test peptides (Peninsula Labs., Belmont, CA) included AM, P072, calcitonin gene-related peptide (CGRP), gastrin releasing peptide (GRP), glucagon-like peptide 1 (GLP 1), vasoactive intestinal peptide (VIP), arginine vasopressin (AVP), growth hormone releasing factor (GRF), cholecystokinin (CCK), amylin, gastrin, oxytocin, calcitonin, a-melanocyte stimulating hormone (aMSH), pancreatic polypeptide, peptide tyrosine-tyrosine (PYY), Tabanus atratus hypotrehalosemic hormone, and BSA (Sigma Chemical Co., St.
Louis, Mo.) as a negative control. These test peptides were chosen because they have a C-terminal tyrosine amide region or are structurally similar to AM. The antibody was tested at serial 2-fold dilutions ranging from 1:100 to 1:204,800.
c. mRNA Extraction, RT-PCR and Cloning: The oligonucleotide primers were synthesized using a MilliGen/Biosearch 8700 DNA synthesizer (Millipore, Marlborough, MA.) Primer sets for AM detection were as follows: sense, AM25o270, 5' -AAGAAGTGGAATAAGTGGGCT-3' (SEQ.
ID. NO. 8); antisense, AMA 6w, 5'-TGGCTTAGAAGACACCAGAGT-3' (SEQ. ID. NO. 9) ; and nested probe antisense, AM541-561 5'-GACGTTGTCCTTGTCCTTATC-3' (SEQ. ID. NO. 10), with a predicted product of 410bp. For AM-R amplification, the following primers were used: sense, AM-R47&4w, 5'-AGCGCCACCAGCACCGAATACG-3' (SEQ. ID. NO. 11); antisense, AM-Rgm- , 5'-AGAGGATGGGGTTGGCGACACAGT-3' (SEQ. ID. NO.
12) ; antisense probe, AM-R788-811, 5' -GGTAGGGCAGCCAGCAGATGACAA-3' (SEQ. ID. NO. 13), yielding a 471bp product. Procedures for RT-PCR, Southern and Western blotting have been described previously (Martinez, et al., EndocrinoloQv 136, 4099 (1995)). In brief, reverse transcription was performed using the SuperScript Preamplification System (Life Technologies). A Perkin-Elmer 9600 Thermocycler was used to amplify the samples for 35 cycles with annealing temperatures of 55 C and 61 C, respectively, for the ligand and its receptor. All buffers, enzymes and nucleotides used were obtained from Applied Biosystems (Perkin-Elmer Cetus, Norwalk, CT). PCR
products were analyzed electrophoretically using 15k agarose gels, and the ethidium bromide staining was observed under W light, followed by Southern analysis with 32P end-labeled probes.
(Martinez, A., et al., Endocrinology 136:4099-4105 (1995)), was used for Western blot analysis.
A monoclonal antibody, designated as MoAb-G6, was developed against the P072 peptide of AM following a modified procedure to previously published methodology (Cuttitta, F., et al., Nature 316:823-826 (1985)). Balb/c mice were hyperimmunized with P072 peptide conjugated to keyhole limpet hemocyanin via glutaraldehyde cross-linkage (1 mg/1 mg coupling ratio). Splenic lymphocytes were fused to mouse myeloma cell line RNS1 following standard protocols. Resulting hybrids were screened for anti-P072 MoAb production using a solid phase ELISA technique.
Responding hybridomas were subcloned twice, expanded in mass culture, and utilized as the seed stock for ascites generation. MoAb-G6 (IgAx isotype) represented the highest titer antibody and was purified from ascites fluid by affinity chromatography on a solid phase P072 coupled TM
resin (BioRad Affi-Prep 10, Richmond, CA, coupling efficiency 10 mmoles peptide/ml resin). The antibody was characterized for binding specificity using a solid phase RIA with 125I-Protein A as the detector (Cuttitta, F., J.
Clin. Endocrinol. Metab. 67:576-583 (1988) (see Figure 13). In brief, test peptides were passively absorbed onto individual wells (50 ng/well; overnight at 4 C) of a 96-well polyvinylchloride microtiter plate (Dynatech Labs., Chantilly, VA) after which the plate was coated with 1.
BSA in PBS to minimize nonspecific binding. Test peptides (Peninsula Labs., Belmont, CA) included AM, P072, calcitonin gene-related peptide (CGRP), gastrin releasing peptide (GRP), glucagon-like peptide 1 (GLP 1), vasoactive intestinal peptide (VIP), arginine vasopressin (AVP), growth hormone releasing factor (GRF), cholecystokinin (CCK), amylin, gastrin, oxytocin, calcitonin, a-melanocyte stimulating hormone (aMSH), pancreatic polypeptide, peptide tyrosine-tyrosine (PYY), Tabanus atratus hypotrehalosemic hormone, and BSA (Sigma Chemical Co., St.
Louis, Mo.) as a negative control. These test peptides were chosen because they have a C-terminal tyrosine amide region or are structurally similar to AM. The antibody was tested at serial 2-fold dilutions ranging from 1:100 to 1:204,800.
c. mRNA Extraction, RT-PCR and Cloning: The oligonucleotide primers were synthesized using a MilliGen/Biosearch 8700 DNA synthesizer (Millipore, Marlborough, MA.) Primer sets for AM detection were as follows: sense, AM25o270, 5' -AAGAAGTGGAATAAGTGGGCT-3' (SEQ.
ID. NO. 8); antisense, AMA 6w, 5'-TGGCTTAGAAGACACCAGAGT-3' (SEQ. ID. NO. 9) ; and nested probe antisense, AM541-561 5'-GACGTTGTCCTTGTCCTTATC-3' (SEQ. ID. NO. 10), with a predicted product of 410bp. For AM-R amplification, the following primers were used: sense, AM-R47&4w, 5'-AGCGCCACCAGCACCGAATACG-3' (SEQ. ID. NO. 11); antisense, AM-Rgm- , 5'-AGAGGATGGGGTTGGCGACACAGT-3' (SEQ. ID. NO.
12) ; antisense probe, AM-R788-811, 5' -GGTAGGGCAGCCAGCAGATGACAA-3' (SEQ. ID. NO. 13), yielding a 471bp product. Procedures for RT-PCR, Southern and Western blotting have been described previously (Martinez, et al., EndocrinoloQv 136, 4099 (1995)). In brief, reverse transcription was performed using the SuperScript Preamplification System (Life Technologies). A Perkin-Elmer 9600 Thermocycler was used to amplify the samples for 35 cycles with annealing temperatures of 55 C and 61 C, respectively, for the ligand and its receptor. All buffers, enzymes and nucleotides used were obtained from Applied Biosystems (Perkin-Elmer Cetus, Norwalk, CT). PCR
products were analyzed electrophoretically using 15k agarose gels, and the ethidium bromide staining was observed under W light, followed by Southern analysis with 32P end-labeled probes.
O
Tumor type Expression of Expression of AM-R
AM mRNA mRNA
Small cell lung 14/15 10/13 cancer Non-small lung 12/14 12/16 cancer Breast cancer 7/7 3/3 Colon cancer 2/2 0/1 Nervous system 11/il nd tumors Ovarian cancer 5/5 2/3 Prostate cancer 1/1 nd Adrenal cancer 1/1 nd Chondrosarcoma 1/1 nd Chronic 1/1 nd monocytic leukemia Total for all 55/58 (95%) 27/36(75%) cancers Table 3 sets forth a summary of tumor cell lines evaluated for AM and AM-R mRNA by RT-PCR analysis showing a widespread expression. The tumor cell lines evaluated come from diverse tissue types that express AM mRNA in 55/58 (95%) and AM-R mRNA in 27/36 (75%) as evaluated by RT-PCR, followed by southern blot analysis. nd=not done.
The fact that certain tissues do not express AM
by Northern blot analysis does not preclude its presence (see Table 4). For example, a heterogenous tissue, such as whole brain, showed AM expression by RT-PCR, but not by Northern blot analysis. Table 4 sets forth a summary of normal tissue evaluated for AM mRNA by RT-PCR analysis.
Many tissues express AM in addition to those reported previously by Northern blot analysis (Kitamura, K., et al., Biochem. Bionhvs. Res. Commun. 194, 720 (1993)). All normal human tissue polyA+ RNA was acquired through Clontech (California) and the primary epithelial cells were obtained from Clonetics (California).
Table 4 sets forth a summary of normal tissue evaluated for AM mRNA by RT-PCR analysis. A comparison of the results obtained by Kitamura, et al. using Northern blot analysis and this evaluation by RT-PCR. Some tissues, which were undetectable by Northern blot analysis were positive after amplification. nd=not done.
Tissue Northern RT-PCR
Lung: Adult + +
Fetal nd +
Heart + +
Liver: Adult - +
Fetal nd +
Skeletal muscle nd +
Testis nd +
Adrenal gland + +
Kidney + +
Uterus nd +
Mammary gland nd +
Prostate nd +
Thyroid nd -Retina nd +
Placenta nd +
Thymus nd -Spleen - -Trachea nd +
Primary bronchial nd +
epithelial cells Brain: Adult - +
Fetal nd -d. Southern Blot Analysis: Gels were denatured in 1.5 M NaCl/0.6M NaOH (30 min. x 2), neutralized in 1.5 M NaCl/2 M Tris (30 min. x 2) and blotted onto a 0.2 m nitrocellulose filter in 20X SSC by capillary flow transfer overnight. The filter was crosslinked at 80 C
under vacuum, then incubated in prehybridization buffer.
The antisense nested probe was 32P-end-labeled by standard procedures using T4 kinase. Hybridization with the labeled probe (1 x 106 cpm/ml) wad one overnight at 42 C.
Room temperature stringency washing was in 5X SSC/0.1% SDS
(30 min.) and 1X SSC/0.1% SDS (30 min.). Filters were air dried and autoradiographed on Kodak XARS film.
e. Western Blotting: Whole cell lysates were generated following a modified protocol that was previously reported (Cuttitta, et al., Nature 316:823-826 (1995)). In summary, cells were harvested 48 hours after their last feeding, washed three times in cold PBS and pelleted by centrifugation (2,000 rpm for 10 minutes at 4 C). The pellet (.5 x 107 cells) was resuspended in 1 ml of PBS containing 1 M final concentration of each of the following protease inhibitors: pefabloc (Centerchem Inc., Stamford, CT), bestatin and phosphoramidon (Sigma). The cell suspension was then homogenized, sonicated, clarified by ultracentrifugation, and the final protein concentration determined (BCA kit, BioRad Laboratories, Richmond, CA). Cell lysates were diluted in 2X Tricine sample buffer to an approximate protein concentration of 35 g/50 Al, heated to 95 C for 3 minutes, and loaded into the sample well.
Cell lysates were electrophoretically fractionated on 10-20% Tricine gels (NOVEX, San Diego, CA) at 100 volts for 2 hours under non-reducing conditions, 2 ng of peptide P072 and AM were added to separate wells as positive control standards. Transfer blotting was accomplished in the same apparatus equipped with a titanium plate electrode and transferred to a polyvinyldifluoride membrane (Immobilon PVDF, Millipore) at 30 volts for 3 hours. The membrane was blocked overnight in 1% BSA-PBS, incubated for 1 hour in 1:1,000 dilution of rabbit anti-P072 (bleed #2343), washed three times in PBS, exposed to 1 x 106 cpm '25I-Protein A for 30 minutes at 4 C, washed 6 times in PBS, dried and autoradiographed overnight at -80 C on Kodak XARS film.
Specificity control consisted of a duplicate membrane incubated in antigen-preadsorbed (10 mmols/ml P072) antiserum.
f. HPLC Characterization: The lung carcinoid cell line, H720, was acclimated to grow in RPMI-1640 under a serum-free/hormone-free environment (RO) and the resulting conditioned medium (ROCM) was subjected to HPLC
fractionation (Siegfried, J.M., et al. J. Biol. Chem.
269:8596-8603; and Reeves, J.R., J. Biol. Chem. 263:1928-1932 (1989)). Protease inhibitors were added, as described for whole cell lysates, to consecutive 1 liter harvests of ROOM and stored at 4 C until further processed. Pooled ROCM (10 liters) was freeze-dried (Freezemobile 12EL, Virtis, Gardiner, NY), reconstituted to 500 ml with distilled water, centrifuged and filter sterilized (0.45 um) to remove particulate matter. The resulting filtrate was loaded onto a semipreparative C18 TM
column (DeltaPak, Millipore, 30 x 300mm) using an auxiliary rotary pump (Ranin, Wobern, MA.) with a flow rate of 15 ml/min. Column reternate was selectively eluted over 150 min. using a 5 to 60. acetonitrile gradient containing 0.1% TFA and monitored at 210 and 280 nm (Beckman System Gold HPLC, San Ramon, CA). Twelve ml/min. fractions were collected, freeze-dried and stored at -80 C until further analysis. Stored fractions were resuspended in 2X Tricine sample buffer and subject to Western blot analysis described above.
g. I=unohistochenmistry: Cell pellets from tumor cell lines grown in RO were fixed in either 4%
paraformaldehyde of Bouin's for 2 hours, embedded in 1%
low melting point agarose, and further embedded in paraffin. Sections were stained using the avidin-biotin complex (ABC) method. Briefly, after an overnight incubation with rabbit anti-human P072 antibody (1:1000), the cells were incubated with biotinylated goat anti-rabbit immunoglobin (1:200, Vectastain, Burlingame, CA) and then with avidin-biotin peroxidase complex (1:100, Vectastain). Pre-incubation of the antiserum with 10 nmols/ml of human P072 was used as the absorption control.
The bound antibodies were visualized using diaminobenzidine (Sigma) and H202. Sections were lightly counterstained with hematoxylin.
h. In situ RT-PCR: Analysis was performed on cell lines and tissues using a direct method as previously described (Martinez, A., et al., J. Histochem. Cytochem.
43:739-747 (1995). In brief, sections were mounted on silanated slides, dewaxed, permeabilized with proteinase K
(10 g/ml, 15 min. at 37 C) and reverse transcription performed (Superscript II, Life Technologies). PCR was completed after 20 cycles in an Omnislide thermocycler (Hybaid, Holbrook, NY). Composition of the PCR mixture was similar to the solution used for standard PCR with the addition of digoxigenin-11-dUTP to label the products.
Digoxigenin tagged amplicons were visualized with a digoxigenin detection kit (Boehringer Mannheim, Indianapolis, IN). Omission of the RT step or of the specific primers in the PCR mix were used as negative controls.
i. Growth Assays: MTT techniques were performed as previously described (Nakanishi, Y.F., et al., Exper.
Cell Biol. 56:74-85 (1988)). In brief, a single cell suspension of 2 x 105 cells/ml (50 Al/well) is seeded into 96-well PVC plates and an appropriate concentration of MoAb-G6 and AM was added in a volume of 50 Al. The assay is performed in TIS medium (RMPI 1640 plus 10 g/ml transferrin, 10 g/ml insulin and 3 x 104M sodium selenite). After 5 days growth at 37 C, 5% C021 in a humid incubator, the dye and solubilization solutions were added from the Promega Proliferation Assay (Madison, WI), which is a variation of the MTT assay (Carmichael, Y.F., et al., Cancer Res. 47:943-946 (1987)). The Biorad Microplate Manager plate reader and software was used to determine the change in number of viable cells from dye reduction measured by absorbance at 570 nm.
% Growth s.d.
Cell Tumor Type MoAb-G6 MoAb-G6 + AM
Line (100 g/ml) (10 M) H157 adenosquamou 68.6% 7.4 91.8% 8.4 s H720 lung 64.3% 100.0% t 14.0 carcinoid 18.3 MCF-7 breast 44.7 k t 89.7% f 5.8 adenoCA 4.3 OVCAR-3 ovarian 64.3 % t 98.0% f 13.5 adenoCA 9.9 SNUC-1 colon 96.8% 4.5 100.0 adenoCA 10.2 Table 5 sets forth a summary of the inhibitory effects caused by MoAb-G6 and recovery with the addition of AN. Growth inhibition ranges between 25-60% in the tested cell lines as compared to control, that is, without the addition of MoAb-G6. Furthermore, specificity is demonstrated by reversing the effects of MoAb-G6 with the addition of synthetic AM. Colon cancer cell line, SNUC-1 did not respond to MoAb-G6. Values are the mean of 24 wells in three different experiments and their standard deviations (s.d.). CA=carcinoma.
J. Receptor Binding: Receptor binding analysis were performed as previously described (Moody, T.W., et al., Proc. Natl. Acad. Sci. U.S.A. 90:4345-4349 (1993)).
Briefly, cells (5 x 104) were placed in 24-well plates coated with fibronectin (20 g). When a monolayer is formed, the cells were washed 4 times in TIS buffer followed by incubation with receptor binding medium (TIS
plus 1% BSA and 1 mg/ml bacitracin). The cells were incubated with "I-AM (Phoenix Pharmaceuticals) for 30 mins at 37 C. After washing the cells 4 times in receptor binding buffer at 4 C, they were dissolved in 0.2 N NaOH
and counted on a gamma counter.
k. cAMP Assays: Cyclic AMP was assayed by RIA
using a kit obtained from New England Nuclear (Boston, MA). Cells in 24-well plates were resuspended in TIS
medium containing 1% BSA, 1 mg/ml bacitracin and 100 M
isobutyl-methyl-xanthine. AM was added ranging from 0.1 pM - 10 AM, and after 5 minutes, the reaction was terminated by adding an equal volume of ethanol. The supernatants were tested for cAMP using the RIA kit following the manufacturer's instructions.
Demonstration of secretion of AM by human tumor cell lines Select cancer cell lines were adapted to grow in serum-free, hormone-free medium (RO), and the resulting whole cell lysates from such tumor cell lines and normal tissue extracts were then examined by Western blot analysis using a previously characterized rabbit antiserum to AM (Martinez, et al., Endocrinology 136, 4099 (1995)).
Figure 14C illustrates the electrophoretic profile of the AM-like immunoreactive peptides identified. Molecular weight species of 18, 14, and 6 kDa were identified and represent AM precursor, processed intermediates, and the authentic peptide, respectively. Not all of the tumor cell lines demonstrated the presence of the 6 kDa entity, which represents the authentic peptide. The specificity of the immune-detection assay was confirmed by an antibody absorption control, which eliminated specific autoradiographic band formation (see Figure 14D).
Tumor type Expression of Expression of AM-R
AM mRNA mRNA
Small cell lung 14/15 10/13 cancer Non-small lung 12/14 12/16 cancer Breast cancer 7/7 3/3 Colon cancer 2/2 0/1 Nervous system 11/il nd tumors Ovarian cancer 5/5 2/3 Prostate cancer 1/1 nd Adrenal cancer 1/1 nd Chondrosarcoma 1/1 nd Chronic 1/1 nd monocytic leukemia Total for all 55/58 (95%) 27/36(75%) cancers Table 3 sets forth a summary of tumor cell lines evaluated for AM and AM-R mRNA by RT-PCR analysis showing a widespread expression. The tumor cell lines evaluated come from diverse tissue types that express AM mRNA in 55/58 (95%) and AM-R mRNA in 27/36 (75%) as evaluated by RT-PCR, followed by southern blot analysis. nd=not done.
The fact that certain tissues do not express AM
by Northern blot analysis does not preclude its presence (see Table 4). For example, a heterogenous tissue, such as whole brain, showed AM expression by RT-PCR, but not by Northern blot analysis. Table 4 sets forth a summary of normal tissue evaluated for AM mRNA by RT-PCR analysis.
Many tissues express AM in addition to those reported previously by Northern blot analysis (Kitamura, K., et al., Biochem. Bionhvs. Res. Commun. 194, 720 (1993)). All normal human tissue polyA+ RNA was acquired through Clontech (California) and the primary epithelial cells were obtained from Clonetics (California).
Table 4 sets forth a summary of normal tissue evaluated for AM mRNA by RT-PCR analysis. A comparison of the results obtained by Kitamura, et al. using Northern blot analysis and this evaluation by RT-PCR. Some tissues, which were undetectable by Northern blot analysis were positive after amplification. nd=not done.
Tissue Northern RT-PCR
Lung: Adult + +
Fetal nd +
Heart + +
Liver: Adult - +
Fetal nd +
Skeletal muscle nd +
Testis nd +
Adrenal gland + +
Kidney + +
Uterus nd +
Mammary gland nd +
Prostate nd +
Thyroid nd -Retina nd +
Placenta nd +
Thymus nd -Spleen - -Trachea nd +
Primary bronchial nd +
epithelial cells Brain: Adult - +
Fetal nd -d. Southern Blot Analysis: Gels were denatured in 1.5 M NaCl/0.6M NaOH (30 min. x 2), neutralized in 1.5 M NaCl/2 M Tris (30 min. x 2) and blotted onto a 0.2 m nitrocellulose filter in 20X SSC by capillary flow transfer overnight. The filter was crosslinked at 80 C
under vacuum, then incubated in prehybridization buffer.
The antisense nested probe was 32P-end-labeled by standard procedures using T4 kinase. Hybridization with the labeled probe (1 x 106 cpm/ml) wad one overnight at 42 C.
Room temperature stringency washing was in 5X SSC/0.1% SDS
(30 min.) and 1X SSC/0.1% SDS (30 min.). Filters were air dried and autoradiographed on Kodak XARS film.
e. Western Blotting: Whole cell lysates were generated following a modified protocol that was previously reported (Cuttitta, et al., Nature 316:823-826 (1995)). In summary, cells were harvested 48 hours after their last feeding, washed three times in cold PBS and pelleted by centrifugation (2,000 rpm for 10 minutes at 4 C). The pellet (.5 x 107 cells) was resuspended in 1 ml of PBS containing 1 M final concentration of each of the following protease inhibitors: pefabloc (Centerchem Inc., Stamford, CT), bestatin and phosphoramidon (Sigma). The cell suspension was then homogenized, sonicated, clarified by ultracentrifugation, and the final protein concentration determined (BCA kit, BioRad Laboratories, Richmond, CA). Cell lysates were diluted in 2X Tricine sample buffer to an approximate protein concentration of 35 g/50 Al, heated to 95 C for 3 minutes, and loaded into the sample well.
Cell lysates were electrophoretically fractionated on 10-20% Tricine gels (NOVEX, San Diego, CA) at 100 volts for 2 hours under non-reducing conditions, 2 ng of peptide P072 and AM were added to separate wells as positive control standards. Transfer blotting was accomplished in the same apparatus equipped with a titanium plate electrode and transferred to a polyvinyldifluoride membrane (Immobilon PVDF, Millipore) at 30 volts for 3 hours. The membrane was blocked overnight in 1% BSA-PBS, incubated for 1 hour in 1:1,000 dilution of rabbit anti-P072 (bleed #2343), washed three times in PBS, exposed to 1 x 106 cpm '25I-Protein A for 30 minutes at 4 C, washed 6 times in PBS, dried and autoradiographed overnight at -80 C on Kodak XARS film.
Specificity control consisted of a duplicate membrane incubated in antigen-preadsorbed (10 mmols/ml P072) antiserum.
f. HPLC Characterization: The lung carcinoid cell line, H720, was acclimated to grow in RPMI-1640 under a serum-free/hormone-free environment (RO) and the resulting conditioned medium (ROCM) was subjected to HPLC
fractionation (Siegfried, J.M., et al. J. Biol. Chem.
269:8596-8603; and Reeves, J.R., J. Biol. Chem. 263:1928-1932 (1989)). Protease inhibitors were added, as described for whole cell lysates, to consecutive 1 liter harvests of ROOM and stored at 4 C until further processed. Pooled ROCM (10 liters) was freeze-dried (Freezemobile 12EL, Virtis, Gardiner, NY), reconstituted to 500 ml with distilled water, centrifuged and filter sterilized (0.45 um) to remove particulate matter. The resulting filtrate was loaded onto a semipreparative C18 TM
column (DeltaPak, Millipore, 30 x 300mm) using an auxiliary rotary pump (Ranin, Wobern, MA.) with a flow rate of 15 ml/min. Column reternate was selectively eluted over 150 min. using a 5 to 60. acetonitrile gradient containing 0.1% TFA and monitored at 210 and 280 nm (Beckman System Gold HPLC, San Ramon, CA). Twelve ml/min. fractions were collected, freeze-dried and stored at -80 C until further analysis. Stored fractions were resuspended in 2X Tricine sample buffer and subject to Western blot analysis described above.
g. I=unohistochenmistry: Cell pellets from tumor cell lines grown in RO were fixed in either 4%
paraformaldehyde of Bouin's for 2 hours, embedded in 1%
low melting point agarose, and further embedded in paraffin. Sections were stained using the avidin-biotin complex (ABC) method. Briefly, after an overnight incubation with rabbit anti-human P072 antibody (1:1000), the cells were incubated with biotinylated goat anti-rabbit immunoglobin (1:200, Vectastain, Burlingame, CA) and then with avidin-biotin peroxidase complex (1:100, Vectastain). Pre-incubation of the antiserum with 10 nmols/ml of human P072 was used as the absorption control.
The bound antibodies were visualized using diaminobenzidine (Sigma) and H202. Sections were lightly counterstained with hematoxylin.
h. In situ RT-PCR: Analysis was performed on cell lines and tissues using a direct method as previously described (Martinez, A., et al., J. Histochem. Cytochem.
43:739-747 (1995). In brief, sections were mounted on silanated slides, dewaxed, permeabilized with proteinase K
(10 g/ml, 15 min. at 37 C) and reverse transcription performed (Superscript II, Life Technologies). PCR was completed after 20 cycles in an Omnislide thermocycler (Hybaid, Holbrook, NY). Composition of the PCR mixture was similar to the solution used for standard PCR with the addition of digoxigenin-11-dUTP to label the products.
Digoxigenin tagged amplicons were visualized with a digoxigenin detection kit (Boehringer Mannheim, Indianapolis, IN). Omission of the RT step or of the specific primers in the PCR mix were used as negative controls.
i. Growth Assays: MTT techniques were performed as previously described (Nakanishi, Y.F., et al., Exper.
Cell Biol. 56:74-85 (1988)). In brief, a single cell suspension of 2 x 105 cells/ml (50 Al/well) is seeded into 96-well PVC plates and an appropriate concentration of MoAb-G6 and AM was added in a volume of 50 Al. The assay is performed in TIS medium (RMPI 1640 plus 10 g/ml transferrin, 10 g/ml insulin and 3 x 104M sodium selenite). After 5 days growth at 37 C, 5% C021 in a humid incubator, the dye and solubilization solutions were added from the Promega Proliferation Assay (Madison, WI), which is a variation of the MTT assay (Carmichael, Y.F., et al., Cancer Res. 47:943-946 (1987)). The Biorad Microplate Manager plate reader and software was used to determine the change in number of viable cells from dye reduction measured by absorbance at 570 nm.
% Growth s.d.
Cell Tumor Type MoAb-G6 MoAb-G6 + AM
Line (100 g/ml) (10 M) H157 adenosquamou 68.6% 7.4 91.8% 8.4 s H720 lung 64.3% 100.0% t 14.0 carcinoid 18.3 MCF-7 breast 44.7 k t 89.7% f 5.8 adenoCA 4.3 OVCAR-3 ovarian 64.3 % t 98.0% f 13.5 adenoCA 9.9 SNUC-1 colon 96.8% 4.5 100.0 adenoCA 10.2 Table 5 sets forth a summary of the inhibitory effects caused by MoAb-G6 and recovery with the addition of AN. Growth inhibition ranges between 25-60% in the tested cell lines as compared to control, that is, without the addition of MoAb-G6. Furthermore, specificity is demonstrated by reversing the effects of MoAb-G6 with the addition of synthetic AM. Colon cancer cell line, SNUC-1 did not respond to MoAb-G6. Values are the mean of 24 wells in three different experiments and their standard deviations (s.d.). CA=carcinoma.
J. Receptor Binding: Receptor binding analysis were performed as previously described (Moody, T.W., et al., Proc. Natl. Acad. Sci. U.S.A. 90:4345-4349 (1993)).
Briefly, cells (5 x 104) were placed in 24-well plates coated with fibronectin (20 g). When a monolayer is formed, the cells were washed 4 times in TIS buffer followed by incubation with receptor binding medium (TIS
plus 1% BSA and 1 mg/ml bacitracin). The cells were incubated with "I-AM (Phoenix Pharmaceuticals) for 30 mins at 37 C. After washing the cells 4 times in receptor binding buffer at 4 C, they were dissolved in 0.2 N NaOH
and counted on a gamma counter.
k. cAMP Assays: Cyclic AMP was assayed by RIA
using a kit obtained from New England Nuclear (Boston, MA). Cells in 24-well plates were resuspended in TIS
medium containing 1% BSA, 1 mg/ml bacitracin and 100 M
isobutyl-methyl-xanthine. AM was added ranging from 0.1 pM - 10 AM, and after 5 minutes, the reaction was terminated by adding an equal volume of ethanol. The supernatants were tested for cAMP using the RIA kit following the manufacturer's instructions.
Demonstration of secretion of AM by human tumor cell lines Select cancer cell lines were adapted to grow in serum-free, hormone-free medium (RO), and the resulting whole cell lysates from such tumor cell lines and normal tissue extracts were then examined by Western blot analysis using a previously characterized rabbit antiserum to AM (Martinez, et al., Endocrinology 136, 4099 (1995)).
Figure 14C illustrates the electrophoretic profile of the AM-like immunoreactive peptides identified. Molecular weight species of 18, 14, and 6 kDa were identified and represent AM precursor, processed intermediates, and the authentic peptide, respectively. Not all of the tumor cell lines demonstrated the presence of the 6 kDa entity, which represents the authentic peptide. The specificity of the immune-detection assay was confirmed by an antibody absorption control, which eliminated specific autoradiographic band formation (see Figure 14D).
To further corroborate the expression of authentic AM by tumor cells, HPLC fractionation of RO-conditioned medium was analyzed from the lung carcinoid cell line NCIH720. Briefly, H720 cells were mass cultured in approximately 5 L of hormone-free medium and freeze dried at lOX concentration. The H720 conditioned medium (CM) was then filter sterilized using a .45 m filter. In preparation for HPLC chromatography, the following protease inhibitors were added to the CM: pefabloc 1 M, bestatin 1 M, and phosphoramidon 1 uM. The CM was loaded onto a semipreparative C18 column (30 x 120 mm) attached to a Beclunan System Gold HPLC using an acetonitrile gradient from 5 to 60% (with 0.116 trifluouroacetic acid) over a time course of 150 min; 12 fractions were collected, freeze-dried and resuspended in the appropriate volume of buffer. Figure 15A illustrates the fractionation of 5L of H720 CM concentrated to 500 mL
before injection, compared with the elution time of synthetic AM at 89.4 min (arrow). Figures 15B and 15C
show that AM immunoreactivity occurs at approximately 88.8 min. in the H720 CM by either solid phase (see Figure 15B) or Western blot analysis (Figure 15C). The Western analysis demonstrates that the fractions at 88 to 92 min contain the 6 kDa entity, and those at 124 to 129 min contain the 14 and 18kDa entities.
The cell line NCIH720 contained AM-like immunoreactivity with a column elution time consistent with synthetic peptide (=89 min) (Figures 15A and 15B).
In addition, immunoblot analysis of consecutive HPLC
fractions within the 88 to 92 min region revealed a major 6 kDa immunoreactive band, while the 122 to 129 min fractions expressed both the 18 and 14 kDa entity (see Figure 15C). Thus, RO adapted human tumor cell lines were shown to express authentic AM by two separate biochemical techniques.
before injection, compared with the elution time of synthetic AM at 89.4 min (arrow). Figures 15B and 15C
show that AM immunoreactivity occurs at approximately 88.8 min. in the H720 CM by either solid phase (see Figure 15B) or Western blot analysis (Figure 15C). The Western analysis demonstrates that the fractions at 88 to 92 min contain the 6 kDa entity, and those at 124 to 129 min contain the 14 and 18kDa entities.
The cell line NCIH720 contained AM-like immunoreactivity with a column elution time consistent with synthetic peptide (=89 min) (Figures 15A and 15B).
In addition, immunoblot analysis of consecutive HPLC
fractions within the 88 to 92 min region revealed a major 6 kDa immunoreactive band, while the 122 to 129 min fractions expressed both the 18 and 14 kDa entity (see Figure 15C). Thus, RO adapted human tumor cell lines were shown to express authentic AM by two separate biochemical techniques.
The regulation of human tumor cell proliferation by AM
Consistent results were observed by immunohistochemical and in situ RT-PCR (Martinez, et al., J. Histochem. Cytochem. 43, 739 (1995)) examination of paraffin-embedded RO-adapted cell lines. Heterogeneous expression of AM was observed with the highest intensity of staining confined to the outer cell layers (proliferative zones) of individual colonies, a finding that implicates AM in growth regulation. To further evaluate this hypothesis, MTT assay techniques were used (D. N. Carney, et al., Proc. Natl. Acad Sci. U.S.A. 79, 3185 (1981)) to examine the effects of AM on the growth of several diverse tumor cell lines, specifically, lung, colon, breast, brain, and ovarian cell lines. Exogenous addition of AM (0.1 nM to 100 nM) to RO-grown cell cultures was ineffective in stimulating growth, although there was some nonspecific toxicity at the higher range.
Since the test cell lines were known to produce authentic AM peptide, it was assumed that this inability to stimulate growth with extrinsic ligand meant that it had already achieved maximal proliferative effects using its own AM-producing mechanism.
In a parallel setting, MoAb-G6 was used to block endogenous AM biological activity. This monoclonal antibody was generated against a synthetic homolog of AM
(P072) and structurally represents two-thirds of the intact peptide (TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2 (SEQ.
ID. NO. 14)). Immunization, fusion, and hybridoma screening strategies were completed as previously described (Cuttitta, et al., Nature 316, 823 (1985)).
MoAb-G6, an IgA subtype, did not cross-react with other known tyrosine amide peptides or with the structurally related CGRP and amylin (see Figure 13). Before its use in vitro, the MoAb-G6 was affinity-purified from ascites fluid using a solid-phase antigen column and eluted at 60 min with 0.1M citric acid (pH 3.0). The addition of synthetic AM alone induced a slight suppression (-10%) at higher ranges (10 um) (Figure 17B). The MTT assay was used to evaluate MoAb-G6 for its effect on the growth of several human tumor cell lines (NCI-H157, NCI-H720, MCF-7, SNUC1 and NIH:OVCAR-3), and in every case (5 out of 5) a dose-dependent suppression was observed. Maximal growth inhibition ranged from 20 to 55% for the cell lines tested. Representative data for MCF-7 are depicted in Figure 17A, which shows that an isotypic control mouse myeloma protein (TEPC 15, IgAK, Sigma) was ineffective in blocking growth over the same dose range. MoAb-G6 induced inhibition of tumor cell growth was abolished by exogenous addition of AM, with maximal recovery at 10 uM, thus verifying the specificity of the immune suppressive growth (Figure 17B).
Determination of the distribution of AM in the Dancreas by immunocytochemistrv Pancreata from rats, hamsters, guinea pigs, cats, and dogs were fixed in Bouin's fluid (Sigma, St.
Louis, MO) and embedded in paraffin. The avidin-biotin--peroxidase complex method (Hsu, et al., J Histochem Cytochem 29:577-580 (1981)) was performed using a polyclonal antibody to AM previously characterized (Martinez, et al., Endocrinology 136, 4099 (1995)) and commercially available antibodies against insulin, glucagon, somatostatin, and pancreatic polypeptide (Accurate Chemical & Scientific Corp., Westbury, NY).
Negative controls included substitution of the primary antibody by preimmune serum from the same rabbit and preabsorption of the antibody with 10 nmols/mL of the synthetic peptide (AM or CGRP). For immunoelectron microscopy three rats were perfused with a mixture of 2.5%
paraformaldehyde + 2.0% glutaraldehyde in cacodylate 0 buffer. Small pieces of pancreas were dehydrated and embedded in resin. Ultrathin sections were mounted in nickel grids and the double immunogold method was performed as previously described (Martinez, et al., J.
Histochem. Cvtochem. 43, 739 (1995)).
Figure 18A shows a rat pancreas with mild immunoreactivity throughout the entire islet of Langerhans and strongly stained cells in the periphery. No counterstaining was applied to this section. Figure 18B
sets forth Hamster pancreas which displays a similar pattern. Figure 18C set forth dog pancreas containing numerous immunoreactive cells scattered throughout the parenchyma. Figure 18D depicts the immunoreactivity in ductal systems of guinea pig pancreas. Note that endocrine cells are more intensely stained than duct cells. Figure 18E shows serial sections of hamster pancreas immunostained for AM and Figure 18F shows pancreatic polypeptide show colocalization of both immunoreactivities (arrows). Figure 18G sets forth double immunogold staining by electron microscopy showing colocalization of AM (small gold particles, 10 nm) and pancreatic polypeptide (large gold particles, 20 nm) in the cell situated to the left. A small fragment of a negative a-cell can be observed to the right. Inset shows two secretory granules containing both immunoreactivities at higher magnification. Figure 18H shows detail of a D-cell showing some immunoreactivity for AM (large particles) in the somatostatin-containing (small particles) secretory granules.
AM increases cAMP and AM receptors are Dresent in human tumor cell lines Following previously established protocols (T.
W. Moody, et al., Proc. Natl. Acad. Sci U.S.A. 90, 4345 (1993)) iodinated ligand (Phoenix Pharmaceuticals) and 0 cAMP response to synthetic AM was used to analyze the presence of AM receptor in responding tumor cell lines.
Several cancer lines demonstrated selective binding of "I-AM, which was not competitively blocked by the synthetic homolog P072 or the gene-related peptide PAMP
(Figure 19A-check). The data show that specific binding is inhibited by AM in a dose-dependent manner with an IC50 of 10 nM. In addition, AM binding to this receptor system induced a rapid linear increase in cellular cAMP over a dose range of 10 pM to 1 AM (ED50 5 nM), thereby resulting in a maximum elevation three times that of the normal control (Figure 19B). In contrast, P072 and PAMP had no effect on cAMP.
Determination of the effects AM and MoAb-G6 on the release of insulin from rat isolated islets Dose-dependent increase of intracellular cAMP in the islets following addition of AM. Islets from six rats were isolated following well-established protocols (Gray, et al., Diabetes 33, 1055 (1984)). Assays were performed in 24-well plates (90 islets per well). After a 45 min incubation in RPMI-1690 medium containing 5.6 mM glucose, a second incubation in RPMI containing 20.6 mM glucose and the proper concentration of AM and/or the antibody was performed. Supernatants from both incubations were tested by radioimmunoassay (RIA) for insulin (Amersham, Arlington Heights, IL). The ratio between the insulin concentration found in the high glucose supernatant and the insulin measured in the low glucose solution is represented in ordinates. After collecting the medium, the islets from the same experiments were saved for analysis of cAMP
contents (Korman, et al., Cancer Res. 46, 1214 (1986)).
Islets were extracted in 50% ethanol and centrifuged, and the supernatants were tested for cAMP using a RIA kit (New England Nuclear, Boston, MA) following manufacturer's instructions. The experiments were repeated three times and a representative example shown. Data are means standard deviations of two wells.
Southern Blot The mRNA used for Southern blotting was either purchased (Clontech, Palo Alto, CA) in the case of the normal tissues, or extracted from the cell lines using the MicroFast Track kit (Invitrogen, San Diego, CA). Reverse transcription (RT), polymerase chain reaction (PCR), and Southern blot were carried out as previously described (Martinez, et al., Endocrinolocrv 136, 4099 (1995)). A set of primers that recognizes the most conserved regions of the AM gene were designed and used. The primer sequences are Sense (AM 250-270) 5'-AAG-AAG-TGG-AAT-AAG-TGG-GCT-3' (SEQ. ID. NO. 15); Antisense (AM 523-542) 5'-TGT-GAA-CTG-GTA-GAT-CTG-GT-3'(SEQ. ID. NO. 16). The probe used for Southern was AM (430-450) 5'-TCT-GGC-GGT-AGC-GCT-TGA-CTC-3' (SEQ. ID. NO. 17).
These primers produce 292 bp products. Base sequence analysis of isolated bands confirmed identity of the RT-PCR product.
Glucose tolerance tests Glucose tolerance tests were performed on Sprague-Dawley rats (250 to 300 g) in the presence (0) or absence (0) of AM. (Figure 21A) Significant differences (p<0.01) in insulin levels can be observed 20 min after intravenous injection of AM. (Figure 21B) Difference in levels of circulating glucose was also highly significant (p<0.01) 1 h after injection. Glucose tolerance methods have been published previously (Brown, et al., Proc. Soc.
Exo. Biol. Med. 150, 557 (1975)). Six rats were administered a glucose solution (400 mg/100 g body weight) 0 via gastric intubation. Ocular blood samples were collected at intervals following glucose loading, and glucose concentration was determined by a colorimetric assay (Sigma). Blood insulin levels were determined on the same samples by radioimmunoassay (Amersham). Three days later, the same rats received 1 L of AM (60 M) per g body weight through intravenous injection and tolerance tests were repeated. Data are means standard deviations for the six animals. Two-tailed Student's test was performed to determine statistical significance. (*) indicates statistical significance (p<0.01).
The Localization of AM mRNA and Immunoreactivi tv in Various Orcrans of Different Species.
In situ RT-PCR and immunohistochemistry were performed as described in Martinez, et al., Endocrinolocrv 136:4099 (1995). Briefly, the tissues used for in situ RT-PCR were fixed in 4% paraformaldehyde, whereas the tissues for immunohistochemistry were fixed in Bouin's fluid (Sigma Chemical Co.). Controls for in situ RT-PCR
included omission of the reverse transcriptase step of substitution of the specific primers by water. Negative controls for immunohistochemistry consisted in preabsorption of the antibody with 10nmols/ml of synthetic AM or substitution of the primary antibody by preimmune serum.
Effect of AMP and PAMP on the Inhibition of Growth of E.
coli.
Inhibition of growth of E. coli was assessed in a microdilutional timed kill assay. (See Figure 23) Bacteria and Candida albicans were grown overnight on trypticase soy agar (TSA) and Sobouraud dextrose agar (SDA) plates, respectively, were suspended into RPMI-1640 medium (Bio-Whittaker) and adjusted to a final concentration of 8x103 cfu/ml in 200 ul in plastic microdilution trays. AM-related peptides, magainins, and albumin were added in equimolar concentrations ranging from 8 uM to 300 uM. Plates were incubated at 37 C with gentle agitation over 24 hours. At 6 hr and 24 hr time points, 10 to 50 ul aliquots from each well were quantitatively cultured by serial 100-fold dilutions onto TSA and SDA plates.
Antimicrobial activity of AM and PAMP.
The antimicrobial activity of AM and PAMP was determined in a macrodilution assay after 6 hours of incubation of E. coli. (See Figure 24A) There was initially no activity observed for AM at 6 hours, moderate activity for magainin, and greater activity generated by PAMP. As of the 24 hour incubation (see Figure 24B) AM
was slightly more active than PAMP in growth inhibition, while magainin (M) was more potent than either AM
(p=0.006) or PAMP (p=0.004). Data were compiled from six experiments. Macrodilution assays were performed in 12 x 75 mm borosilicate glass tubes. Organisms were grown and harvested, as described in Roilides, E., et al., J Infect Dis. 163:579 (1991), and adjusted to a final inoculum concentration of 8 x 103 cfu/ml in 400 ul. AM-related peptides, magainins, and albumin were added in equimolar concentrations ranging from 8 uM to 300 uM. Tubes were incubated at 37oC with gentle agitation over 24 hours. At 6 and 24 hour time points, 100 ul aliquots from each tube were quantitatively cultured by serial 100-fold dilutions onto TSA and SDA plates.
Consistent results were observed by immunohistochemical and in situ RT-PCR (Martinez, et al., J. Histochem. Cytochem. 43, 739 (1995)) examination of paraffin-embedded RO-adapted cell lines. Heterogeneous expression of AM was observed with the highest intensity of staining confined to the outer cell layers (proliferative zones) of individual colonies, a finding that implicates AM in growth regulation. To further evaluate this hypothesis, MTT assay techniques were used (D. N. Carney, et al., Proc. Natl. Acad Sci. U.S.A. 79, 3185 (1981)) to examine the effects of AM on the growth of several diverse tumor cell lines, specifically, lung, colon, breast, brain, and ovarian cell lines. Exogenous addition of AM (0.1 nM to 100 nM) to RO-grown cell cultures was ineffective in stimulating growth, although there was some nonspecific toxicity at the higher range.
Since the test cell lines were known to produce authentic AM peptide, it was assumed that this inability to stimulate growth with extrinsic ligand meant that it had already achieved maximal proliferative effects using its own AM-producing mechanism.
In a parallel setting, MoAb-G6 was used to block endogenous AM biological activity. This monoclonal antibody was generated against a synthetic homolog of AM
(P072) and structurally represents two-thirds of the intact peptide (TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2 (SEQ.
ID. NO. 14)). Immunization, fusion, and hybridoma screening strategies were completed as previously described (Cuttitta, et al., Nature 316, 823 (1985)).
MoAb-G6, an IgA subtype, did not cross-react with other known tyrosine amide peptides or with the structurally related CGRP and amylin (see Figure 13). Before its use in vitro, the MoAb-G6 was affinity-purified from ascites fluid using a solid-phase antigen column and eluted at 60 min with 0.1M citric acid (pH 3.0). The addition of synthetic AM alone induced a slight suppression (-10%) at higher ranges (10 um) (Figure 17B). The MTT assay was used to evaluate MoAb-G6 for its effect on the growth of several human tumor cell lines (NCI-H157, NCI-H720, MCF-7, SNUC1 and NIH:OVCAR-3), and in every case (5 out of 5) a dose-dependent suppression was observed. Maximal growth inhibition ranged from 20 to 55% for the cell lines tested. Representative data for MCF-7 are depicted in Figure 17A, which shows that an isotypic control mouse myeloma protein (TEPC 15, IgAK, Sigma) was ineffective in blocking growth over the same dose range. MoAb-G6 induced inhibition of tumor cell growth was abolished by exogenous addition of AM, with maximal recovery at 10 uM, thus verifying the specificity of the immune suppressive growth (Figure 17B).
Determination of the distribution of AM in the Dancreas by immunocytochemistrv Pancreata from rats, hamsters, guinea pigs, cats, and dogs were fixed in Bouin's fluid (Sigma, St.
Louis, MO) and embedded in paraffin. The avidin-biotin--peroxidase complex method (Hsu, et al., J Histochem Cytochem 29:577-580 (1981)) was performed using a polyclonal antibody to AM previously characterized (Martinez, et al., Endocrinology 136, 4099 (1995)) and commercially available antibodies against insulin, glucagon, somatostatin, and pancreatic polypeptide (Accurate Chemical & Scientific Corp., Westbury, NY).
Negative controls included substitution of the primary antibody by preimmune serum from the same rabbit and preabsorption of the antibody with 10 nmols/mL of the synthetic peptide (AM or CGRP). For immunoelectron microscopy three rats were perfused with a mixture of 2.5%
paraformaldehyde + 2.0% glutaraldehyde in cacodylate 0 buffer. Small pieces of pancreas were dehydrated and embedded in resin. Ultrathin sections were mounted in nickel grids and the double immunogold method was performed as previously described (Martinez, et al., J.
Histochem. Cvtochem. 43, 739 (1995)).
Figure 18A shows a rat pancreas with mild immunoreactivity throughout the entire islet of Langerhans and strongly stained cells in the periphery. No counterstaining was applied to this section. Figure 18B
sets forth Hamster pancreas which displays a similar pattern. Figure 18C set forth dog pancreas containing numerous immunoreactive cells scattered throughout the parenchyma. Figure 18D depicts the immunoreactivity in ductal systems of guinea pig pancreas. Note that endocrine cells are more intensely stained than duct cells. Figure 18E shows serial sections of hamster pancreas immunostained for AM and Figure 18F shows pancreatic polypeptide show colocalization of both immunoreactivities (arrows). Figure 18G sets forth double immunogold staining by electron microscopy showing colocalization of AM (small gold particles, 10 nm) and pancreatic polypeptide (large gold particles, 20 nm) in the cell situated to the left. A small fragment of a negative a-cell can be observed to the right. Inset shows two secretory granules containing both immunoreactivities at higher magnification. Figure 18H shows detail of a D-cell showing some immunoreactivity for AM (large particles) in the somatostatin-containing (small particles) secretory granules.
AM increases cAMP and AM receptors are Dresent in human tumor cell lines Following previously established protocols (T.
W. Moody, et al., Proc. Natl. Acad. Sci U.S.A. 90, 4345 (1993)) iodinated ligand (Phoenix Pharmaceuticals) and 0 cAMP response to synthetic AM was used to analyze the presence of AM receptor in responding tumor cell lines.
Several cancer lines demonstrated selective binding of "I-AM, which was not competitively blocked by the synthetic homolog P072 or the gene-related peptide PAMP
(Figure 19A-check). The data show that specific binding is inhibited by AM in a dose-dependent manner with an IC50 of 10 nM. In addition, AM binding to this receptor system induced a rapid linear increase in cellular cAMP over a dose range of 10 pM to 1 AM (ED50 5 nM), thereby resulting in a maximum elevation three times that of the normal control (Figure 19B). In contrast, P072 and PAMP had no effect on cAMP.
Determination of the effects AM and MoAb-G6 on the release of insulin from rat isolated islets Dose-dependent increase of intracellular cAMP in the islets following addition of AM. Islets from six rats were isolated following well-established protocols (Gray, et al., Diabetes 33, 1055 (1984)). Assays were performed in 24-well plates (90 islets per well). After a 45 min incubation in RPMI-1690 medium containing 5.6 mM glucose, a second incubation in RPMI containing 20.6 mM glucose and the proper concentration of AM and/or the antibody was performed. Supernatants from both incubations were tested by radioimmunoassay (RIA) for insulin (Amersham, Arlington Heights, IL). The ratio between the insulin concentration found in the high glucose supernatant and the insulin measured in the low glucose solution is represented in ordinates. After collecting the medium, the islets from the same experiments were saved for analysis of cAMP
contents (Korman, et al., Cancer Res. 46, 1214 (1986)).
Islets were extracted in 50% ethanol and centrifuged, and the supernatants were tested for cAMP using a RIA kit (New England Nuclear, Boston, MA) following manufacturer's instructions. The experiments were repeated three times and a representative example shown. Data are means standard deviations of two wells.
Southern Blot The mRNA used for Southern blotting was either purchased (Clontech, Palo Alto, CA) in the case of the normal tissues, or extracted from the cell lines using the MicroFast Track kit (Invitrogen, San Diego, CA). Reverse transcription (RT), polymerase chain reaction (PCR), and Southern blot were carried out as previously described (Martinez, et al., Endocrinolocrv 136, 4099 (1995)). A set of primers that recognizes the most conserved regions of the AM gene were designed and used. The primer sequences are Sense (AM 250-270) 5'-AAG-AAG-TGG-AAT-AAG-TGG-GCT-3' (SEQ. ID. NO. 15); Antisense (AM 523-542) 5'-TGT-GAA-CTG-GTA-GAT-CTG-GT-3'(SEQ. ID. NO. 16). The probe used for Southern was AM (430-450) 5'-TCT-GGC-GGT-AGC-GCT-TGA-CTC-3' (SEQ. ID. NO. 17).
These primers produce 292 bp products. Base sequence analysis of isolated bands confirmed identity of the RT-PCR product.
Glucose tolerance tests Glucose tolerance tests were performed on Sprague-Dawley rats (250 to 300 g) in the presence (0) or absence (0) of AM. (Figure 21A) Significant differences (p<0.01) in insulin levels can be observed 20 min after intravenous injection of AM. (Figure 21B) Difference in levels of circulating glucose was also highly significant (p<0.01) 1 h after injection. Glucose tolerance methods have been published previously (Brown, et al., Proc. Soc.
Exo. Biol. Med. 150, 557 (1975)). Six rats were administered a glucose solution (400 mg/100 g body weight) 0 via gastric intubation. Ocular blood samples were collected at intervals following glucose loading, and glucose concentration was determined by a colorimetric assay (Sigma). Blood insulin levels were determined on the same samples by radioimmunoassay (Amersham). Three days later, the same rats received 1 L of AM (60 M) per g body weight through intravenous injection and tolerance tests were repeated. Data are means standard deviations for the six animals. Two-tailed Student's test was performed to determine statistical significance. (*) indicates statistical significance (p<0.01).
The Localization of AM mRNA and Immunoreactivi tv in Various Orcrans of Different Species.
In situ RT-PCR and immunohistochemistry were performed as described in Martinez, et al., Endocrinolocrv 136:4099 (1995). Briefly, the tissues used for in situ RT-PCR were fixed in 4% paraformaldehyde, whereas the tissues for immunohistochemistry were fixed in Bouin's fluid (Sigma Chemical Co.). Controls for in situ RT-PCR
included omission of the reverse transcriptase step of substitution of the specific primers by water. Negative controls for immunohistochemistry consisted in preabsorption of the antibody with 10nmols/ml of synthetic AM or substitution of the primary antibody by preimmune serum.
Effect of AMP and PAMP on the Inhibition of Growth of E.
coli.
Inhibition of growth of E. coli was assessed in a microdilutional timed kill assay. (See Figure 23) Bacteria and Candida albicans were grown overnight on trypticase soy agar (TSA) and Sobouraud dextrose agar (SDA) plates, respectively, were suspended into RPMI-1640 medium (Bio-Whittaker) and adjusted to a final concentration of 8x103 cfu/ml in 200 ul in plastic microdilution trays. AM-related peptides, magainins, and albumin were added in equimolar concentrations ranging from 8 uM to 300 uM. Plates were incubated at 37 C with gentle agitation over 24 hours. At 6 hr and 24 hr time points, 10 to 50 ul aliquots from each well were quantitatively cultured by serial 100-fold dilutions onto TSA and SDA plates.
Antimicrobial activity of AM and PAMP.
The antimicrobial activity of AM and PAMP was determined in a macrodilution assay after 6 hours of incubation of E. coli. (See Figure 24A) There was initially no activity observed for AM at 6 hours, moderate activity for magainin, and greater activity generated by PAMP. As of the 24 hour incubation (see Figure 24B) AM
was slightly more active than PAMP in growth inhibition, while magainin (M) was more potent than either AM
(p=0.006) or PAMP (p=0.004). Data were compiled from six experiments. Macrodilution assays were performed in 12 x 75 mm borosilicate glass tubes. Organisms were grown and harvested, as described in Roilides, E., et al., J Infect Dis. 163:579 (1991), and adjusted to a final inoculum concentration of 8 x 103 cfu/ml in 400 ul. AM-related peptides, magainins, and albumin were added in equimolar concentrations ranging from 8 uM to 300 uM. Tubes were incubated at 37oC with gentle agitation over 24 hours. At 6 and 24 hour time points, 100 ul aliquots from each tube were quantitatively cultured by serial 100-fold dilutions onto TSA and SDA plates.
The effect of AM on the Qermination of C. albicans There was a significant inhibition of germination of C. albicans by increasing concentrations of AM at 4 hours incubation (p=0.048, ANOVA) (see Figure 25).
The trend in suppression of germination after 2 hours incubation was not significant. Data were compiled from 11 experiments. Germination was determined by incubating colonies of C. albicans that were harvested from an overnight growth on SDA and suspended on RPMI-1640 containing concentrations of AM from 8 to 85 uM.
Organisms were incubated at 37 C and germination was measured at 2h and 4h by reading 100 to 200 organisms per concentration per time point in each experiment. Percent germination was assessed as the proportion of blastoconidia of C. albicans bearing the characteristic parallel-walled tubular element to the total number of blastoconidia.
The trend in suppression of germination after 2 hours incubation was not significant. Data were compiled from 11 experiments. Germination was determined by incubating colonies of C. albicans that were harvested from an overnight growth on SDA and suspended on RPMI-1640 containing concentrations of AM from 8 to 85 uM.
Organisms were incubated at 37 C and germination was measured at 2h and 4h by reading 100 to 200 organisms per concentration per time point in each experiment. Percent germination was assessed as the proportion of blastoconidia of C. albicans bearing the characteristic parallel-walled tubular element to the total number of blastoconidia.
REFERENCES
1. Kitamura K., et al., Biochem Biophvs Res Commun 192:553-560 (1993).
2. Eguchi S., et al., Endocrinology 135:2454-2458 (1994).
3. Kitamura K., et al., Biochem Biophys Res Commun 194:720-725 (1993).
4. Ishimitsu T., et al., Biochem Biophvs Res Commun 203:631-639 (1994).
5. Kitamura K., et al., FEES Lett 338:306-310 (1994).
6. Sakata J., et al., Biochem Biophys Res Commun 195:921-927 (1993).
7. Nuki C., et al., Biochem Biophvs Res Commun 196:245-251 (1993).
8. Ishiyama Y., et al., Eur J Pharmacol 241:271-273 (1993).
9. Perret M., et al., Life Sci 53:PL377-PL379 (1993).
10. Lippton H., et al., Life Sci 54:PL409-PL412 (1994).
11. Santiago J.A., et al., Eur J. Pharmacol 272:115-118 (1995).
12. Lippton H., et al., J Appl Physiol 76:2154-2156 (1994).
13. Sugo S., et al., Biochem Biophys Res Commun 201:1160-1166 (1994).
14. Eguchi S., et al., FEBS Lett 340:226-230 (1994).
15. Ishizaka Y., et al., Biochem Biophys Res Commun 200:642-646 (1994).
16. Kawada N., et al., FEES Lett 356:109-113 (1994).
17. Ebara T., et al., Eur J. Pharmacol 263:69-73 (1994).
18. Nossaman B.D., et al., Life Sci 56:PL63-PL66 (1995).
19. Kanazawa H., et al., Biochem Biophys Res Commun 205:251-254 (1994).
20. Kitamura K., et al., FEES Lett 341:288-290 (1994).
21. Siegfried J.M., et al., J Biol Chem 269:8596-8603 (1994).
1. Kitamura K., et al., Biochem Biophvs Res Commun 192:553-560 (1993).
2. Eguchi S., et al., Endocrinology 135:2454-2458 (1994).
3. Kitamura K., et al., Biochem Biophys Res Commun 194:720-725 (1993).
4. Ishimitsu T., et al., Biochem Biophvs Res Commun 203:631-639 (1994).
5. Kitamura K., et al., FEES Lett 338:306-310 (1994).
6. Sakata J., et al., Biochem Biophys Res Commun 195:921-927 (1993).
7. Nuki C., et al., Biochem Biophvs Res Commun 196:245-251 (1993).
8. Ishiyama Y., et al., Eur J Pharmacol 241:271-273 (1993).
9. Perret M., et al., Life Sci 53:PL377-PL379 (1993).
10. Lippton H., et al., Life Sci 54:PL409-PL412 (1994).
11. Santiago J.A., et al., Eur J. Pharmacol 272:115-118 (1995).
12. Lippton H., et al., J Appl Physiol 76:2154-2156 (1994).
13. Sugo S., et al., Biochem Biophys Res Commun 201:1160-1166 (1994).
14. Eguchi S., et al., FEBS Lett 340:226-230 (1994).
15. Ishizaka Y., et al., Biochem Biophys Res Commun 200:642-646 (1994).
16. Kawada N., et al., FEES Lett 356:109-113 (1994).
17. Ebara T., et al., Eur J. Pharmacol 263:69-73 (1994).
18. Nossaman B.D., et al., Life Sci 56:PL63-PL66 (1995).
19. Kanazawa H., et al., Biochem Biophys Res Commun 205:251-254 (1994).
20. Kitamura K., et al., FEES Lett 341:288-290 (1994).
21. Siegfried J.M., et al., J Biol Chem 269:8596-8603 (1994).
22. Glisin V., et al., Biochemistry 13:2633-2637 (1974).
23. Cuttitta F., et al., J Clin Endocrinol Metab 67:576-583 (1988).
24. Hsu S.M., et al., J Histochem Cvtochem 29:577-580 (1981).
25. Martinez A., et al., J Histochem Cvtochem, 43, 739 (1995).
26. Sugo S., et al., Biochem Biophys Res Commun 203:719-726 (1994).
27. Springall D.R., et al., J Auton Nerv Syst 20:155-166 (1987).
28. Takahashi H., et al., Am J Hvpertens 7:478-482 (1994).
29. Giaid A., et al., Am J Respir Cell Mol Biol 4:50-56 (1990).
30. Diamond G., et al., Proc Natl Acad Sci USA 90:4596-4600 (1993).
31. Diamond G., et al., Proc Natl Acad Sci USA 88:3952-3956 (1991).
32. Saldise L., et al., 8th National Congress of Histology, Jaen, Spain, 1993, pp 195-196 (Abstract).
33. Ishizuka J., et al., Cancer Res 54:2129-2135 (1994).
34. Moody T.W., et al., Proc Natl Acad Sci USA 90:4345-4349 (1993).
35. Weinstat-Saslow D., Steeg P.S., FASEB 8:401-407 (1994).
36. Bloom S.R., Polak J.M., Adv Clin Chem 21:177-244 (1980).
37. Vane J.R., Botting R.M., J Physiol Pharmacol 43:195-207 (1992).
38. Kitamura, K., et al., Biochem. Biophvs. Res. Commun.
194, 720 (1993).
40. Shimosawa, T., et al., J. Clin. Invest. 96, 1672 (1995).
41. Ishizaka, Y., et al., Biochem. Biophys. Res. Commun.
200, 642 (1994).
23. Cuttitta F., et al., J Clin Endocrinol Metab 67:576-583 (1988).
24. Hsu S.M., et al., J Histochem Cvtochem 29:577-580 (1981).
25. Martinez A., et al., J Histochem Cvtochem, 43, 739 (1995).
26. Sugo S., et al., Biochem Biophys Res Commun 203:719-726 (1994).
27. Springall D.R., et al., J Auton Nerv Syst 20:155-166 (1987).
28. Takahashi H., et al., Am J Hvpertens 7:478-482 (1994).
29. Giaid A., et al., Am J Respir Cell Mol Biol 4:50-56 (1990).
30. Diamond G., et al., Proc Natl Acad Sci USA 90:4596-4600 (1993).
31. Diamond G., et al., Proc Natl Acad Sci USA 88:3952-3956 (1991).
32. Saldise L., et al., 8th National Congress of Histology, Jaen, Spain, 1993, pp 195-196 (Abstract).
33. Ishizuka J., et al., Cancer Res 54:2129-2135 (1994).
34. Moody T.W., et al., Proc Natl Acad Sci USA 90:4345-4349 (1993).
35. Weinstat-Saslow D., Steeg P.S., FASEB 8:401-407 (1994).
36. Bloom S.R., Polak J.M., Adv Clin Chem 21:177-244 (1980).
37. Vane J.R., Botting R.M., J Physiol Pharmacol 43:195-207 (1992).
38. Kitamura, K., et al., Biochem. Biophvs. Res. Commun.
194, 720 (1993).
40. Shimosawa, T., et al., J. Clin. Invest. 96, 1672 (1995).
41. Ishizaka, Y., et al., Biochem. Biophys. Res. Commun.
200, 642 (1994).
42. Santago, J.A., et al., Life Sci. 55, 85 (1994).
43. Cheng, D.Y., et al., Life Sci. 55, 251 (1994).
44. Shimekake, Y., et al., J. Biol. Chem. 270,4412 (1995).
45. Ebara, T., et al., Eur. J. Pharmacol. 263, 69 (1994).
46. Jougasaki, M., et al., Amer. J. Physiol. 37, F657 (1995).
47. Murphy, T.A. and W. K. Samson, Endocrinology 136, 2459 (1995).
48. Yamaguchi, T., et al., Life Sci. 56, 379 (1995).
49. Samson, W.K., et al., Endocrinology 136, 2349 (1995).
50. Satoh, F., et al., J. Clin. Endocrinol. Metabol. 80, 1750 (1995).
51. Martinez, A., et al., Endocrinology 136, 4099 (1995).
52. Carney, D.N., et al., Proc. Natl. Acad Sci. U.S.A.
79, 3185 (1981).
53. Cuttitta, F., et al., Nature 316, 823 (1985).
54. Cho-Chung, Y.S., et al., Life Sci. 48, 1123 (1991).
55. Hoosein, N.M., Regul. Pept. 24, 1S (1989).
56. Yu, D., et al., Endocrinology 131, 1188 (1992).
57. Lohmann, S.M. and U. Walter, in Advances in Cyclin Nucleotide and Protein PhosDhorvlation Research, P. Greengard, et al., Eds. (Raven Press, New York, 1984), vol. 18, pp. 63-117.
58. Ally, S., et al., Proc. Natl. Acad. Sci. U.S.A.
85, 6322 (1988).
59. Sugo, S., et al., Biochem. Biophys. Res. Commun. 207, 25 (1995).
60. Minamino, N., et al., Biochem. Biophys. Res.
Commun. 211, 686 (1995).
61. Sugo, S., et al., FEES Lett. 369, 311 (1995).
62. Ames, B.N., et al., Proc. Natl. Acad. Sci.
U.S.A. 92, 5258 (1995).
63. Hao, Q., et al., Life Sci. 54, 265 (1994).
64. Feng, C.J., et al., Life Sci., 55,433 (1994).
43. Cheng, D.Y., et al., Life Sci. 55, 251 (1994).
44. Shimekake, Y., et al., J. Biol. Chem. 270,4412 (1995).
45. Ebara, T., et al., Eur. J. Pharmacol. 263, 69 (1994).
46. Jougasaki, M., et al., Amer. J. Physiol. 37, F657 (1995).
47. Murphy, T.A. and W. K. Samson, Endocrinology 136, 2459 (1995).
48. Yamaguchi, T., et al., Life Sci. 56, 379 (1995).
49. Samson, W.K., et al., Endocrinology 136, 2349 (1995).
50. Satoh, F., et al., J. Clin. Endocrinol. Metabol. 80, 1750 (1995).
51. Martinez, A., et al., Endocrinology 136, 4099 (1995).
52. Carney, D.N., et al., Proc. Natl. Acad Sci. U.S.A.
79, 3185 (1981).
53. Cuttitta, F., et al., Nature 316, 823 (1985).
54. Cho-Chung, Y.S., et al., Life Sci. 48, 1123 (1991).
55. Hoosein, N.M., Regul. Pept. 24, 1S (1989).
56. Yu, D., et al., Endocrinology 131, 1188 (1992).
57. Lohmann, S.M. and U. Walter, in Advances in Cyclin Nucleotide and Protein PhosDhorvlation Research, P. Greengard, et al., Eds. (Raven Press, New York, 1984), vol. 18, pp. 63-117.
58. Ally, S., et al., Proc. Natl. Acad. Sci. U.S.A.
85, 6322 (1988).
59. Sugo, S., et al., Biochem. Biophys. Res. Commun. 207, 25 (1995).
60. Minamino, N., et al., Biochem. Biophys. Res.
Commun. 211, 686 (1995).
61. Sugo, S., et al., FEES Lett. 369, 311 (1995).
62. Ames, B.N., et al., Proc. Natl. Acad. Sci.
U.S.A. 92, 5258 (1995).
63. Hao, Q., et al., Life Sci. 54, 265 (1994).
64. Feng, C.J., et al., Life Sci., 55,433 (1994).
65. Korman, Y., et al., Diabetes 34, 717 (1985).
66. Wollheim, C.B., et al., Diabetes 29, 74 (1980).
67. Kato, F., et al., J. Neurochem. 64, 459 (1995).
68. Martinez, A., et al., Endocrinology 136, 4099 (1995).
69. Walsh, T., et al., Science (under editorial consideration) .
70. Washimine, H., et al., Histochemistry 103, 251 (1995).
71. Kitamura, K., et al., Drugs 49, 485 (1995).
66. Wollheim, C.B., et al., Diabetes 29, 74 (1980).
67. Kato, F., et al., J. Neurochem. 64, 459 (1995).
68. Martinez, A., et al., Endocrinology 136, 4099 (1995).
69. Walsh, T., et al., Science (under editorial consideration) .
70. Washimine, H., et al., Histochemistry 103, 251 (1995).
71. Kitamura, K., et al., Drugs 49, 485 (1995).
72. Mulder, H., et al., Cell Tissue Res. 274, 467 (1993).
73. Ahren, B. and F. Sundler, Cell Tissue Res. 269, 315 (1992).
74. Miller, M.J., et al., Science (under editorial consideration).
75. Pittner, R.A., et al., J. Cell. Biochem. 55S, 19 (1994).
76. Holz, G. G., et al., J. Biol. Chem. 270, 17749 (1995).
77. Hall, J.M., et al., Brit. J. Pharmacol. 114, 592 (1995).
78. Zimmermann, U., et al., Peptides 16, 421 (1995).
79. Hotamisligil, G.S. and B. M. Spiegelman, Diabetes 43, 1271 (1994).
80. Jones, T.H., Clin. Endocrinol. 40, 703 (1994).
81. Feng, C.J., et al., Life Sci. 55, 433 (1994).
82. Fiscus, R.R., et al., Neuropeptides 26, 133 (1994).
83. Schmidt, H.H.H.W., et al., Science 255, 721 (1992).
84. Worl, J., et al., Histochemistrv 102, 353 (1994).
85. Hsu, S. M., J. Histochem. Cytochem. 29, 577 (1981).
86. Martinez, M., et al., J. Histochem. Cytochem. 41, 375 (1993).
C 87. Gray, D. W. R., Diabetes 33, 1055 (1984).
88. Korman, L. Y., Cancer Res. 46, 1214 (1986).
89. Brown, E. D., Proc. Soc. Exp. Biol. Med. 150, 557 (1975).
90. Ishiyama, et al. Clin. Exper. Pharmacol.
Physiol. 22:614(1995).
91. Allen, M.A., et al., Proc. Soc. Neurosci. (Abstract) 21:889 (1995) 92. Schonwetter, B.S., et al., Science 267:1645 (1995).
93. Zasloff, M., Proc. Natl. Acad. Sci. USA 84:5449 (1987).
94. Ghannoum, M.A., et al., Candida Adherence to Epithelial Cells. CRC Press; Boca Raton, FLA. 1990;
pp.72-104.
95. Walsh, T.J., et al., Antimicrob Chemother. 17:75 (1986).
96. Roilides, E., et al., J Infect Dis. 163:579 (1991) 97. Roilides, E., et al., J Leukocyte Biol. 57:651 (1995).
98. Maloy, W.L. and Kari, U.P., Biopolvmers (Peptide Science) 37:105 (1995).
99. Lehrer, R.I., et al., Cell 64:229 (1991).
100. Tytler, E.M., et al., Biochemistry 34:4394 (1995).
101. Oppenheim, F.G., et al., J Biol Chem 263:7472 (1988).
102. Shoji, H., et al., Biochemical and Biophysical Research, 215:531 (1995).
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 63198-1382 Seq 02-06-10 vl.txt).
A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.
The sequences in the sequence listing in electronic form are reproduced in the following table.
SEQUENCE TABLE
<110> CUTTITTA, FRANK
MARTINEZ, ALFREDO
MILLER, MAE JEAN
UNSWORTH, EDWARD J.
HOOK, WILLIAM
WALSH, THOMAS
GRAY, KAREN
MACRI, CHARLES
The Government of the United States of America, as represented by the Secretary, Health and Human Services <120> Functional Role of Adrenomedullin (AM) and the Gene-Related Product (PAMP) in Human Pathology and Physiology <130> 4239-63842-03 <150> 11/517,599 <151> 2006-09-05 <150> 09/931,700 <151> 2001-08-16 <150> 09/011,922 <151> 1998-02-17 <150> PCT/US96/13286 <151> 1996-08-16 <150> US/60/013,172 <151> 1996-03-12 <150> US60/002,936 <151> 1995-08-30 <150> US/60/002,514 <151> 1995-08-18 <160> 17 <170> Patentln Ver. 2.1 <210> 1 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, P070, YY-PreproAM (amino acids 34-41) <400> 1 Tyr Tyr Trp Asn Lys Trp Ala Leu Ser Arg <210> 2 <211> 13 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, P071, YGG-PreproAM (amino acids 122-131) <400> 2 Tyr Gly Gly His Gln Ile Tyr Gln Phe Thr Asp Lys Asp <210> 3 <211> 31 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, P072, PreproAM (amino acids 116-146) <400> 3 Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr <210> 4 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, sense primer, AM, (nucleotides 94-114) <400> 4 aagaagtgga ataagtgggc t 21 <210> 5 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, antisense primer, AM, (nucleotide 444-464) <400> 5 tggcttagaa gacaccagag t 21 <210> 6 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, antisense probe, AM, (nucleotides 289-309) <400> 6 ctggaagttg ttcatgctct g 21 <210> 7 <211> 20 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide PAMP-20, Proadrenomedullin N-terminal 20 amino acids <400> 7 Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg <210> 8 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, sense primer, AM, (nucleotides 250-270) <400> 8 aagaagtgga ataagtgggc t 21 <210> 9 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, antisense primer, AN, (nucleotides 640-660) <400> 9 tggcttagaa gacaccagag t 21 <210> 10 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, Nested Antisense probe, AM, (nucleotides 541-561) <400> 10 gacgttgtcc ttgtccttat c 21 <210> 11 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, AM-R amplification sense primer (nucleotides 476-497) <400> 11 agcgccacca gcaccgaata cg 22 <210> 12 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, AM-R amplification antisense primer (nucleotides 923-946) <400> 12 agaggatggg gttggcgaca cagt 24 <210> 13 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, AM-R antisense probe (nucleotides 788-811) <400> 13 ggtagggcag ccagcagatg acaa 24 <210> 14 <211> 31 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, Synthetic homolog of AM (P072), Structural amino acid sequence representing two-thirds of the intact AM peptide <400> 14 Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr <210> 15 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, Sense primer, AM, (nucleotides 250-270);
Recognizes the most conserved regions of the AM
gene <400> 15 aagaagtgga ataagtgggc t 21 <210> 16 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, Antisense primer, AN, (nucleotides 523-542);
Recognizes the most conserved regions of the AM
gene <400> 16 tgtgaactgg tagatctggt 20 <210> 17 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic acid probe, AM, (nucleotides 430-450); Detects the AM
gene via Southern Blot <400> 17 tctggcggta gcgcttgact c 21
C 87. Gray, D. W. R., Diabetes 33, 1055 (1984).
88. Korman, L. Y., Cancer Res. 46, 1214 (1986).
89. Brown, E. D., Proc. Soc. Exp. Biol. Med. 150, 557 (1975).
90. Ishiyama, et al. Clin. Exper. Pharmacol.
Physiol. 22:614(1995).
91. Allen, M.A., et al., Proc. Soc. Neurosci. (Abstract) 21:889 (1995) 92. Schonwetter, B.S., et al., Science 267:1645 (1995).
93. Zasloff, M., Proc. Natl. Acad. Sci. USA 84:5449 (1987).
94. Ghannoum, M.A., et al., Candida Adherence to Epithelial Cells. CRC Press; Boca Raton, FLA. 1990;
pp.72-104.
95. Walsh, T.J., et al., Antimicrob Chemother. 17:75 (1986).
96. Roilides, E., et al., J Infect Dis. 163:579 (1991) 97. Roilides, E., et al., J Leukocyte Biol. 57:651 (1995).
98. Maloy, W.L. and Kari, U.P., Biopolvmers (Peptide Science) 37:105 (1995).
99. Lehrer, R.I., et al., Cell 64:229 (1991).
100. Tytler, E.M., et al., Biochemistry 34:4394 (1995).
101. Oppenheim, F.G., et al., J Biol Chem 263:7472 (1988).
102. Shoji, H., et al., Biochemical and Biophysical Research, 215:531 (1995).
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 63198-1382 Seq 02-06-10 vl.txt).
A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.
The sequences in the sequence listing in electronic form are reproduced in the following table.
SEQUENCE TABLE
<110> CUTTITTA, FRANK
MARTINEZ, ALFREDO
MILLER, MAE JEAN
UNSWORTH, EDWARD J.
HOOK, WILLIAM
WALSH, THOMAS
GRAY, KAREN
MACRI, CHARLES
The Government of the United States of America, as represented by the Secretary, Health and Human Services <120> Functional Role of Adrenomedullin (AM) and the Gene-Related Product (PAMP) in Human Pathology and Physiology <130> 4239-63842-03 <150> 11/517,599 <151> 2006-09-05 <150> 09/931,700 <151> 2001-08-16 <150> 09/011,922 <151> 1998-02-17 <150> PCT/US96/13286 <151> 1996-08-16 <150> US/60/013,172 <151> 1996-03-12 <150> US60/002,936 <151> 1995-08-30 <150> US/60/002,514 <151> 1995-08-18 <160> 17 <170> Patentln Ver. 2.1 <210> 1 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, P070, YY-PreproAM (amino acids 34-41) <400> 1 Tyr Tyr Trp Asn Lys Trp Ala Leu Ser Arg <210> 2 <211> 13 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, P071, YGG-PreproAM (amino acids 122-131) <400> 2 Tyr Gly Gly His Gln Ile Tyr Gln Phe Thr Asp Lys Asp <210> 3 <211> 31 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, P072, PreproAM (amino acids 116-146) <400> 3 Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr <210> 4 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, sense primer, AM, (nucleotides 94-114) <400> 4 aagaagtgga ataagtgggc t 21 <210> 5 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, antisense primer, AM, (nucleotide 444-464) <400> 5 tggcttagaa gacaccagag t 21 <210> 6 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, antisense probe, AM, (nucleotides 289-309) <400> 6 ctggaagttg ttcatgctct g 21 <210> 7 <211> 20 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide PAMP-20, Proadrenomedullin N-terminal 20 amino acids <400> 7 Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg <210> 8 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, sense primer, AM, (nucleotides 250-270) <400> 8 aagaagtgga ataagtgggc t 21 <210> 9 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, antisense primer, AN, (nucleotides 640-660) <400> 9 tggcttagaa gacaccagag t 21 <210> 10 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, Nested Antisense probe, AM, (nucleotides 541-561) <400> 10 gacgttgtcc ttgtccttat c 21 <210> 11 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, AM-R amplification sense primer (nucleotides 476-497) <400> 11 agcgccacca gcaccgaata cg 22 <210> 12 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, AM-R amplification antisense primer (nucleotides 923-946) <400> 12 agaggatggg gttggcgaca cagt 24 <210> 13 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, AM-R antisense probe (nucleotides 788-811) <400> 13 ggtagggcag ccagcagatg acaa 24 <210> 14 <211> 31 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide, Synthetic homolog of AM (P072), Structural amino acid sequence representing two-thirds of the intact AM peptide <400> 14 Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr <210> 15 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, Sense primer, AM, (nucleotides 250-270);
Recognizes the most conserved regions of the AM
gene <400> 15 aagaagtgga ataagtgggc t 21 <210> 16 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic Acid, Antisense primer, AN, (nucleotides 523-542);
Recognizes the most conserved regions of the AM
gene <400> 16 tgtgaactgg tagatctggt 20 <210> 17 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Nucleic acid probe, AM, (nucleotides 430-450); Detects the AM
gene via Southern Blot <400> 17 tctggcggta gcgcttgact c 21
Claims (20)
1. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO. 3), in the manufacture of a medicament for use in treating a patient suffering from a cancer or tumor.
NO. 3), in the manufacture of a medicament for use in treating a patient suffering from a cancer or tumor.
2. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3), for the treatment of a patient suffering from a cancer or tumor.
NO: 3), for the treatment of a patient suffering from a cancer or tumor.
3. The use according to claim 1 or 2 wherein the cancer or tumor is adrenal, neurological, lung, colonic, ovarian, prostate, chondrosarcoma, pancreas, or breast.
4 An antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3), for use in the treatment of a patient suffering from a cancer or tumor.
NO: 3), for use in the treatment of a patient suffering from a cancer or tumor.
5. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3), in the manufacture of a medicament for use in prevention or treatment of a patient suffering from type II diabetes, wherein said medicament is effective to regulate insulin secretion and blood glucose metabolism.
NO: 3), in the manufacture of a medicament for use in prevention or treatment of a patient suffering from type II diabetes, wherein said medicament is effective to regulate insulin secretion and blood glucose metabolism.
6. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3) for treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism
NO: 3) for treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism
7. An antibody reactive with adrenomedullin peptide PO72 (SEQ ID NO: 3) for use in treatment of a patient suffering from type II diabetes, wherein said antibody is effective to regulate insulin secretion and blood glucose metabolism.
8. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3) for diagnosis of preeclampsia or diabetes.
NO: 3) for diagnosis of preeclampsia or diabetes.
9. An antibody reactive with adrenomedullin peptide PO72 (SEQ ID NO: 3) for use in diagnosis of preeclampsia or diabetes
10. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3), in the manufacture of a medicament for regulating neuronal activity in areas of the central nervous system.
NO: 3), in the manufacture of a medicament for regulating neuronal activity in areas of the central nervous system.
11. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3), for regulating neuronal activity in areas of the central nervous system.
NO: 3), for regulating neuronal activity in areas of the central nervous system.
12. An antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3), for use in regulating neuronal activity in areas of the central nervous system.
NO: 3), for use in regulating neuronal activity in areas of the central nervous system.
13. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3) in the manufacture of a medicament for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said medicament is effective to lessen or inhibit the degranulation of mast cells.
NO: 3) in the manufacture of a medicament for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said medicament is effective to lessen or inhibit the degranulation of mast cells.
14. Use of an antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3) for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells.
NO: 3) for regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells.
15. An antibody reactive with adrenomedullin peptide PO72 (SEQ ID
NO: 3) for use in regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells.
NO: 3) for use in regulating, lessening, or inhibiting an allergic or inflammatory response due to the degranulation of mast cells, wherein said antibody is effective to lessen or inhibit the degranulation of mast cells.
16. A pharmaceutical composition comprising an antibody reactive with adrenomedullin peptide PO72 (SEQ ID NO: 3) and a pharmaceutically acceptable excipient.
17. Use of isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) in the manufacture of a medicament for treatment of a bacterial infection in a subject, wherein said medicament is effective to inhibit or prevent bacterial growth.
18. Use of isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) for treatment of a bacterial infection in a subject, wherein said peptide is effective to inhibit or prevent bacterial growth.
19. An isolated adrenomedullin peptide PAMP-20 (SEQ ID NO: 7) for use in treatment of a bacterial infection in a subject, wherein said peptide is effective to inhibit or prevent bacterial growth.
20. An isolated adrenomedullin oligonucleotide, wherein the oligonucleotide is AM94-114 (SEQ ID NO: 4), AM444-464 (SEQ ID NO: 5) or AM289-309 (SEQ ID
NO: 6).
NO: 6).
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US251495P | 1995-08-18 | 1995-08-18 | |
US60/002,514 | 1995-08-18 | ||
US293695P | 1995-08-30 | 1995-08-30 | |
US60/002,936 | 1995-08-30 | ||
US1317296P | 1996-03-12 | 1996-03-12 | |
US60/013,172 | 1996-03-12 | ||
PCT/US1996/013286 WO1997007214A1 (en) | 1995-08-18 | 1996-08-16 | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2229741A1 CA2229741A1 (en) | 1997-02-27 |
CA2229741C true CA2229741C (en) | 2012-05-08 |
Family
ID=27357180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2229741A Expired - Fee Related CA2229741C (en) | 1995-08-18 | 1996-08-16 | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
Country Status (7)
Country | Link |
---|---|
US (4) | US6320022B1 (en) |
EP (1) | EP0845036B1 (en) |
JP (2) | JPH11512087A (en) |
AT (1) | ATE180832T1 (en) |
CA (1) | CA2229741C (en) |
DE (1) | DE69602756T2 (en) |
WO (1) | WO1997007214A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5888963A (en) * | 1996-04-18 | 1999-03-30 | Auckland Uniservices Limited | Treatment of bone disorders with adrenomedullin |
US6440421B1 (en) * | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
WO1999016406A2 (en) * | 1997-09-26 | 1999-04-08 | Auckland Uniservices Limited | Therapeutic method |
EP1214600B1 (en) | 1999-09-10 | 2005-12-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Determination of adrenomedullin-binding proteins |
WO2002040571A1 (en) * | 2000-11-17 | 2002-05-23 | Lee Jin Kyu | Poly (methylsilsesquioxane) copolymers and preparation method thereof |
FR2821080B1 (en) * | 2001-02-20 | 2003-12-19 | Sanofi Synthelabo | SPECIFIC ANTIBODIES TO HUMAN ADRENOMEDULLINE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ITS THERAPEUTIC APPLICATIONS |
US20110087312A1 (en) * | 2001-03-02 | 2011-04-14 | Erchonia Corporatin | Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy |
JP2005508838A (en) | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | Combination therapy for pancreatic cancer |
US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
EP1489093A4 (en) * | 2002-03-19 | 2005-07-20 | Oncorex Inc | Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer |
US20040127445A1 (en) * | 2002-08-28 | 2004-07-01 | Chondrogene Limited | Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation |
US20040121375A1 (en) * | 2002-09-30 | 2004-06-24 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
EP1549676A1 (en) * | 2002-09-30 | 2005-07-06 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human myeloid leukemia |
CA2501282C (en) | 2002-10-04 | 2012-12-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vasoregulating compounds and methods of their use |
AU2003295422B2 (en) * | 2002-11-07 | 2009-01-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A new target for angiogenesis and anti-angiogenesis therapy |
CN1781023A (en) | 2003-03-28 | 2006-05-31 | 埃弗顿有限公司 | Gastrin hormone immunoassays |
US7228658B2 (en) | 2003-08-27 | 2007-06-12 | Weyerhaeuser Company | Method of attaching an end seal to manufactured seeds |
EP2339351A1 (en) * | 2003-09-08 | 2011-06-29 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
US8691575B2 (en) * | 2003-09-30 | 2014-04-08 | Weyerhaeuser Nr Company | General method of classifying plant embryos using a generalized Lorenz-Bayes classifier |
CA2484533C (en) * | 2003-11-25 | 2008-12-02 | Weyerhaeuser Company | Systems and method of embryo delivery for manufactured seeds |
US7555865B2 (en) * | 2003-11-25 | 2009-07-07 | Weyerhaeuser Nr Company | Method and system of manufacturing artificial seed coats |
CA2486289C (en) * | 2003-11-25 | 2008-01-08 | Weyerhaeuser Company | Combination end seal and restraint |
US20050108929A1 (en) * | 2003-11-25 | 2005-05-26 | Edwin Hirahara | Method and system for creating manufactured seeds |
US20050108935A1 (en) * | 2003-11-25 | 2005-05-26 | Edwin Hirahara | Method and system of manufacturing artificial seed coats |
US7356965B2 (en) * | 2003-12-11 | 2008-04-15 | Weyerhaeuser Co. | Multi-embryo manufactured seed |
US7591287B2 (en) * | 2003-12-18 | 2009-09-22 | Weyerhaeuser Nr Company | System and method for filling a seedcoat with a liquid to a selected level |
US7568309B2 (en) * | 2004-06-30 | 2009-08-04 | Weyerhaeuser Nr Company | Method and system for producing manufactured seeds |
KR101333168B1 (en) | 2004-09-22 | 2013-11-28 | 리셉터 바이오로직스 인크 | Monoclonal antibodies to progastrin |
US20060064930A1 (en) * | 2004-09-27 | 2006-03-30 | Carlson William C | Manufactured seed having a live end seal coating |
CA2518166C (en) * | 2004-09-27 | 2012-02-21 | Weyerhaeuser Company | Manufactured seed having a live end seal |
US7547488B2 (en) * | 2004-12-15 | 2009-06-16 | Weyerhaeuser Nr Company | Oriented strand board panel having improved strand alignment and a method for making the same |
US7654037B2 (en) * | 2005-06-30 | 2010-02-02 | Weyerhaeuser Nr Company | Method to improve plant somatic embryo germination from manufactured seed |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
US9829494B2 (en) * | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
DE102006052916A1 (en) * | 2006-11-08 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of diabetes mellitus using MR-proADM |
AU2008297542A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
FR2934597B1 (en) * | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | ANTIBODIES BINDING TO ADRENOMEDULLINE RECEPTORS AND USES THEREOF AS MEDICAMENT. |
JP2012507021A (en) * | 2008-10-31 | 2012-03-22 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Methods and assays for classifying foods and / or beverages and / or diets and / or nutrition plans and / or drugs for effects on the cardiovascular system |
PT3178835T (en) | 2009-02-03 | 2019-06-19 | Amunix Pharmaceuticals Inc | Extended recombinant polypeptides and compositions comprising same |
EP2389799A1 (en) * | 2010-05-25 | 2011-11-30 | BioMass Booster, S.L. | Method for increasing plant biomass |
EP2583106A1 (en) * | 2010-06-18 | 2013-04-24 | Cézanne S.A.S. | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
FR2964103B1 (en) * | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | ANTIBODIES BINDING TO ADRENOMEDULLINE AND RECEPTORS OF ADRENOMEDULLINE AND THEIR USES AS A MEDICINAL PRODUCT |
JP5932279B2 (en) * | 2011-10-07 | 2016-06-08 | ポーラ化成工業株式会社 | Screening method |
US8776012B2 (en) * | 2011-10-25 | 2014-07-08 | International Business Machines Corporation | Automatic scheduling of review meetings |
ES2707878T3 (en) | 2011-11-16 | 2019-04-05 | Adrenomed Ag | Antiadrenomedullin antibody (ADM) or anti-ADM antibody fragment or non-Ig anti-ADM scaffold to regulate fluid balance in a patient with a chronic or acute disease |
SI3553084T1 (en) | 2011-11-16 | 2023-05-31 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
PL2780717T3 (en) | 2011-11-16 | 2017-06-30 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
WO2013072513A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
JP5953108B2 (en) * | 2012-05-14 | 2016-07-20 | ポーラ化成工業株式会社 | Screening method |
EP2905029B1 (en) * | 2012-10-04 | 2018-11-21 | Shionogi&Co., Ltd. | Drug for inhibiting malignant tumor metastasis |
JP6673847B2 (en) * | 2013-12-20 | 2020-03-25 | アンギオビオメト ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adrenomedullin binder for use in cancer treatment |
ES2754478T3 (en) * | 2015-03-12 | 2020-04-17 | Fund Rioja Salud | Use of an adrenomedullin inhibitor for the manufacture of a medicine useful in the prevention and treatment of diseases that reduce bone density |
CA3064962A1 (en) | 2017-05-26 | 2018-11-29 | The Governors Of The University Of Alberta | Self-assembling peptide for activating human mast cells |
AU2018283284A1 (en) | 2017-06-15 | 2020-01-30 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
EP3438668A1 (en) * | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
DK3682247T3 (en) | 2017-09-13 | 2022-03-21 | Brahms Gmbh | PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL BLOOD PLATE LEVELS |
EP4058466A1 (en) | 2019-11-13 | 2022-09-21 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2452130A1 (en) * | 1992-03-05 | 1993-09-16 | Francis J. Burrows | Methods and compositions for targeting the vasculature of solid tumors |
CA2161108A1 (en) | 1993-04-23 | 1994-11-10 | Herbert J. Evans | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site |
JP2774769B2 (en) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | Adrenomedullin |
-
1996
- 1996-08-16 WO PCT/US1996/013286 patent/WO1997007214A1/en active IP Right Grant
- 1996-08-16 US US09/011,922 patent/US6320022B1/en not_active Expired - Lifetime
- 1996-08-16 AT AT96928205T patent/ATE180832T1/en not_active IP Right Cessation
- 1996-08-16 DE DE69602756T patent/DE69602756T2/en not_active Expired - Lifetime
- 1996-08-16 EP EP96928205A patent/EP0845036B1/en not_active Expired - Lifetime
- 1996-08-16 JP JP9509499A patent/JPH11512087A/en not_active Withdrawn
- 1996-08-16 CA CA2229741A patent/CA2229741C/en not_active Expired - Fee Related
-
2001
- 2001-08-16 US US09/931,700 patent/US7101548B2/en not_active Expired - Fee Related
-
2006
- 2006-09-05 US US11/517,599 patent/US7622272B2/en not_active Expired - Fee Related
- 2006-12-26 JP JP2006349430A patent/JP4077861B2/en not_active Expired - Fee Related
-
2009
- 2009-09-29 US US12/569,821 patent/US7939639B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU6776596A (en) | 1997-03-12 |
EP0845036B1 (en) | 1999-06-02 |
US7101548B2 (en) | 2006-09-05 |
ATE180832T1 (en) | 1999-06-15 |
US7622272B2 (en) | 2009-11-24 |
DE69602756T2 (en) | 2000-02-10 |
US20070004630A1 (en) | 2007-01-04 |
AU710662B2 (en) | 1999-09-23 |
US7939639B2 (en) | 2011-05-10 |
JP4077861B2 (en) | 2008-04-23 |
WO1997007214A1 (en) | 1997-02-27 |
US20020055615A1 (en) | 2002-05-09 |
JP2007145850A (en) | 2007-06-14 |
US20100021469A1 (en) | 2010-01-28 |
DE69602756D1 (en) | 1999-07-08 |
EP0845036A1 (en) | 1998-06-03 |
US6320022B1 (en) | 2001-11-20 |
JPH11512087A (en) | 1999-10-19 |
CA2229741A1 (en) | 1997-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2229741C (en) | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology | |
US7659081B2 (en) | Determination of AM-binding proteins and the association of adrenomedullin (AM) therewith | |
AU2012338730B2 (en) | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
KR101016476B1 (en) | Antibodies Against Fibroblast Growth Factor 23 | |
WO2005025616A1 (en) | Use of antibody | |
JP2005510212A (en) | Antibody inhibitors of GDF-8 and uses thereof | |
TWI224620B (en) | Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same | |
WO2006137597A1 (en) | Novel physiological substance nesfatin, substance relevant thereto, and use of the substances | |
Ohning et al. | Gastrin mediates the gastric mucosal proliferative response to feeding | |
US5821218A (en) | Regeneration of kidney tissue and use of autocrine growth factors | |
EP0725649A1 (en) | Class i mhc modulation of surface receptor activity | |
AU710662C (en) | Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology | |
EP1773392A2 (en) | Method for preventing and treating mast cell mediated diseases | |
US20110301332A1 (en) | Anti-pamp therapeutic antibodies | |
US6348571B1 (en) | Corticotropin release inhibiting factor and methods of using same | |
EP0862631A1 (en) | Luminal cholecystokinin-releasing factor | |
US6039956A (en) | Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder | |
WO1997015671A9 (en) | Luminal cholecystokinin-releasing factor | |
AU708857C (en) | Luminal cholecystokinin-releasing factor | |
TW202323289A (en) | Anti-growth hormone antibody | |
CN116262791A (en) | Antibodies to sodium potassium ATPase and uses thereof | |
WO2008096905A1 (en) | Anti-brak (cxcl14) human monoclonal antibody and use thereof | |
WO1999060112A1 (en) | Antibodies and utilization thereof | |
WO2004037863A1 (en) | Antibody and utilization of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140818 |